


**THE** *Towards Precision Medicine in  
Practice and Research of Hepatology*

**LI**  **ER WEEK**

**2024** **June 27-29, 2024**  
**Walkerhill, Seoul, Korea**







## ABOUT THE LIVER WEEK

The Liver Week is a multidisciplinary international conference at which the liver-related societies in Korea - the Korean Association for the Study of the Liver, the Korean Association of HBP Surgery, the Korean Liver Cancer Association, and the Korean Liver Transplantation Society gathered together for the first time in 2014 as hosting organizations. It is being held as an annual meeting with more than 1,000 participants each year.

The Liver Week is held not only for the study of recent research trends and views on liver disorders from the perspectives of eminent professors and researchers around the world, but also for exchanges of information between participants, which contributes to the revitalization of our study and researches. The Liver Week imbues delegates with authoritative lectures and discussions from both domestic and foreign speakers on the major issues on liver diseases, such as viral hepatitis, liver fibrosis, liver cirrhosis, liver cancer, and more.



**Program Book  
Abstract Book  
E-Posters  
and View More**

[www.theliverweek.org](http://www.theliverweek.org)


WELCOME MESSAGE	01
ORGANIZING COMMITTEE	02
INVITED FACULTY	03
VENUE	08
FLOOR PLAN & SESSION	10
INDUSTRY LUNCHEON SYMPOSIA	16
SCIENTIFIC PROGRAM	19
FREE PAPER PRESENTATION	53
ORAL POSTER PRESENTATION	65
E-POSTER EXHIBITION	82
GENERAL INFORMATION	112
INDUSTRIAL EXHIBITION FLOOR PLAN	116
BOOTH TOUR	



In 1L unresectable Hepatocellular Carcinoma

# TECENTRIQ® + Bevacizumab (AVASTIN®) combination therapy is the first immunotherapy<sup>1</sup> that demonstrated survival benefit vs. existing therapy

- Median OS :  
19.2 months with TECENTRIQ® + Bevacizumab  
(AVASTIN®) vs 13.4 months with sorafenib  
(HR=0.66; 95% CI, 0.52,0.85; P<0.001)<sup>2</sup>



**IMbrave150** : 504patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib. The coprimary endpoints were OS and IRF assessed PFS.  
**HR** : Hazard ratio **CI** : Confidence interval **OS** : Overall survival **IRF** : Independent review facility **PFS** : Progression free survival **References** 1. Finn et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382:1894-905. May 14, 2020.  
 2. AL Cheng, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021 Dec 10;50(6):8278-2(10):22418. \*descriptive purpose only

\*보다 자세한 제품정보 문의 및 제품 관련 부직용 보고는 (주)한글리수 (02-3451-3600) 로 연락 주시기 바랍니다. \*타겟트릭과 아바스틴의 최신 제품정보는 QR code 를 스캔하여 확인하실 수 있습니다. (주)한글리수 서울특별시 서초구 서동대로 411, GT Tower(East) 빌딩 17층 (06615) Tel.02.3451.3600 / www.roche.co.kr



# WELCOME MESSAGE

The Liver Week 2024

Dear Colleagues and Friends,

We are delighted to welcome you to The Liver Week 2024 in Korea's most beautiful city, Seoul.

The theme of this year's Liver Week is "Towards Precision Medicine in Practice and Research of Hepatology," focusing on how personalized treatment is applied in all fields of hepatology.

The liver meeting provides a unique opportunity to hear from leading experts in liver research, learn about the latest discoveries, and get updates on diagnostics, therapeutics, and patient care. You can explore the latest advancements in liver disease, participate in educational sessions, and engage in interactive workshops. It's also a great chance to meet other professionals in the field and explore new collaborations.

Moreover, your knowledge will be enhanced by Seoul, an amazing city with 2,000 years of history, ancient palaces, delicious Korean cuisine, and modern culture. We promise that The Liver Week 2024 will be a fantastic experience for you to meet experts worldwide and share your rich experiences.

We hope you enjoy The Liver Week 2024.

Thank you.



**Young Oh Kweon**  
Chairman



**Yoon Jun Kim**  
President



**Ki-Hun Kim**  
Vice President



**Jong Young Choi**  
Vice President



**Kwang-Woong Lee**  
Vice President



# ORGANIZING COMMITTEE

## Congress Chairman

*Young Oh Kweon (Kyungpook National Univ.)*

## Congress President

*Yoon Jun Kim (Seoul National Univ.)*

## Congress Vice President

*Ki-Hun Kim (Univ. of Ulsan)*

*Jong Young Choi (The Catholic Univ. of Korea)*

*Kwang-Woong Lee (Seoul National Univ.)*

## Secretary General

*Hyung Joon Kim (Chung-Ang Univ.)*

*Dong-Hwan Jung (Univ. of Ulsan)*

*Jeong Won Jang (The Catholic Univ. of Korea)*

*YoungRok Choi (Seoul National Univ.)*

## Scientific Committee Chair

*Ju Hyun Shim (Univ. of Ulsan)*

## Scientific Committee Vice Chair

*Jongman Kim (Sungkyunkwan Univ.)*

*Su Jong Yu (Seoul National Univ.)*

*Hae Won Lee (Seoul National Univ.)*

## Treasurer

*Bo Hyun Kim (National Cancer Center)*

*Do Young Kim (Yonsei Univ.)*

## Publication

*Won Kim (Seoul National Univ.)*

## Public Relations

*Sung-Eun Kim (Hallym Univ.)*

## Scientific Committee Members

*\* Executive Scientific Members for The Liver Week 2024*

*Do Seon Song (The Catholic Univ. of Korea) \**

*Jihyun An (Hanyang Univ.) \**

*Young-Sun Lee (Korea Univ.) \**

*Eun Sun Jang (Seoul National Univ.) \**

*Young Eun Chon (CHA Univ.) \**

*Soon Sun Kim (Ajou Univ.)*

*Seong Kyun Na (Inje Univ.)*

*Byeong Geun Song (Sungkyunkwan Univ.)*

*In Hye Song (Univ. of Ulsan)*

*Seung Kak Shin (Gachon Univ.)*

*Hyuk Soo Eun (Chungnam National Univ.)*

*Jae Seung Lee (Yonsei Univ.)*

*Yu Rim Lee (Kyungpook National Univ.)*

*Young Chang (Soonchunhyang Univ.)*

*Ju-Yeon Cho (Chosun Univ.)*

*Sang Hyun Choi (Univ. of Ulsan)*

*Won-Mook Choi (Univ. of Ulsan)*

*Yong-Hyun Han (Kangwon National Univ.)*

*Moon Haeng Hur (Seoul National Univ.)*

*Sang Youn Hwang (Dongnam Institute of Radiological & Medical Sciences)*

## INVITED FACULTY

Hanyu Jiang	<i>Sichuan Univ.</i>	<i>China</i>
Wenhui Li	<i>Tsinghua Univ.</i>	<i>China</i>
Xiong Ma	<i>Shanghai Jiao Tong Univ.</i>	<i>China</i>
Xiao Xu	<i>Zhejiang Univ.</i>	<i>China</i>
Wai-Kay Seto	<i>The Univ. of Hong Kong</i>	<i>Hong Kong SAR, China</i>
Man-Fung Yuen	<i>The Univ. of Hong Kong</i>	<i>Hong Kong SAR, China</i>
Ari Fahrial Syam	<i>Univ. of Indonesia</i>	<i>Indonesia</i>
Rakhi Maiwall	<i>Institute of Liver and Biliary Sciences</i>	<i>India</i>
Ashwin Rammohan	<i>Rela Hospital</i>	<i>India</i>
Barjesh Chander Sharma	<i>Govind Ballabh Pant Hospital</i>	<i>India</i>
Tatsuya Kanto	<i>National Center for Global Health and Medicine</i>	<i>Japan</i>
Takahiro Kodama	<i>Osaka Univ.</i>	<i>Japan</i>
Atsumasa Komori	<i>Nagasaki Univ.</i>	<i>Japan</i>
Masatoshi Kudo	<i>Kindai Univ.</i>	<i>Japan</i>
Michiie Sakamoto	<i>Keio Univ.</i>	<i>Japan</i>
Tetsuo Takehara	<i>Osaka Univ.</i>	<i>Japan</i>
Pierce Chow	<i>National Cancer Centre</i>	<i>Singapore</i>
Alfred Kow	<i>National Univ. of Singapore</i>	<i>Singapore</i>
Mark Muthiah	<i>National Univ. Hospital</i>	<i>Singapore</i>
Chow Wei Too	<i>Singapore General Hospital</i>	<i>Singapore</i>
Pi-Yi Chang	<i>Taichung Veterans General Hospital</i>	<i>Taiwan</i>
Yi-Hsiang Huang	<i>National Yang Ming Chiao Tung Univ.</i>	<i>Taiwan</i>
I-Cheng Lee	<i>National Yang Ming Chiao Tung Univ.</i>	<i>Taiwan</i>
Shang-Yu Wang	<i>Chang Gung Memorial Hospital</i>	<i>Taiwan</i>
Nutchapinjaroen	<i>Chulalongkorn Univ.</i>	<i>Thailand</i>
Wipusit Taesombat	<i>Chulalongkorn Univ.</i>	<i>Thailand</i>
Jean-Charles Nault	<i>Sorbonne Université</i>	<i>France</i>
Pierre-Emmanuel Rautou	<i>Université Paris-Cité</i>	<i>France</i>
Andrea Casadei Gardini	<i>Vita-Salute San Raffaele Univ.</i>	<i>Italy</i>
Maria Buti	<i>Univ. of Barcelona</i>	<i>Spain</i>
Richard S. Finn	<i>Univ. of California, Los Angeles</i>	<i>USA</i>
Guadalupe Garcia-Tsao	<i>Yale Univ.</i>	<i>USA</i>
Tim F. Greten	<i>National Cancer Institute</i>	<i>USA</i>
Steve Hack	<i>Genentech</i>	<i>USA</i>
Julie K. Heimbach	<i>Mayo Clinic</i>	<i>USA</i>
Yujin Hoshida	<i>Univ. of Texas Southwestern Medical Center</i>	<i>USA</i>
W. Ray Kim	<i>Stanford Univ.</i>	<i>USA</i>
Rohit Loomba	<i>Univ. of California San Diego</i>	<i>USA</i>
Grace L. Su	<i>Univ. of Michigan</i>	<i>USA</i>
Elliot B. Tapper	<i>Univ. of Michigan</i>	<i>USA</i>
Leland Yee	<i>Gilead Sciences, Inc.</i>	<i>USA</i>

## INVITED FACULTY

Sang Hoon Ahn	<i>Yonsei Univ.</i>	Chul Ju Han	<i>Korea Cancer Center Hospital</i>
Jihyun An	<i>Hanyang Univ.</i>	Ji Won Han	<i>The Catholic Univ. of Korea</i>
Si Hyun Bae	<i>The Catholic Univ. of Korea</i>	Seul Ki Han	<i>Yonsei Univ. Wonju</i>
Soon Koo Baik	<i>Yonsei Univ. Wonju</i>	Seungbong Han	<i>Korea Univ.</i>
Hee Bok Chae	<i>Chungbuk National Univ.</i>	Yong-Hyun Han	<i>Kangwon National Univ.</i>
Yuna Chae	<i>Dong-A ST Co., Ltd.</i>	Young Seok Han	<i>Daegu Catholic Univ.</i>
Young Chang	<i>Soonchunhyang Univ.</i>	Jeong Heo	<i>Pusan National Univ.</i>
Gab Jin Cheon	<i>Univ. of Ulsan</i>	Nae-Yun Heo	<i>Inje Univ.</i>
Jaeyoun Cheong	<i>Ajou Univ.</i>	Subin Heo	<i>Univ. of Ulsan</i>
Eun Ju Cho	<i>Seoul National Univ.</i>	Geun Hong	<i>Ewha Womans Univ.</i>
Eun Young Cho	<i>Wonkwang Univ.</i>	Gun Young Hong	<i>Kwangju Christian Hospital</i>
Hyo Jung Cho	<i>Ajou Univ.</i>	Seung Baek Hong	<i>Pusan National Univ.</i>
Sehyun Cho	<i>The Catholic Univ. of Korea</i>	Seungheui Hong	<i>Samsung Medical Center</i>
Sung Bum Cho	<i>Chonnam National Univ.</i>	Jin Won Huh	<i>Univ. of Ulsan</i>
Young Youn Cho	<i>Chung-Ang Univ.</i>	Moon Haeng Hur	<i>Seoul National Univ.</i>
Yuri Cho	<i>National Cancer Center</i>	Jaeseok Hwang	<i>Keimyung Univ.</i>
Won Hyeok Choe	<i>Konkuk Univ.</i>	Jungwook Hwang	<i>Hanyang Univ.</i>
Gi Hong Choi	<i>Yonsei Univ.</i>	Sang Youn Hwang	<i>Dongnam Institute of Radiological &amp; Medical Sciences</i>
Gyu-seong Choi	<i>Sungkyunkwan Univ.</i>	Dongho Hyun	<i>Sungkyunkwan Univ.</i>
Ho Joong Choi	<i>The Catholic Univ. of Korea</i>	Byoung Kuk Jang	<i>Keimyung Univ.</i>
Jin Sub Choi	<i>Yonsei Univ.</i>	Eun Sun Jang	<i>Seoul National Univ.</i>
Jin Woo Choi	<i>Seoul National Univ.</i>	Jae Young Jang	<i>Soonchunhyang Univ.</i>
Jong Young Choi	<i>The Catholic Univ. of Korea</i>	Jeong Won Jang	<i>The Catholic Univ. of Korea</i>
Moon Seok Choi	<i>Sungkyunkwan Univ.</i>	Kyoung Ock Jeon	<i>Severance Hospital</i>
Nam Kyu Choi	<i>Chosun Univ.</i>	Jae Yoon Jeong	<i>Ewha Womans Univ.</i>
Sae Byeol Choi	<i>Korea Univ.</i>	Sook-Hyang Jeong	<i>Seoul National Univ.</i>
Sung Kyu Choi	<i>Chonnam National Univ.</i>	Soung Won Jeong	<i>Soonchunhyang Univ.</i>
Taewon Choi	<i>Ajou Univ.</i>	Won-Il Jeong	<i>KAIST</i>
Won-Mook Choi	<i>Univ. of Ulsan</i>	Young-Joo Jin	<i>Inha Univ.</i>
Young Il Choi	<i>Kosin Univ.</i>	Jae-Won Joh	<i>Sungkyunkwan Univ.</i>
YoungRok Choi	<i>Seoul National Univ.</i>	Dong Jin Joo	<i>Yonsei Univ.</i>
Hee Ho Chu	<i>Univ. of Ulsan</i>	Dong-Hwan Jung	<i>Univ. of Ulsan</i>
Jin Wook Chung	<i>Seoul National Univ.</i>	Janghan Jung	<i>Hallym Univ.</i>
Woo Jin Chung	<i>Keimyung Univ.</i>	Kyu-Hwan Jung	<i>Sungkyunkwan Univ.</i>
Hyuk Soo Eun	<i>Chungnam National Univ.</i>	Yong Jin Jung	<i>Seoul National Univ.</i>
Geum-Youn Gwak	<i>Sungkyunkwan Univ.</i>	Young Kul Jung	<i>Korea Univ.</i>
Bong-Jin Hahm	<i>Seoul National Univ.</i>		



## INVITED FACULTY

Danbee Kang	<i>Sungkyunkwan Univ.</i>	Nam Young Kim	<i>HIRA</i>
Mi Young Kang	<i>HIRA</i>	Sang Geon Kim	<i>Dongguk Univ.</i>
Sangwook Kang	<i>Yonsei Univ.</i>	Sang Gyune Kim	<i>Soonchunhyang Univ.</i>
Seong Hee Kang	<i>Korea Univ.</i>	Sang Jin Kim	<i>Korea Univ.</i>
Wonseok Kang	<i>Sungkyunkwan Univ.</i>	Say-June Kim	<i>The Catholic Univ. of Korea</i>
Woo-Hyoung Kang	<i>Univ. of Ulsan</i>	Sehee Kim	<i>Univ. of Ulsan</i>
Yeowool Kang	<i>Dong-A Univ.</i>	Sejoong Kim	<i>Seoul National Univ.</i>
Beom Kyung Kim	<i>Yonsei Univ.</i>	Seong Jae Kim	<i>Gyeongsang National Univ.</i>
Bo Hyun Kim	<i>National Cancer Center</i>	Seung Up Kim	<i>Yonsei Univ.</i>
Bohyun Kim	<i>The Catholic Univ. of Korea</i>	So Yeon Kim	<i>Univ. of Ulsan</i>
Bong-Wan Kim	<i>Ajou Univ.</i>	Soon Sun Kim	<i>Ajou Univ.</i>
Byung Ik Kim	<i>Sungkyunkwan Univ.</i>	Suk Bae Kim	<i>Dankook Univ.</i>
Byung Seok Kim	<i>Daegu Catholic Univ.</i>	Sung-Eun Kim	<i>Hallym Univ.</i>
Chang Wook Kim	<i>The Catholic Univ. of Korea</i>	Tae Hun Kim	<i>Ewha Womans Univ.</i>
Do Hoon Kim	<i>Univ. of Ulsan</i>	Tae Hyun Kim	<i>National Cancer Center</i>
Do Young Kim	<i>Yonsei Univ.</i>	Tae Hyung Kim	<i>Hallym Univ.</i>
Dong Joon Kim	<i>Hallym Univ.</i>	Tae-Seok Kim	<i>Keimyung Univ.</i>
Dong-Sik Kim	<i>Korea Univ.</i>	Tae-Suk Kim	<i>Kangwon National Univ.</i>
Doojin Kim	<i>Gachon Univ.</i>	Won Kim	<i>Univ. of Ulsan</i>
Haeryoung Kim	<i>Seoul National Univ.</i>	Won Kim	<i>Seoul National Univ.</i>
Hong Soo Kim	<i>Soonchunhyang Univ.</i>	Yoon Jun Kim	<i>Seoul National Univ.</i>
Hyeyoung Kim	<i>Soonchunhyang Univ.</i>	Young Seok Kim	<i>Soonchunhyang Univ.</i>
Hyo-Cheol Kim	<i>Seoul National Univ.</i>	Kwang Cheol Koh	<i>Sungkyunkwan Univ.</i>
Hyung Joon Kim	<i>Chung-Ang Univ.</i>	Yang-Seok Koh	<i>Chonnam National Univ.</i>
In Hee Kim	<i>Jeonbuk National Univ.</i>	Young Oh Kweon	<i>Kyungpook National Univ.</i>
Ja Kyung Kim	<i>Yonsei Univ.</i>	Jae Hyun Kwon	<i>Hallym Univ.</i>
Jeong Han Kim	<i>Konkuk Univ.</i>	Jung Hyun Kwon	<i>The Catholic Univ. of Korea</i>
Ji Hoon Kim	<i>Korea Univ.</i>	Oh Sang Kwon	<i>Gachon Univ.</i>
Jin-Wook Kim	<i>Seoul National Univ.</i>	So Young Kwon	<i>Konkuk Univ.</i>
Jongman Kim	<i>Sungkyunkwan Univ.</i>	Beom Hee Lee	<i>Univ. of Ulsan</i>
Junil Kim	<i>Soongsil Univ.</i>	Boram Lee	<i>Seoul National Univ.</i>
Kang Mo Kim	<i>Univ. of Ulsan</i>	Byung Seok Lee	<i>Chungnam National Univ.</i>
Kyung Sik Kim	<i>Yonsei Univ.</i>	Chang Hun Lee	<i>Jeonbuk National Univ.</i>
Kyung-Ah Kim	<i>Inje Univ.</i>	Chang Hyeong Lee	<i>Daegu Catholic Univ.</i>
Kyun-Hwan Kim	<i>Sungkyunkwan Univ.</i>	Chang-Woo Lee	<i>Sungkyunkwan Univ.</i>
Mi Na Kim	<i>Yonsei Univ.</i>	Danbi Lee	<i>Univ. of Ulsan</i>
Moon Young Kim	<i>Yonsei Univ. Wonju</i>	Dong Ho Lee	<i>Seoul National Univ.</i>

## INVITED FACULTY

Hae Lim Lee	<i>The Catholic Univ. of Korea</i>	Kwon Joong Na	<i>Seoul National Univ.</i>
Hae Won Lee	<i>Seoul National Univ.</i>	Minkyung Nam	<i>Hanyang Univ. Hospital</i>
Han Ah Lee	<i>Chung-Ang Univ.</i>	Soon Woo Nam	<i>The Catholic Univ. of Korea</i>
Han Chu Lee	<i>Univ. of Ulsan</i>	Yong-Han Paik	<i>Sungkyunkwan Univ.</i>
Hye Jung Lee	<i>Daewoong Pharmaceutical Co., Ltd.</i>	Cheon Soo Park	<i>The Catholic Univ. of Korea</i>
Hye Won Lee	<i>Yonsei Univ.</i>	Hyo Jung Park	<i>Univ. of Ulsan</i>
Hyun Woong Lee	<i>Yonsei Univ.</i>	Hyun Suk Park	<i>Asan Medical Center</i>
Jae Geun Lee	<i>Yonsei Univ.</i>	Joo Kyung Park	<i>Sungkyunkwan Univ.</i>
Jae Seung Lee	<i>Yonsei Univ.</i>	Joong-Won Park	<i>Myongji Hospital, Hanyang Univ.</i>
Ji Eun Lee	<i>Severance Hospital</i>	Jun Yong Park	<i>Yonsei Univ.</i>
Jin-Woo Lee	<i>Inha Univ.</i>	Jung Gil Park	<i>Yeungnam Univ.</i>
Jooho Lee	<i>CHA Univ.</i>	Keun-Gyu Park	<i>Kyungpook National Univ.</i>
Joon Hyeok Lee	<i>Sungkyunkwan Univ.</i>	Min Kyung Park	<i>Seoul National Univ.</i>
June Sung Lee	<i>Inje Univ.</i>	Min-Su Park	<i>Kyung Hee Univ.</i>
Jung Il Lee	<i>Yonsei Univ.</i>	Neung Hwa Park	<i>Univ. of Ulsan</i>
Kwang-Woong Lee	<i>Seoul National Univ.</i>	Pyoung Jae Park	<i>Korea Univ.</i>
Minjong Lee	<i>Ewha Womans Univ.</i>	Sang Hoon Park	<i>Hallym Univ.</i>
Nuri Lee	<i>Veterans Health Care Medical Center</i>	Seo Young Park	<i>Korea National Open Univ.</i>
Sae Hwan Lee	<i>Soonchunhyang Univ.</i>	Soo Young Park	<i>Kyungpook National Univ.</i>
Sanghoon Lee	<i>Sungkyunkwan Univ.</i>	Su Cheol Park	<i>Korea Cancer Center Hospital</i>
Sang Hyub Lee	<i>Seoul National Univ.</i>	Sung Jae Park	<i>Inje Univ.</i>
Seung Eun Lee	<i>Chung-Ang Univ.</i>	Young Nyun Park	<i>Yonsei Univ.</i>
Soon Kyu Lee	<i>The Catholic Univ. of Korea</i>	Hyungjin Rhee	<i>Yonsei Univ.</i>
So-Ryoung Lee	<i>Seoul National Univ.</i>	Hyunchul Rhim	<i>Sungkyunkwan Univ.</i>
Sung Hak Lee	<i>The Catholic Univ. of Korea</i>	Seoung Yoon Rho	<i>Yonsei Univ.</i>
Sung Hwan Lee	<i>CHA Univ.</i>	Jinsoo Rhu	<i>Sungkyunkwan Univ.</i>
Sung Won Lee	<i>The Catholic Univ. of Korea</i>	Woo Sun Rou	<i>Chungnam National Univ.</i>
Sunyoung Lee	<i>Yonsei Univ.</i>	Dong-Wan Seo	<i>Univ. of Ulsan</i>
Tae-Hee Lee	<i>Konyang Univ.</i>	Haeng Ran Seo	<i>Institut Pasteur Korea</i>
Young-Mi Lee	<i>Yuhan Corp.</i>	Jessie Jeong Ju Seo	<i>Eisai Korea Inc.</i>
Young-Sun Lee	<i>Korea Univ.</i>	Wonhyo Seo	<i>Ewha Womans Univ.</i>
Yu Rim Lee	<i>Kyungpook National Univ.</i>	Yeon Seok Seo	<i>Korea Univ.</i>
Yun Bin Lee	<i>Seoul National Univ.</i>	Jinsil Seong	<i>Yonsei Univ.</i>
Yun Nah Lee	<i>Soonchunhyang Univ.</i>	Ju Hyun Shim	<i>Univ. of Ulsan</i>
Young-Suk Lim	<i>Univ. of Ulsan</i>	Hyun Phil Shin	<i>Kyung Hee Univ.</i>
Juik Moon	<i>Konyang Univ.</i>	Jung Woo Shin	<i>Univ. of Ulsan</i>

## INVITED FACULTY

Min-Ho Shin	<i>Chonnam National Univ.</i>	Jeong Il Yu	<i>Sungkyunkwan Univ.</i>
Seung Kak Shin	<i>Gachon Univ.</i>	Jung Hwan Yu	<i>Inha Univ.</i>
Joo Hyun Sohn	<i>Hanyang Univ.</i>	Su Jong Yu	<i>Seoul National Univ.</i>
Won Sohn	<i>Sungkyunkwan Univ.</i>	Young-Dong Yu	<i>Korea Univ.</i>
Myung Jin Son	<i>KRIBB</i>	Sung Su Yun	<i>Yeungnam Univ.</i>
Byung-Cheol Song	<i>Jeju National Univ.</i>		
Do Seon Song	<i>The Catholic Univ. of Korea</i>		
Gi-Won Song	<i>Univ. of Ulsan</i>		
Il Han Song	<i>Dankook Univ.</i>		
Jeong Eun Song	<i>Daegu Catholic Univ.</i>		
Myeong Jun Song	<i>The Catholic Univ. of Korea</i>		
Kyung-Suk Suh	<i>Seoul National Univ.</i>		
Ki Tae Suk	<i>Hallym Univ.</i>		
Pil Soo Sung	<i>The Catholic Univ. of Korea</i>		
Eunyoung Tak	<i>Asan Medical Center</i>		
Won Young Tak	<i>Kyungpook National Univ.</i>		
Jin Mo Yang	<i>The Catholic Univ. of Korea</i>		
Jin Seon Yang	<i>Korea Disease Control and Prevention Agency</i>		
Kwangho Yang	<i>Pusan National Univ.</i>		
Jong Eun Yeon	<i>Korea Univ.</i>		
Kiyoun Yi	<i>Pusan National Univ.</i>		
Hyung Joon Yim	<i>Korea Univ.</i>		
Sun Young Yim	<i>Korea Univ.</i>		
Jeong-Ju Yoo	<i>Soonchunhyang Univ.</i>		
Yang Jae Yoo	<i>Korea Univ.</i>		
Eileen L. Yoon	<i>Hanyang Univ.</i>		
Jae Hyun Yoon	<i>Chonnam National Univ.</i>		
Jung-Hwan Yoon	<i>Seoul National Univ.</i>		
Ki Tae Yoon	<i>Pusan National Univ.</i>		
Sang Min Yoon	<i>Univ. of Ulsan</i>		
Seung Kew Yoon	<i>The Catholic Univ. of Korea</i>		
Young Chul Yoon	<i>The Catholic Univ. of Korea</i>		
Ga Ram You	<i>Chonnam National Univ.</i>		
Seng Chan You	<i>Yonsei Univ.</i>		
Young Kyoung You	<i>The Catholic Univ. of Korea</i>		
Hee Chul Yu	<i>Jeonbuk National Univ.</i>		

## 1. Walkerhill Free Shuttle Bus





You can use Free Shuttle Bus at subway stations -  
Gangbyeon Station (Line 2) or Gwangnaru Station (Line 5).

### Free Shuttle Bus Route

The first and last bus time is based on the time of departure.

Interval of 15 min. · First Bus - 06:00AM · Last Bus - 23:30PM

· Gwangnaru Station → Walkerhill: 8 min. · Gangbyeon Station → Walkerhill: 15 min.



## 2. Free Parking

Please park your car in the parking tower.




\* Additional Transportation Information for International Participants



# FLOOR PLAN & SESSION

★ QR Scanner

B2



## DAY 1

Thursday, June 27, 2024

### ROOM 1 Vista I+II

- 09:00-10:40 PG Course 1 K
- 10:55-12:15 PG Course 2 K
- 12:15-13:15 Luncheon Symposium 1 L GILEAD
- 13:15-13:55 New KASL Guidelines 2024 K
- 13:55-15:35 PG Course 3 K
- 15:50-17:10 PG Course 4 K

### ROOM 2 Vista III


- 09:00-10:40 Translational Research 1
- 10:55-12:15 Young Investigator Meeting
- 12:15-13:15 Luncheon Symposium 2 K L abbvie
- 13:15-13:55 Current Issues in Nomenclature for Steatotic Liver Diseases K
- 13:55-15:35 Collaboration Workshop K
- 15:50-17:10 Procedures in Liver Diseases K

# FLOOR PLAN & SESSION


## DAY 2

Friday, June 28, 2024

### ROOM 1 Vista I+II

- 09:10-10:30 KASL Symposium 1
- 10:30-10:50 KASL Leading Research Achievement Award **K**
- 10:50-11:10 **Opening Ceremony**
- 11:10-11:40 Commemorative Lecture
- 11:40-12:40 Plenary Presentation 1
- 12:40-13:30 Luncheon Symposium 3  **L**
- 13:30-14:50 KASL-AASLD Joint Symposium
- 14:50-16:10 KASL Symposium 2


### ROOM 2 Vista III

- 08:00-09:00 Meet the Editor: CMH & AASLD Journals 
- 09:10-10:30 KLCA Symposium 1
- 12:40-13:30 KLCA General Meeting **K** **L**
- 13:30-14:50 KLCA-JLCA Joint Symposium
- 14:50-16:10 KLCA Symposium 2
- 16:10-16:30 HCC in Korea **K**

## DAY 3

Saturday, June 29, 2024

### ROOM 1 Vista I+II

- 09:10-10:30 KASL Symposium 4
- 10:50-11:20 State-of-the-Art Lecture
- 11:20-12:20 Plenary Presentation 2
- 12:20-13:10 Luncheon Symposium 7  **L**
- 13:10-13:40 President's Choice Lecture
- 13:40-15:00 KASL Symposium 5
- 15:20-16:20 The Liver Week 2024 Debrief
- 16:20-16:40 **Closing & Award Ceremony**


### ROOM 2 Vista III

- 08:00-09:00 KASL-AASLD Morning Workshop 
- 09:10-10:30 KLCA-TLCA Joint Symposium
- 12:20-13:10 Luncheon Symposium 8  **L**
- 13:40-15:00 KLCA-KASL Joint Symposium

# FLOOR PLAN & SESSION

★ QR Scanner

**B1**



## DAY 2

Friday, June 28, 2024

### Exhibition Hall

- 16:30-17:30 Oral Poster Presentation
- 17:50-19:00 Welcome Reception

### ROOM 5 Grand IV

- 07:30-08:00 KASL Branch EMW 1
- 08:00-09:00 Radiology Seminar
- 09:10-10:30 Free Paper 1
- 13:30-14:50 Free Paper 2
- 14:50-16:30 Radioembolization Symposium






# FLOOR PLAN & SESSION



## DAY 2

Friday, June 28, 2024

### ROOM 6 Grand V

- 07:30-08:00 KASL Branch EMW 2 
- 08:00-09:00 Basic Research 1  
- 09:10-10:30 Translational Research 2
- 13:30-14:50 Data Science Camp 1
- 14:50-16:10 Data Science Camp 2

### ROOM 7 Grand VI

- 07:30-08:00 KASL Branch EMW 3 
- 08:00-09:00 Industry Forum 1 
- 09:10-10:30 Free Paper 3
- 13:30-14:50 Free Paper 4
- 14:50-16:10 Free Paper 5





## DAY 3

Saturday, June 29, 2024



### Exhibition Hall

- 09:30-10:30 Oral Poster Presentation

### ROOM 5 Grand IV

- 07:30-08:00 KASL Branch EMW 5 
- 08:00-09:00 Pathology Seminar 
- 09:10-10:30 Free Paper 9
- 12:20-13:10 KAHBPS Town Hall Meeting  
- 13:40-15:00 Free Paper 10

### ROOM 6 Grand V

- 07:30-08:00 KASL Branch EMW 6 
- 08:00-09:00 Basic Research 2 
- 09:10-10:30 Free Paper 11
- 13:40-15:00 Special Interest Group 2


### ROOM 7 Grand VI

- 09:10-10:30 Free Paper 12
- 13:40-15:00 Free Paper 13

# FLOOR PLAN & SESSION

1F

★ QR Scanner



## DAY 2

Friday, June 28, 2024

### ROOM 3 Walker I

09:10-10:30 Special Symposium 1

12:40-13:30 Luncheon Symposium 4

13:30-14:50 KASL Symposium 3

14:50-16:10 Special Interest Group 1

16:30-17:50 Hepatology Associates

### ROOM 4 Walker II

09:10-10:30 KLTS Symposium 1

11:40-12:40 KLTS Coordinator Session

12:40-13:30 Luncheon Symposium 5

13:30-14:50 KLTS Symposium 2

14:50-16:10 KLTS Symposium 3

## DAY 1

Thursday, June 27, 2024

### ROOM 3 Walker I

14:00-15:00 Ultrasound Trainee Session

15:10-17:10 Ultrasound Hands-On Course

### ROOM 4 Walker II

14:00-15:00 Ultrasound Trainer Session 1

15:10-17:10 Ultrasound Trainer Session 2

## DAY 3

Saturday, June 29, 2024

### ROOM 3 Walker I

09:10-10:30 Special Symposium 2

12:20-13:10 Luncheon Symposium 9

13:40-15:00 Special Symposium 3

### ROOM 4 Walker II

08:00-09:00 KAHBPS Symposium 1

09:10-10:30 KAHBPS Symposium 2


12:20-13:10 Luncheon Symposium 10

13:40-15:00 KAHBPS Symposium 3

# FLOOR PLAN & SESSION

★ QR Scanner

4F



## DAY 2 Friday, June 28, 2024

### Room 8 Art

- 07:30-08:00 KASL Branch EMW 4 ⓘ
- 09:10-10:30 KLTS-KAHBPS-KLCA Joint Symposium
- 12:40-13:30 Luncheon Symposium 6 DONG-A ST K L
- 13:30-14:50 Health Insurance, Policy Forum K
- 14:50-16:10 KLTS-KAHBPS-KASL Joint Symposium

### ROOM 9 Pine

- 08:00-09:00 Industry Forum 2 ⓘ
- 09:10-10:30 Free Paper 6
- 13:30-14:50 Free Paper 7
- 14:50-16:10 Free Paper 8

### ROOM 10 Oak

- 12:40-13:30 Press Conference (Closed)

## DAY 3 Saturday, June 29, 2024

### ROOM 8 Art

- 07:30-08:00 KASL Branch EMW 7 ⓘ
- 09:10-10:30 Clinical Hepatology K
- 12:20-13:10 Luncheon Symposium 11 BORYUNG L
- 13:40-15:00 Special Interest Group 3

### ROOM 9 Pine

- 09:10-10:30 Free Paper 14
- 13:40-15:00 Free Paper 15

### ROOM 10 Oak

- 12:20-13:10 KASL-CRO MOU (Closed)

# INDUSTRY LUNCHEON SYMPOSIA

**DAY 1** Thursday, June 27, 2024

**L** Lunch box will be served.

<b>Room 1</b> Vista I+II	<p><b>12:15-13:15 Luncheon Symposium 1</b> <i>Sang Hoon Ahn (Yonsei Univ.)</i></p> <p><b>GILEAD</b></p> <p>Patient Centric CHB Treatment Strategy for the Future <i>Maria Buti (Univ. of Barcelona, Spain)</i></p>
<b>Room 2</b> Vista III	<p><b>12:15-13:15 Luncheon Symposium 2</b> <b>K</b> <i>Young-Suk Lim (Univ. of Ulsan)</i></p> <p><b>abbvie</b></p> <p>HCV Cure: Benefits of 8 Weeks Regimen <i>Su Jong Yu (Seoul National Univ.)</i></p> <p>Efficacy and Safety of G/P in Korean Patients with CHC <i>Young-Sun Lee (Korea Univ.)</i></p>

**DAY 2** Friday, June 28, 2024





**L** Lunch box will be served.

<b>Room 1</b> Vista I+II	<p><b>12:40-13:30 Luncheon Symposium 3</b> <i>Won Young Tak (Kyungpook National Univ.)</i></p> <p><b>Roche</b></p> <p>Exploring the Use of Atezolizumab and Bevacizumab Therapy in Earlier Stage HCC <i>Richard S. Finn (Univ. of California Los Angeles, USA)</i></p>
<b>Room 3</b> Walker I	<p><b>12:40-13:30 Luncheon Symposium 4</b> <i>Ari Fahrial Syam (Univ. of Indonesia, Indonesia)</i></p> <p><b>DAEWONG</b></p> <p>Fexuclue: Therapeutic Benefits on GERD <i>Do Hoon Kim (Univ. of Ulsan)</i></p>
<b>Room 4</b> Walker II	<p><b>12:40-13:30 Luncheon Symposium 5</b> <i>Do Young Kim (Yonsei Univ.)</i></p> <p><b>AstraZeneca</b></p> <p>Himalaya: The Only IO-IO Regimen to Demonstrate 4 Year Long-Term OS Outcome in HCC <i>Bo Hyun Kim (National Cancer Center)</i></p>
<b>Room 8</b> Art	<p><b>12:40-13:30 Luncheon Symposium 6</b> <b>K</b></p> <p><b>DONG-A ST</b></p> <p>Development of DA-1726, a Novel GLP-1/Glucagon Receptor Dual Agonist <i>Yuna Chae (Dong-A ST Co., Ltd.)</i></p>

# INDUSTRY LUNCHEON SYMPOSIA

**DAY 3** Saturday, June 29, 2024

**L** Lunch box will be served.

<p><b>Room 1</b> Vista I+II</p>	<p><b>12:20-13:10 Luncheon Symposium 7</b> <i>Moon Seok Choi (Sungkyunkwan Univ.)</i></p> <p>Curable Chronic Hepatitis C: Evolving Treatment Strategies to Eliminate HCV <i>Moon Seok Choi (Sungkyunkwan Univ.)</i></p> <hr/> <p>Advanced and Evolving HCV Treatment in the Era of Pan-Genotypic DAAs: A Pan-Genotypic, Pan-Fibrotic*, PI-Free Treatment Option <i>Wonseok Kang (Sungkyunkwan Univ.)</i></p>	 <p><b>YUHAN</b></p>
<p><b>Room 2</b> Vista III</p>	<p><b>12:20-13:10 Luncheon Symposium 8</b> <i>Yong-Han Paik (Sungkyunkwan Univ.)</i></p> <p>European uHCC Treatment Practice: Why LEN Is Still One of the Optimal Treatment Strategy? <i>Andrea Casadei Gardini (Vita-Salute San Raffaele Univ., Italy)</i></p>	
<p><b>Room 3</b> Walker I</p>	<p><b>12:20-13:10 Luncheon Symposium 9</b> <i>Won Young Tak (Kyungpook National Univ.)</i></p> <p>Effect of BCAA on Muscle Mass in MASLD <i>Seung Up Kim (Yonsei Univ.)</i></p>	
<p><b>Room 4</b> Walker II</p>	<p><b>12:20-13:10 Luncheon Symposium 10</b> <i>Do Young Kim (Yonsei Univ.)</i></p> <p>The Effect of L-Carnitine on Steatosis and Inflammatory Mediators in MASLD <i>Pil Soo Sung (The Catholic Univ. of Korea)</i></p>	
<p><b>Room 8</b> Art</p>	<p><b>12:20-13:10 Luncheon Symposium 11</b> <i>June Sung Lee (Inje Univ.)</i></p> <p>Management of Cachexia in Patients Receiving Chemotherapy or Radiotherapy <i>Sung Won Lee (The Catholic Univ. of Korea)</i></p>	<p><b>BORYUNG</b></p>

The new wave of GERD Treatment, P-CAB

# FEXUOLUE

Fexuprazan hydrochloride



**[Product name]** Fexuolue Tab, 40mg **[Formulation]** Active Pharmaceutical Ingredient: Fexuprazan HCl 40 mg, Additives: lactose hydrate (excipient), mks, Yellow NaCl, Monocrythine Oil, Iron, Magnesium stearate, Copoly Green MUB2 054010038, Copoly White 03030706, Croscarmellose Sodium, Yellow Iron Oxide. **[Appearance]** Pink-cream, oblong, film-coated tablet with the breaking line on the tablet. **[Indication]** Treatment of erosive esophagitis (EE). **[Dosage and Administration]** The Product is administered to adults as follows. • Treatment of erosive esophagitis (EE) + 40 mg is administered orally, once a day for 4 weeks. In the case of patients with untreated esophagitis or symptoms persisting, the administration given for another 4 weeks. The Product can be administered with or without meals. **[Contraindications]** 1) Patients who have a history of hypersensitivity to the Product or its components 2) Patients taking a drug containing statins, rifampin, or clozapine (refer to 10.10). **[Precautions]** 3) Pregnant and lactating women (refer to 10.10). **[Administration to Pregnant and Lactating Women]** 4) Patients who have congenital conditions for factors such as galactosemia, milk-enzyme, Lapp lactase deficiency or 6) concomitant medication, as the medicine contains lactose. **[The following patients should be administered with care.]** 1) Patients with hepatic impairment (no experience of use) 2) Patients with renal impairment (no experience of use) 3) Body fluid refer to 10.10. **[Sustained Release]** 4) Patients who have a history of hypersensitivity or allergy to Yellow NaCl. **[Storage]** Store at temperatures not exceeding 30°C in an airtight container. **[Shelf-life]** 24 months. **[Packaging]** 2011 Box (77 PTP), 5611 Box (77 PTP), 2871 Box (100T Box), 20071 Box. **[Manufactured by]** Daewoong Pharmaceutical Co., Ltd. 1, Donggeonmyeong 2-ro, Dongseong, Heungdeok-gu, Chungbuk, Chungcheongbuk-do, Republic of Korea. \* This medicine has passed strict quality control. If the seal is damaged or expiration date has passed at the time of purchase, or if the drug is swollen, contaminated, or damaged, it can be exchanged or refunded through the pharmacy or drug distributor where it was purchased in accordance with the Fair Trade Commission Notice (Consumer Dispute Resolution Standard). \* Report side effects and apply for damage relief: Korea Pharmaceutical Safety Management Agency (14-2330, 1644-8223).  
 \* For detailed and up-to-date approval information, please refer to the Ministry of Food and Drug Safety's integrated drug information system (<https://mequm.mfds.go.kr>) or the product leaflet.



The Liver Week 2014  
June 12-14, 2014  
Haevichi Hotel & Resort, Jeju, Korea

The Liver Week 2015  
September 10-12, 2015  
BEXCO, Busan, Korea

# DAY 1

## Thursday, June 27, 2024

### Program at a Glance

	ROOM 1 Vista I+II	ROOM 2 Vista III	ROOM 3 Walker I	ROOM 4 Walker II	Exhibition Hall
09:00	<b>PG Course 1</b> <i>Viral Hepatitis</i> 09:00-10:40 (K)	<b>Translational Research 1</b> <i>Non-Oncologic Disorders</i> 09:00-10:40			
10:00					
	Coffee Break 10:40-10:55				
11:00	<b>PG Course 2</b> <i>Alcoholic &amp; Steatotic Liver Diseases</i> 10:55-12:15 (K)	<b>Young Investigator Meeting</b> 10:55-12:15			
12:00					
	<b>Luncheon Symposium 1</b> (L) [Gilead] 12:15-13:15	<b>Luncheon Symposium 2</b> (L) [AbbVie] 12:15-13:15 (K)			Booth & Poster Exhibition
13:00	<b>New KASL Guidelines 2024</b> (K) 13:15-13:55	<b>Current Issues in Nomenclature for SLD</b> (K) 13:15-13:55			
14:00	<b>PG Course 3</b> <i>Cirrhosis &amp; Portal Hypertension</i> 13:55-15:35 (K)	<b>Collaboration Workshop</b> 13:55-15:35 (K)	<b>Ultrasound Trainee Session</b> (K) 14:00-15:00	<b>Ultrasound Trainer Session 1</b> (K) 14:00-15:00	Allday Coffee & Tea Station
15:00			Break		
	Coffee Break 15:35-15:50		<b>Ultrasound Hands-On Course</b> (K) 15:10-17:10	<b>Ultrasound Trainer Session 2</b> (K) 15:10-17:10	
16:00	<b>PG Course 4</b> <i>Liver Neoplasms</i> 15:50-17:10 (K)	<b>Procedures in Liver Diseases</b> (K) 15:50-17:10			
17:00					
18:00	<b>Faculty Dinner</b> 18:00-20:00 * Invitation Only *				
19:00					
20:00					



PG Courses & Parallel Sessions: Practical Steps for Moving Forward with Precision Hepatology

## ROOM 1 / VISTA I+II

### PG Course 1

#### 09:00-10:40 *Viral Hepatitis*

*Chul Ju Han (Korea Cancer Center Hospital), Hyung Joon Kim (Chung-Ang Univ.)*

- 09:00-09:25 Recent Strategies for Hepatitis B Virus Treatment: When and for Whom?  
*Jun Yong Park (Yonsei Univ.)*
- 09:25-09:50 Novel Anti-HBV Drugs Close to the Practice  
*Nae-Yun Heo (Inje Univ.)*
- 09:50-10:15 Treatment of Chronic Hepatitis C in Difficult-to-Treat Patients with Various Comorbidities  
*Jung Hyun Kwon (The Catholic Univ. of Korea)*
- 10:15-10:40 Viral Hepatitis Elimination: Progress Towards WHO's 2030 Goal - Where Are We Now?  
*In Hee Kim (Jeonbuk National Univ.)*

## ROOM 2 / VISTA III

### Translational Research 1

#### 09:00-10:40 *Microbiomes and Signaling Dynamics in Liver Disorders*

*Young Seok Kim (Soonchunhyang Univ.), Wonhyo Seo (Ewha Womans Univ.)*

- 09:00-09:25 Functional Microbiomes in Immune Homeostasis in Liver Transplant Patients  
*Soon Kyu Lee (The Catholic Univ. of Korea)*
- 09:25-09:50 Microbiome-Released Metabolites to Modulate Liver Disease  
*Ki Tae Suk (Hallym Univ.)*
- 09:50-10:15 Friend or Foe: Neurological Transmitter and Alcohol-Associated Liver Disease  
*Won-Il Jeong (KAIST)*
- 10:15-10:40 Inflammasome: Key Factor to Progress Liver Inflammation and Fibrosis  
*Yong-Hyun Han (Kangwon National Univ.)*

## ROOM 1 / VISTA I+II

**PG Course 2** 


**10:55-12:15** *Alcoholic and Steatotic Liver Diseases*  
*Kwang Cheol Koh (Sungkyunkwan Univ.), Sehyun Cho (The Catholic Univ. of Korea)*

- 10:55-11:15 Alcohol and Its Contribution to Steatotic Liver Disease  
*Young-Joo Jin (Inha Univ.)*
- 11:15-11:35 Alcohol Use Disorders in Liver Transplant Recipients  
*Bong-Jin Hahm (Seoul National Univ.)*
- 11:35-11:55 Extrahepatic Complications of Steatotic Liver Disease  
*Seung Kak Shin (Gachon Univ.)*
- 11:55-12:15 Multidisciplinary Approach to the Management of Steatotic Liver Disease  
*Hyuk Soo Eun (Chungnam National Univ.)*

## ROOM 2 / VISTA III

**Young Investigator Meeting**

**10:55-12:15** *Inspiring the Next Wave: A Roadmap for Young Investigators in Academia*  
*Soon Koo Baik (Yonsei Univ. Wonju), Young-Suk Lim (Univ. of Ulsan)*


- 10:55-11:25 Why Should We Pursue an Academic Career?   
*Soon Koo Baik (Yonsei Univ. Wonju)*
- 11:25-11:50 From Research to Manuscript: Case 1  
*Won-Mook Choi (Univ. of Ulsan)*
- 11:50-12:15 From Research to Manuscript: Case 2  
*Han Ah Lee (Chung-Ang Univ.)*

## ROOM 1 / VISTA I+II

**13:15-13:55** **New KASL Guidelines 2024**   
*Young Oh Kweon (Kyungpook National Univ.)*

13:15-13:55 KASL Clinical Practice Guidelines for Noninvasive Tests to Assess Liver Fibrosis in Chronic Liver Disease  
*Seung Up Kim (Yonsei Univ.)*

## ROOM 2 / VISTA III

**13:15-13:55** **Current Issues in Nomenclature for Steatotic Liver Diseases**   
*Korean Terminology for Steatotic Liver Diseases*  
*Yoon Jun Kim (Seoul National Univ.)*

13:15-13:25 Historical Background: Transition from NAFLD to SLD  
*Su Jong Yu (Seoul National Univ.)*

13:25-13:45 Critical Appraisal: MAFLD vs MASLD  
*Won Sohn (Sungkyunkwan Univ.)*

13:45-13:55 KASL's Perspective  
*Byoung Kuk Jang (Keimyung Univ.)*

## ROOM 1 / VISTA I+II

**13:55-15:35** **PG Course 3**   
***Cirrhosis and Portal Hypertension***  
*So Young Kwon (Konkuk Univ.), Il Han Song (Dankook Univ.)*

13:55-14:20 Pathophysiology, Diagnosis, and Management of HRS-AKI in Cirrhosis  
*Seong Hee Kang (Korea Univ.)*

14:20-14:45 When to Start and Stop Anticoagulation Therapy for Benign Portal Vein Thrombosis  
*Jung Gil Park (Yeungnam Univ.)*

14:45-15:10 Ammonia: Predictive Marker and Therapeutic Target in Cirrhotic Complications  
*Do Seon Song (The Catholic Univ. of Korea)*

15:10-15:35 Differentiation and Management of Infected Ascites in Patients with Cirrhosis  
*Danbi Lee (Univ. of Ulsan)*

## ROOM 2 / VISTA III

**Collaboration Workshop** 

13:55-15:35

**Uniting Two Worlds: Success Stories in Basic and Clinical Research Collaboration***Neung Hwa Park (Univ. of Ulsan), Yong-Han Paik (Sungkyunkwan Univ.)*

13:55-14:20

Intervening to Improve Collaboration in Translational Research:  
A Basic Scientist's Perspective  
*Sang Geon Kim (Dongguk Univ.)*

14:20-14:45

Intervening to Improve Collaboration in Translational Research:  
A Clinician's Perspective  
*Jaeyoun Cheong (Ajou Univ.)*

14:45-15:10

Positive Collaboration Experiences: Case 1 (Basic)  
*Wonhyo Seo (Ewha Womans Univ.)*

15:10-15:35

Positive Collaboration Experiences: Case 2 (Clinical)  
*Hyun Woong Lee (Yonsei Univ.)*

## ROOM 3 / WALKER I

14:00-15:00

**Ultrasound Trainee Session** *Moon Young Kim (Yonsei Univ. Wonju)*

14:00-14:30

The Beginning of Abdominal US: Anatomy of US  
*Young Chang (Soonchunhyang Univ.)*

14:30-15:00

How to Get 12 Masterpiece Photos from US Scan  
*Young Youn Cho (Chung-Ang Univ.)*

**Ultrasound Hands-On Course** 

15:10-17:10

*Tutor: Nae-Yun Heo (Inje Univ.), Woo Sun Rou (Chungnam National Univ.),  
Hae Lim Lee (The Catholic Univ. of Korea), Yang Jae Yoo (Korea Univ.)*

- \* 대한내과학회 전공의 초음파교육은 6월 27일(목), Ultrasound Trainee Session과 Ultrasound Hands-On Course 수강 시 인정됩니다.
- \* 위 평점이 필요하신 경우, 꼭 해당 Room 앞에서 **입실 및 퇴실시 QR을 스캔**하여 주시기 바랍니다.

## ROOM 4 / WALKER II

**14:00-15:00** **Ultrasound Trainer Session 1** **K***Jae Young Jang (Soonchunhyang Univ.)*

- 14:00-14:30 Ultrasound Training in Korea: Current and Future Perspective  
*Tae-Suk Kim (Kangwon National Univ.)*
- 14:30-15:00 Quality Improvement and Patient Safety in US Examination  
*Hyo Jung Cho (Ajou Univ.)*

**15:10-17:10** **Ultrasound Trainer Session 2** **K***Soon Koo Baik (Yonsei Univ. Wonju), Young Seok Kim (Soonchunhyang Univ.)*

- 15:10-15:30 What Is the Role of US and Elastography in the MASLD Era?  
*Hye Won Lee (Yonsei Univ.)*
- 15:30-15:50 Clinical Practice Guidelines for the Management of Benign Neoplasm of Liver  
*Janghan Jung (Hallym Univ.)*
- 15:50-16:10 Liver Doppler: When and How to Use It?  
*Soung Won Jeong (Soonchunhyang Univ.)*
- 16:10-16:30 Case-Based Approach of RFA  
*Soo Young Park (Kyungpook National Univ.)*
- 16:30-16:50 Complications during Liver Intervention  
*Yu Rim Lee (Kyungpook National Univ.)*
- 16:50-17:10 Overview in AI Applications to US Imaging  
*Seung Kak Shin (Gachon Univ.)*

\* 대한간학회 복부초음파 세부전문의, 대한임상초음파학회 평점은 6월 27일(목), Ultrasound Trainer Session 또는 Ultrasound Trainee Session & Abdominal Ultrasound Hands-On Course 수강 시 인정됩니다.

\* 대한내과학회 초음파 지도전문의 교육 평점은 6월 27일(목), Ultrasound Trainer Session 수강 시 인정됩니다.

\* 위 평점이 필요하신 경우, 꼭 해당 Room 앞에서 **입실 및 퇴실시 QR**을 스캔하여 주시기 바랍니다.

## ROOM 1 / VISTA I+II

**PG Course 4** **15:50-17:10** *Liver Neoplasms**Jin Mo Yang (The Catholic Univ. of Korea), Sung Kyu Choi (Chonnam National Univ.)*

15:50-16:10 The Difference in Pathogenesis and Clinical Care between MASLD- and Viral-Related HCC

*Young-Sun Lee (Korea Univ.)*

16:10-16:30 Advances in the Imaging Diagnosis and Evaluation of Solid Liver Lesions

*Dong Ho Lee (Seoul National Univ.)*

16:30-16:50 Subclassification-Based Treatment Strategies for BCLC Stages B and C HCC

*Sang Youn Hwang (Dongnam Institute of Radiological & Medical Sciences)*

16:50-17:10 Recent Updates on the Management of Intrahepatic Cholangiocarcinoma

*Joo Kyung Park (Sungkyunkwan Univ.)*

## ROOM 2 / VISTA III

**Procedures in Liver Diseases** **15:50-17:10** *Advances in Diagnostic and Therapeutic Procedures for Liver Disease**Byung Ik Kim (Sungkyunkwan Univ.), Jaeseok Hwang (Keimyung Univ.)*

15:50-16:10 Approach and Precautions for Liver Biopsy

*Bohyun Kim (The Catholic Univ. of Korea)*

16:10-16:30 Role of Contrast-Enhanced Ultrasound in Liver Disease

*Jooho Lee (CHA Univ.)*

16:30-16:50 Endoscopic Treatments for Variceal Bleeding

*Byung Seok Kim (Daegu Catholic Univ.)*

16:50-17:10 Interventional Approaches for Portal Hypertension-Related Complications

*Hee Ho Chu (Univ. of Ulsan)*

gnostic fibrosis

1000	0.000
2000	0.000
3000	0.000
4000	0.000
5000	0.000
6000	0.000
7000	0.000
8000	0.000
9000	0.000
10000	0.000



# The Liver Week 2016

"Next Wave in Hepatology"

June 16-18, 2016 | Grand Hyatt Incheon, Korea | [www.theliverweek.org](http://www.theliverweek.org)



# The Liver Week 2017

Striving for a Complete Cure of Liver Disease

June 22-24, 2017 | Grand Hyatt Incheon, Korea



PROGRAM  
Friday, June 28, 2024

The Liver Week 2016  
June 16-18, 2016  
Grand Hyatt, Incheon, Korea

The Liver Week 2017  
June 22-24, 2017  
Grand Hyatt, Incheon, Korea

# DAY 2

Friday, June 28, 2024

## Program at a Glance

	ROOM 1 Vista I+II	ROOM 2 Vista III	ROOM 3 Walker I	ROOM 4 Walker II	Exhibition Hall
07:30					
08:00		Meet the Editor CMH & AASLD Journals			
09:00		08:00-09:00			
10:00	KASL Symposium 1 <i>Chronic Viral Hepatitis</i> 09:10-10:30	KLCA Symposium 1 <i>Translational Tools for HCC</i> 09:10-10:30	Special Symposium 1 <i>Practice Guidelines</i> 09:10-10:30	KLTS Symposium 1 <i>Unusual Liver Transplants</i> 09:10-10:30	
	KASL Leading Research Achievement Award 10:30-10:50		Coffee Break 10:30-10:50		
11:00	Opening Ceremony 10:50-11:10				
	Commemorative Lecture: Prof. W. Ray Kim 11:10-11:40				
12:00	Plenary Presentation 1 11:40-12:40			KLTS Coordinator Session 11:40-12:40	Booth & Poster Exhibition
13:00	Luncheon Symposium 3 [Roche] 12:40-13:30	KLCA General Meeting 12:40-13:30	Luncheon Symposium 4 [Daewoong] 12:40-13:30	Luncheon Symposium 5 [AstraZeneca] 12:40-13:30	—
14:00	KASL-AASLD Joint Symposium <i>Risks and Therapies for HCC</i> 13:30-14:50	KLCA-JLCA Joint Symposium <i>10 Strategies for HCC</i> 13:30-14:50	KASL Symposium 3 <i>Steatotic Liver Disease</i> 13:30-14:50	KLTS Symposium 2 <i>Complications of Liver Transplant</i> 13:30-14:50	Allday Coffee & Tea Station
15:00	KASL Symposium 2 <i>Alcohol-Related Liver Disease</i> 14:50-16:10	KLCA Symposium 2 <i>Evolving Cares for HCC</i> 14:50-16:10	Special Interest Group 1 <i>ACLF</i> 14:50-16:10	KLTS Symposium 3 <i>Minimally Invasive Transplantation</i> 14:50-16:10	
16:00		HCC in Korea 16:10-16:30	Coffee Break 16:10-16:30		
17:00			Hepatology Associates 16:30-17:50		Oral Poster Presentation 16:30-17:30
18:00					Welcome Reception 17:50-19:00
19:00					*All Participants*



# Program at a Glance

# DAY 2

Friday, June 28, 2024

ROOM 5 Grand IV	ROOM 6 Grand V	ROOM 7 Grand VI	ROOM 8 Art	ROOM 9 Pine	ROOM 10 Oak
KASL Branch EMW 1	KASL Branch EMW 2	KASL Branch EMW 3	KASL Branch EMW 4		
Radiology Seminar <i>LI-RADS</i> 08:00-09:00	Basic Research 1 <i>Spatial and Organoid Techniques</i> 08:00-09:00	Industry Forum 1 08:00-09:00		Industry Forum 2 08:00-08:40	
Free Paper 1 <i>MASLD, Clinical</i> 09:10-10:30	Translational Research 2 <i>Hepatic Oncology</i> 09:10-10:30	Free Paper 3 <i>LC &amp; Others, Basic</i> 09:10-10:30	KLTS-KAHBPS -KLCA Joint Symposium <i>HCC with Biliary Invasion</i> 09:10-10:30	Free Paper 6 <i>DILI &amp; Infectious Disease</i> 09:10-10:30	
Coffee Break 10:30-10:50					
			Luncheon Symposium 6 [Dong-A ST] 12:40-13:30		Press Conference (Closed)
Free Paper 2 <i>HCC, Clinical 1</i> 13:30-14:50	Data Science Camp 1 <i>Statistical Methodologies</i> 13:30-14:50	Free Paper 4 <i>Surgery, Technical Issues</i> 13:30-14:50	Health Insurance, Policy Forum 13:30-14:50	Free Paper 7 <i>ALD &amp; Genetics</i> 13:30-14:50	
Radioembolization Symposium 14:50-16:30	Data Science Camp 2 <i>Health Data Researches</i> 14:50-16:10	Free Paper 5 <i>HCC, Basic</i> 14:50-16:10	KLTS-KAHBPS -KASL Joint Symposium <i>Cystic Liver Disease</i> 14:50-16:10	Free Paper 8 <i>Autoimmune Disease</i> 14:50-16:10	

**ROOM 5 / GRAND IV**

**KASL Branch EMW 1 [Gwangju-Chonnam]** 

07:30-08:00

*Strategies to Reach HCV Elimination in Prevalent Lesion of Korea*

*Gun Young Hong (Kwangju Christian Hospital),  
Sung Bum Cho (Chonnam National Univ.)*

07:30-07:45

Overview of HCV in Gwangju and Cheolla Province  
*Ga Ram You (Chonnam National Univ.)*

07:45-08:00

Strategies to HCV Elimination  
*Jae Hyun Yoon (Chonnam National Univ.)*

**ROOM 6 / GRAND V**

07:30-08:00

**KASL Branch EMW 2 [Daejeon-Sejong-Chungcheong]** 

*Tae-Hee Lee (Konyang Univ.)*

07:30-07:50

Management of High-Risk HCC Patients  
*Myeong Jun Song (The Catholic Univ. of Korea)*

07:50-08:00

Discussion

**ROOM 7 / GRAND VI**

**KASL Branch EMW 3 [Gangwon]** 

07:30-08:00

*Research Journey of Gangwon Branch of KASL: Cirrhosis and Its Complications*

*Gab Jin Cheon (Univ. of Ulsan)*

07:30-07:40

History and Clinical Indications of NSBB  
*Seul Ki Han (Yonsei Univ. Wonju)*


07:40-07:50

New Insights of SEPSIS-3  
*Tae-Suk Kim (Kangwon National Univ.)*

07:50-08:00

Panel Discussion  
*Panelist: Sang Gyune Kim (Soonchunhyang Univ.),  
Moon Young Kim (Yonsei Univ. Wonju)*

## ROOM 8 / ART

**07:30-08:00 KASL Branch EMW 4 [Gyeonggi-Incheon]** 
  
*Soon Woo Nam (The Catholic Univ. of Korea)*


- 07:30-07:40 Before and After TIPS: Practical Insights from the Perspective of Internal Medicine  
*Min Kyung Park (Seoul National Univ.)*
- 07:40-07:50 Before and After TIPS: Practical Insights from the Perspective of Radiology  
*Taewon Choi (Ajou Univ.)*
- 07:50-08:00 Discussion

## ROOM 2 / VISTA III

**08:00-09:00 Meet the Editor** 
  
**CMH & AASLD Journals**  
*Guadalupe Garcia-Tsao (Yale Univ., USA), Yoon Jun Kim (Seoul National Univ.)*

- 08:00-08:15 Tips for Getting an Acceptance from AASLD Journals  
*Elliot B. Tapper (Univ. of Michigan, USA)*
- 08:15-08:30 Tips for Getting an Acceptance from CMH  
*Won Kim (Seoul National Univ.)*
- 08:30-08:45 Hepatology Editor's Picks: Noticeable Publications in 2023-2024  
*Yujin Hoshida (Univ. of Texas Southwestern Medical Center, USA)*
- 08:45-09:00 CMH Editor's Picks: Noticeable Publications in 2023-2024  
*Seung Up Kim (Yonsei Univ.)*

## ROOM 5 / GRAND IV

**08:00-09:00 Radiology Seminar** 
  
**LI-RADS in Focus: Past, Present, and Future Challenges in HCC Imaging**  
*So Yeon Kim (Univ. of Ulsan), Sung Won Lee (The Catholic Univ. of Korea)*

- 08:00-08:20 Past and Present of LI-RADS in HCC Diagnosis  
*Sunyoung Lee (Yonsei Univ.)*
- 08:20-08:40 LI-RADS: It Is Time to Focus on Prognosis  
*Subin Heo (Univ. of Ulsan)*
- 08:40-09:00 Future Perspectives and New Challenges in LI-RADS  
*Hanyu Jiang (Sichuan Univ., China)*

ROOM 6 / GRAND V

**Basic Research 1**  

**08:00-09:00** *From Cells and Systems: Spatial and Organoid Technologies*  
Sang Geon Kim (Dongguk Univ.), Haeng Ran Seo (Institut Pasteur Korea)

08:00-08:25 Understanding Spatial Transcriptomics in Hepatology:  
From Sample Preparation to Application  
*Kwon Joong Na (Seoul National Univ.)*

08:25-08:50 Emerging Organoid Technologies to Apply for Precision Medicine  
in Hepatology  
*Myung Jin Son (Korea Research Institute of Bioscience and Biotechnology)*

08:50-09:00 Discussion

ROOM 7 / GRAND VI

**08:00-09:00** **Industry Forum 1 with**  **YUHAN**  **DAEWOONG**  **GILEAD**   
*Jae Seung Lee (Yonsei Univ.)*

08:00-08:20 MASH (Metabolic Steatohepatitis) & Fibrosis, and Beyond  
*Se-Woong Oh (Yuhan Corp.)*

08:20-08:40 Re-Evaluation of the Efficacy of UDCA Tab. 100 mg in  
Liver Function Improvement  
*Hye Jung Lee (Daewoong Pharmaceutical Co., Ltd.)*  
*Jae Young Jang (Soonchunhyang Univ.)*

08:40-09:00 Gilead's Commitment to Liver Diseases  
*Leland Yee (Gilead Sciences, USA)*

ROOM 9 / PINE

**08:00-08:40** **Industry Forum 2 with**  **Roche**  **Eisai**   
*Yu Rim Lee (Kyungpook National Univ.)*

08:00-08:20 Developing the Next Generation of Treatments  
for HCC: A Perspective from Roche/Genentech  
*Steve Hack (Genentech)*

 **Real-Time Lecture**

08:20-08:40 Corporate Social Innovation (Eisai, Human Health Care Company)  
*Jessie Jeong Ju Seo (Eisai Korea Inc.)*

## ROOM 1 / VISTA I+II

**KASL Symposium 1**

**09:10-10:30** *Tailoring Hepatitis Management: From Antiviral Therapy to Post-Cure Surveillance*

*Man-Fung Yuen (The Univ. of Hong Kong, Hong Kong), Jong Eun Yeon (Korea Univ.)*

09:10-09:30 Standardized and Individualized Criteria for Cessation of Antiviral Therapy in Chronic Hepatitis B  
*Hyung Joon Yim (Korea Univ.)*

09:30-09:50 Monitoring and Prevention of Reactive and Progressive Properties of Occult Hepatitis B Virus Infection  
*Jeong Won Jang (The Catholic Univ. of Korea)*

09:50-10:10 Precision Strategy for HCC Surveillance after Curing Hepatitis C: Debates across Guidelines  
*Tatsuya Kanto (National Center for Global Health and Medicine, Japan)*

10:10-10:30 Experimental Drugs and Therapeutic Endpoints of Chronic Hepatitis D  
*Maria Buti (Univ. of Barcelona, Spain)*

## ROOM 2 / VISTA III

**KLCA Symposium 1**

**09:10-10:30** *Cutting-Edge Translational Tools for HCC*

*Hyunchul Rhim (Sungkyunkwan Univ.), Young Nyun Park (Yonsei Univ.)*

09:10-09:30 Current and Future Perspective of Spatial Omics in HCC  
*Junil Kim (Soongsil Univ.)*

09:30-09:50 Precision Medicine for Designing Future Clinical Trials for Immuno-Oncology Treatment  
*Sun Young Yim (Korea Univ.)*

09:50-10:10 Radiogenomics and Radiomics in Liver Cancers  
*Hyungjin Rhee (Yonsei Univ.)*

10:10-10:30 Discovery of Blood Biomarkers for Immune-Based Treatments of HCC: Protein vs. cfDNA/snRNA  
*Hye Won Lee (Yonsei Univ.)*

ROOM 3 / WALKER I

**Special Symposium 1**

**09:10-10:30** *Evolving Standards in Liver Disease Management: Guidelines from Theory to Practice*

*Masatoshi Kudo (Kindai Univ., Japan), Woo Jin Chung (Keimyung Univ.)*

09:10-09:30 *Attributes and Principles for Better Practice Guidelines: An Experience on the KLCA-NCC Korea HCC Guidelines*  
*Joong-Won Park (Myongji Hospital, Hanyang Univ.)*

*Cornerstones and Issues of High-Quality Guidelines in Recent Years*

09:30-10:00 *AASLD Guidelines on Clinical Assessment and Management of MASLD*  
*Rohit Loomba (Univ. of California San Diego, USA)*

 **Real-Time Lecture**

10:00-10:30 *EASL Guidelines on Vascular Liver Disease*  
*Pierre-Emmanuel Rautou (Université Paris-Cité, France)*

ROOM 4 / WALKER II

**KLTS Symposium 1**

**09:10-10:30** *Beyond Boundaries: The Promise of Liver Transplants in Unusual Situations*

*Gi-Won Song (Univ. of Ulsan), Wipusit Taesombat (Chulalongkorn Univ., Thailand)*

09:10-09:30 *Patient Selection and Result for Unresectable Hepatic Metastasis from Colorectal Cancer*  
*Jongman Kim (Sungkyunkwan Univ.)*

09:30-09:50 *Perihilar Cholangiocarcinoma: Current Strategy and Future Directions*  
*Julie K. Heimbach (Mayo Clinic, USA)*

09:50-10:10 *The Role of Liver Transplantation for Intrahepatic Cholangiocarcinoma*  
*Ho Joong Choi (The Catholic Univ. of Korea)*

10:10-10:30 *HCC with Portal Vein Tumor Thrombosis*  
*Kwangho Yang (Pusan National Univ.)*

ROOM 6 / GRAND V

**Translational Research 2**

**09:10-10:30** *Metabolic Mechanisms and Therapeutic Innovations in Hepatic Oncology*

*Seung Kew Yoon (The Catholic Univ. of Korea), Won-Il Jeong (KAIST)*

09:10-09:40 HCC in RNA Biology: Long Concoding RNA/miRNA and Circular RNA in HCC

*Jungwook Hwang (Hanyang Univ.)*

09:40-10:05 Dysregulation of Liver Regeneration by Hepatitis B Virus Infection: Impact on Development of HCC

*Kyun-Hwan Kim (Sungkyunkwan Univ.)*

10:05-10:30 Modulation of Amino Acid Metabolism as a Therapeutic Target of Liver Cancer

*Keun-Gyu Park (Kyungpook National Univ.)*

ROOM 8 / ART

**KLTS-KAHBPS-KLCA Joint Symposium**

**09:10-10:30** *Multidisciplinary Approaches for HCC with Bile Duct Invasion*

*Yi-Hsiang Huang (National Yang Ming Chiao Tung Univ., Taiwan), Kyung-Suk Suh (Seoul National Univ.)*

09:10-09:20 Case Presentation 1. Internal Medicine  
*Yuri Cho (National Cancer Center)*

09:20-09:30 Case Presentation 2. Surgery  
*Jae Geun Lee (Yonsei Univ.)*

09:30-09:50 Endoscopic and Percutaneous Biliary Decompression  
*Sang Hyub Lee (Seoul National Univ.)*

 Real-Time Lecture

09:50-10:10 Transarterial Intervention Treatments  
*Dongho Hyun (Sungkyunkwan Univ.)*

10:10-10:30 Liver Resection and Transplantation  
*Xiao Xu (Zhejiang Univ., China)*

ROOM 1 / VISTA I+II **ROOM 2 / VISTA III**  Live

**10:30-10:50 KASL Leading Research Achievement Award** 

10:30-10:50 Current Status of Steatotic Liver Disease in Korea  
*Won Kim (Seoul National Univ.)*

**10:50-11:10 Opening Ceremony**

**11:10-11:40 Commemorative Lecture**  
*Young Oh Kweon (Kyungpook National Univ.)*

11:10-11:40 The Journey of a Hepatologist  
*W. Ray Kim (Stanford Univ., USA)*

**11:40-12:40 Plenary Presentation 1**  
*Kyung Sik Kim (Yonsei Univ.), Han Chu Lee (Univ. of Ulsan), Kwang-Woong Lee (Seoul National Univ.)*

11:40-11:55 [PP 1-1] Transarterial Radioembolization versus Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma with Portal Vein Thrombosis  
*Youngsu Park (Seoul National Univ.)*

11:55-12:10 [PP 1-2] LI-RADS Imaging Diagnosis of Hepatocellular Carcinoma in Noncirrhotic Patients with Chronic Hepatitis C: A Multicenter Development and Validation Cohort  
*Ha Il Kim (Hanyang Univ.)*

12:10-12:25 [PP 1-3] Anatomical Risk Factors for Portal Vein Complications Following Right Hepatectomy in Living Donors: Analysis of Results from 4720 Cases  
*Young-In Yoon (Univ. of Ulsan)*

12:25-12:40 [PP 1-4] Persistent Systemic Inflammation Is Important Driver of Acute-on-Chronic Liver Failure and Organ Failure Development  
*Do Seon Song (The Catholic Univ. of Korea)*



## ROOM 4 / WALKER II

**KLTS Coordinator Session** **11:40-12:40** *Concerns for Living Liver Donors**Kyoung Ock Jeon (Severance Hospital), Seungheui Hong (Samsung Medical Center)*

11:40-12:10 Long-Term Follow-Up and Support Programs for Living Liver Donors in Korea

*YoungRok Choi (Seoul National Univ.)*

12:10-12:25 Current Status of Living Liver Donor Management at Low Volume Center

*Minkyung Nam (Hanyang Univ. Hospital)*

12:25-12:40 Considerations for Liver Donor Management

*Ji Eun Lee (Severance Hospital)*

## ROOM 2 / VISTA III

**12:40-13:30** **KLCA General Meeting** 

## ROOM 1 / VISTA I+II

**KASL-AASLD Joint Symposium****13:30-14:50** *HCC Evolution: Understanding Risks and Therapeutic Approaches**W. Ray Kim (Stanford Univ., USA), Si Hyun Bae (The Catholic Univ. of Korea)*

13:30-13:50 Temporal and Spatial Cancer Evolution of Dysplastic Nodules in the Liver

*Ju Hyun Shim (Univ. of Ulsan)*

13:50-14:10 Genomic and Epigenetic Clues to Persistent Risk of HCC after Curing Hepatitis C

*Yujin Hoshida (Univ. of Texas Southwestern Medical Center, USA)*

14:10-14:30 Clinical and Subclinical Risk Factors of Non-Viral HCC: Is It Preventable?

*Do Young Kim (Yonsei Univ.)*

14:30-14:50 Guidelines and Evidence-Based Recommendations for Sequential Systemic Therapy of HCC

*Grace L. Su (Univ. of Michigan, USA)*

**ROOM 2 / VISTA III**

**KLCA-JLCA Joint Symposium**

- 13:30-14:50** *Paving the Way Forward: Novel Immunotherapy Strategies for HCC*  
*Jong Young Choi (The Catholic Univ. of Korea), Michiie Sakamoto (Keio Univ., Japan)*
- 13:30-13:50 *Trailblazing First-Line Therapies: Which Immuno-Oncology Therapy Would Be the Best for Advanced HCC?*  
*Yong-Han Paik (Sungkyunkwan Univ.)*
- 13:50-14:10 *Navigating the Post-Immunotherapy: Second-Line Options for HCC*  
*Masatoshi Kudo (Kindai Univ., Japan)*
- 14:10-14:30 *Overcoming Resistance and Relapse against HCC Immunotherapy*  
*Pil Soo Sung (The Catholic Univ. of Korea)*
- 14:30-14:50 *Predictive Biomarker Research of Combination Immunotherapy: Current Status and Future Perspectives*  
*Takahiro Kodama (Osaka Univ., Japan)*

**ROOM 3 / WALKER I**

**KASL Symposium 3**

- 13:30-14:50** *Emerging Therapies and Diagnostics in Steatotic Liver Disease*  
*Sang Hoon Park (Hallym Univ.), Won Kim (Seoul National Univ.)*
- 13:30-13:50 *Clinical Data Based on Old NAFLD and New MASLD: Shared vs. Separated*  
*Mark Muthiah (National Univ. Hospital, Singapore)*
- 13:50-14:10 *Diagnostic Criteria and Clinical Impact of Steatotic Liver Disease Sub-Classification*  
*Byoung Kuk Jang (Keimyung Univ.)*
- 14:10-14:30 *Pathophysiology-Based Treatment Targets and Successful Trials in MASH*  
*Mi Na Kim (Yonsei Univ.)*
- 14:30-14:50 *Tumor Immunity and Immunotherapeutic Susceptibility of Steatotic HCC*  
*Tetsuo Takehara (Osaka Univ., Japan)*

## ROOM 4 / WALKER II

**KLTS Symposium 2**

**13:30-14:50** *A Little Less Seriously: Can Long-Term Complications Be Prevented in Liver Transplantation?*

*Dong-Sik Kim (Korea Univ.), Dong Jin Joo (Yonsei Univ.)*

13:30-13:50 De Novo Malignancies: Long-Term Experience and Surveillance Strategy  
*Woo-Hyoung Kang (Univ. of Ulsan)*

13:50-14:10 How to Prevent Chronic Kidney Disease after Liver Transplantation?  
*Jae Geun Lee (Yonsei Univ.)*

14:10-14:30 Treading a Tightrope: A Strategy That Provides Minimal Immune Suppression While Reducing Rejection and Graft Fibrosis  
*Sanghoon Lee (Sungkyunkwan Univ.)*

14:30-14:50 Physical Therapy and Exercise to Improve Quality of Life after Liver Transplantation  
*Won Kim (Univ. of Ulsan)*

## ROOM 6 / GRAND V

**Data Science Camp 1**

**13:30-14:50** *Statistical Methodologies in Clinical Research*

*Geum-Youn Gwak (Sungkyunkwan Univ.), Sangwook Kang (Yonsei Univ.)*

13:30-13:50 Practical Approach for Causal Inference  
*Danbee Kang (Sungkyunkwan Univ.)*

13:50-14:10 Advanced Survival Analysis  
*Seo Young Park (Korea National Open Univ.)*

14:10-14:30 Development of Clinical Prediction Models  
*Sehee Kim (Univ. of Ulsan)*

14:30-14:50 Various Model Performance Measures  
*Seungbong Han (Korea Univ.)*

ROOM 8 / ART

**Health Insurance and Policy Forum K**

**13:30-14:50** *In Hee Kim (Jeonbuk National Univ.), Hyun Woong Lee (Yonsei Univ.)*  
*Panelist: Jin Sun Yang (Korea Disease Control and Prevention Agency)*

- 13:30-13:50 Quality Assessment of Liver Cancer Care in Korea: A Comprehensive Approach and Future Challenge  
*Nam Young Kim (Health Insurance Review & Assessment Service)*
- 13:50-14:10 Process and Criteria for the Reimbursement of Oncologic Pharmacotherapies  
*Mi Young Kang (Health Insurance Review & Assessment Service)*
- 14:10-14:30 Management Model after Screening for Viral Hepatitis B and C in Korea  
*Young Chang (Soonchunhyang Univ.)*
- 14:30-14:50 Local Government-Based Hepatitis C Elimination Project: Jeollanam-do Performance Report  
*Min-Ho Shin (Chonnam National Univ.)*

ROOM 1 / VISTA I+II

**KASL Symposium 2**

**14:50-16:10** *Comprehensive Approaches in Alcohol-Related Liver Disease: From Genetics to Therapy*  
*Ki Tae Suk (Hallym Univ.), Won Hyeok Choe (Konkuk Univ.)*

- 14:50-15:10 Genetic Vulnerabilities of Alcohol-Related Hepatitis and HCC in the East and West  
*Jean-Charles Nault (Sorbonne Université, France)*
- 15:10-15:30 Biomarkers in Alcohol-Related Liver Diseases  
*Pierre-Emmanuel Rautou (Université Paris-Cité, France)*
- 15:30-15:50 Principles of and Debates on Indication and Duration of Use of Corticosteroids in Severe Alcoholic Hepatitis  
*Young Kul Jung (Korea Univ.)*
- 15:50-16:10 Optimal Timing of Liver Transplantation in Severe Alcoholic Hepatitis  
*Julie K. Heimbach (Mayo Clinic, USA)*

## ROOM 2 / VISTA III

**KLCA Symposium 2****14:50-16:10** *Epoch-Making Changes for HCC Care**Jinsil Seong (Yonsei Univ.), Jin Wook Chung (Seoul National Univ.)*

14:50-15:10 Maximizing Indication and Safety in Living Donor Liver Transplantation for HCC

*Pyoung Jae Park (Korea Univ.)*

15:10-15:30 Making an Impact with Radioembolization for HCC Management

*Hyo-Cheol Kim (Seoul National Univ.)*

15:30-15:50 Harnessing the Power of Radiotherapies for HCC Treatment

*Jeong Il Yu (Sungkyunkwan Univ.)*

15:50-16:10 Evolving Strategies: Treatment Patterns of HCC from Korean Claims Data

*Ji Won Han (The Catholic Univ. of Korea)*

## ROOM 3 / WALKER I

**Special Interest Group 1****14:50-16:10** *Critical Care Strategies for Acute-on-Chronic Liver Failure**Barjesh Chander Sharma (Govind Ballabh Pant Hospital, India),  
Hong Soo Kim (Soonchunhyang Univ.)*

14:50-15:10 Different Definitions and Prognostic Stratification of Acute-on-Chronic Liver Failure

*Rakhi Maiwall (Institute of Liver and Biliary Sciences, India)*

15:10-15:30 Respiratory Support in Acute-on-Chronic Liver Failure

*Jin Won Huh (Univ. of Ulsan)*

15:30-15:50 Workup and Management of Acute Kidney Injury in Patients with Acute-on-Chronic Liver Failure

*Guadalupe Garcia-Tsao (Yale Univ., USA)*

15:50-16:10 Discussion

**ROOM 4 / WALKER II**

**KLTS Symposium 3**

**14:50-16:10** *Minimally Invasive Surgery for Recipients of Living Donor Liver Transplantation*

*Jae-Won Joh (Sungkyunkwan Univ.), Young Kyoung You (The Catholic Univ. of Korea)*

14:50-15:10 **Seoul National University Hospital Experience**  
*Kwang-Woong Lee (Seoul National Univ.)*

15:10-15:30 **Samsung Medical Center Experience**  
*Gyu-seong Choi (Sungkyunkwan Univ.)*

15:30-15:50 **Dr. Rela Institute Experience**  
*Ashwin Rammohan (Rela Hospital, India)*



15:50-16:10 **Discussion**

**ROOM 5 / GRAND IV**

**Radioembolization Symposium**

**14:50-16:30** *Experience of TARE for the Treatment of Liver Cancer in Asian-Pacific Region*

*Yoon Jun Kim (Seoul National Univ.),  
Pierce Chow (National Cancer Centre Singapore, Singapore)*

14:50-14:55 **Introduction**

14:55-15:15 **Recent Advances in TARE**  
*Dongho Hyun (Sungkyunkwan Univ.)*

15:15-15:35 **Role of TARE in the Management of BCLC Stage A HCC**  
*Nutcha Pinjaroen (Chulalongkorn Univ., Thailand)*

15:35-15:55 **Role of TARE in the Management of BCLC Stage B HCC**  
*Pi-Yi Chang (Taichung Veterans General Hospital, Taiwan)*

15:55-16:15 **Role of TARE in the Management of BCLC Stage C HCC**  
*Chow Wei Too (Singapore General Hospital, Singapore)*

16:15-16:30 **Closing**

## ROOM 6 / GRAND V

**Data Science Camp 2****14:50-16:10** *Harnessing Health Data in Medicine**Sung Bum Cho (Chonnam National Univ.), Seungbong Han (Korea Univ.)*

14:50-15:10 Common Data Model (CDM) for Observational Research  
*Seng Chan You (Yonsei Univ.)*

15:10-15:30 AI's Role in Diagnosis and Prognosis  
*Kyu-Hwan Jung (Sungkyunkwan Univ.)*

15:30-15:50 Big Data in Healthcare: Research and Applications  
*So-Ryoung Lee (Seoul National Univ.)*

15:50-16:10 Guide for Radiomics Study to Clinical Researchers  
*Hyo Jung Park (Univ. of Ulsan)*

## ROOM 8 / ART

**KLTS-KAHBPS-KASL Joint Symposium****14:50-16:10** *Updates on Cystic Liver Disease**Jin-Woo Lee (Inha Univ.), Alfred Kow (National Univ. of Singapore, Singapore)*

14:50-15:10 Epidemiologic and Genetic Landscapes of Polycystic Liver Disease  
*Beom Kyung Kim (Yonsei Univ.)*

15:10-15:30 Radiological Diagnosis for Cystic Liver Disease  
*Seung Baek Hong (Pusan National Univ.)*

15:30-15:50 EUS-Guided or Percutaneous Therapies for Cystic Liver Disease  
*Dong-Wan Seo (Univ. of Ulsan)*

15:50-16:10 Surgical Treatments of Large Hepatic Cysts  
*Seoung Yoon Rho (Yonsei Univ.)*

**ROOM 2 / VISTA III**

**16:10-16:30 HCC in Korea: The Past, Present, and the Future <sup>K</sup>**  
*Hyunchul Rhim (Sungkyunkwan Univ.), Jong Young Choi (The Catholic Univ. of Korea)*

16:10-16:30 HCC in Korea: The Past, Present, and the Future  
*Hae Lim Lee (The Catholic Univ. of Korea)*

**ROOM 3 / WALKER I**

**16:30-17:50 Hepatology Associates <sup>K</sup>**  
*Oh Sang Kwon (Gachon Univ.), Hee Bok Chae (Chungbuk National Univ.)*

16:30-16:50 Approach to Abnormal Liver Blood Tests in Inpatients and Outpatients  
*Myeong Jun Song (The Catholic Univ. of Korea)*

16:50-17:10 Adverse Events of Systemic Therapy in HCC Patients:  
 Assessment and Education  
*Eun Ju Cho (Seoul National Univ.)*

17:10-17:30 Role of Artificial Intelligence to Assist Clinical Research Coordinators  
*Hyun Suk Park (Asan Medical Center)*

17:30-17:50 Current Status and Prospects of Site Management Organization (SMO)  
 in Clinical Trials  
*Seong Jae Kim (Gyeongsang National Univ.)*





**PROGRAM**  
Saturday, June 29, 2024



The Liver Week 2018  
June 14-16, 2018  
Grand Hyatt, Incheon, Korea

The Liver Week 2019  
June 20-22, 2019  
BEXCO, Busan, Korea

# DAY 3

Saturday, June 29, 2024

## Program at a Glance

	ROOM 1 Vista I+II	ROOM 2 Vista III	ROOM 3 Walker I	ROOM 4 Walker II	Exhibition Hall
07:30					
08:00					
08:00-09:00		<b>KASL-AASLD Morning Workshop</b> <i>TIPS Timing for Bleeders</i> 08:00-09:00		<b>KAHBPS Symposium 1</b> <i>Minimally Invasive Surgery</i> 08:00-09:00	
09:00					
10:00	<b>KASL Symposium 4</b> <i>Portal Hypertension</i> 09:10-10:30	<b>KLCA-TLCA Joint Symposium</b> <i>Precision Cares for HCC</i> 09:10-10:30	<b>Special Symposium 2</b> <i>MASH-HCC Nexus</i> 09:10-10:30	<b>KAHBPS Symposium 2</b> <i>Pancreatobiliary Surgery in Cirrhotics</i> 09:10-10:30	<b>Oral Poster Presentation</b> 09:30-10:30
10:30-10:50	<b>Coffee Break</b>				
11:00	<b>State-of-the-Art Lecture: Prof. Rohit Loomba</b> 10:50-11:20				
11:20-12:20	<b>Plenary Presentation 2</b>				
12:00					
13:00	<b>Luncheon Symposium 7</b> [Yuhan] 12:20-13:10	<b>Luncheon Symposium 8</b> [Eisai] 12:20-13:10	<b>Luncheon Symposium 9</b> [Samil] 12:20-13:10	<b>Luncheon Symposium 10</b> [Celltrion] 12:20-13:10	<b>Booth &amp; Poster Exhibition</b>
13:00-13:40	<b>President's Choice Lecture: Prof. Tim F. Greten</b>				
14:00	<b>KASL Symposium 5</b> <i>Precision Hepatology</i> 13:40-15:00	<b>KLCA-KASL Joint Symposium</b> <i>Combinational Therapies for HCC</i> 13:40-15:00	<b>Special Symposium 3</b> <i>Prediction Models</i> 13:40-15:00	<b>KAHBPS Symposium 3</b> <i>Various Surgical Candidates</i> 13:40-15:00	<b>Allday Coffee &amp; Tea Station</b>
15:00	<b>Coffee Break</b> 15:00-15:20				
16:00	<b>The Liver Week 2024 Debrief</b> 15:20-16:20				
16:20-16:40	<b>Closing &amp; Award</b>				

# Program at a Glance

# DAY 3

## Saturday, June 29, 2024

ROOM 5 Grand IV	ROOM 6 Grand V	ROOM 7 Grand VI	ROOM 8 Art	ROOM 9 Pine	ROOM 10 Oak	
KASL Branch EMW 5 	KASL Branch EMW 6 		KASL Branch EMW 7 			07:30
Pathology Seminar <i>Clinical Pathology for Liver Disease</i> 08:00-09:00 	Basic Research 2 <i>Liver Fibrosis and Cancer</i> 08:00-09:00 					08:00
Free Paper 9 <i>HBV</i> 09:10-10:30	Free Paper 11 <i>Liver TPL 1</i> 09:10-10:30	Free Paper 12 <i>MASLD, Basic</i> 09:10-10:30	Clinical Hepatology 09:10-10:30 	Free Paper 14 <i>LC, Clinical &amp; Liver Failure</i> 09:10-10:30		09:00
Coffee Break 10:30-10:50						10:00
						11:00
KAHBPS Town Hall Meeting 12:20-13:10  			Luncheon Symposium 11 [Boryung] 12:20-13:10 		KASL-CRO MOU (Closed)	12:00
						13:00
Free Paper 10 <i>HCC, Clinical 2</i> 13:40-15:00	Special Interest Group 2 <i>Rare Liver Disease</i> 13:40-15:00	Free Paper 13 <i>HBV &amp; HCV</i> 13:40-15:00	Special Interest Group 3 <i>HBV Cure</i> 13:40-15:00	Free Paper 15 <i>Liver TPL 2</i> 13:40-15:00		14:00
						15:00
						16:00

 Session in Korean  Lunch Box  Korean Breakfast

**ROOM 5 / GRAND IV****07:30-08:00 KASL Branch EMW 5 [Daegu-Gyeongbuk]** *Byoung Kuk Jang (Keimyung Univ.)*

07:30-07:50 Is There a Complete Biochemical Response Indicative of  
Histological Remission in Autoimmune Hepatitis?

*Jeong Eun Song (Daegu Catholic Univ.)*

07:50-08:00 Discussion

**ROOM 6 / GRAND V****07:30-08:00 KASL Branch EMW 6 [Jeonbuk]** *Eun Young Cho (Wonkwang Univ.)*

07:30-07:50 Noninvasive Assessment of MASLD and Liver Fibrosis:  
Clinical Perspectives and Case Reviews

*Chang Hun Lee (Jeonbuk National Univ.)*

07:50-08:00 Discussion

**ROOM 8 / ART****07:30-08:00 KASL Branch EMW 7 [Busan-Ulsan-Gyeongnam]** *Jeong Heo (Pusan National Univ.), Nae-Yun Heo (Inje Univ.)*

07:30-07:40 Is the Early Treatment of Chronic Hepatitis B Reasonable? : Pros.  
*Yeowool Kang (Dong-A Univ.)*

07:40-07:50 Is the Early Treatment of Chronic Hepatitis B Reasonable? : Cons.  
*Kiyoun Yi (Pusan National Univ.)*

07:50-08:00 Discussion

## ROOM 2 / VISTA III

**KASL-AASLD Morning Workshop** **08:00-09:00** *Impact of Early TIPS for the Management of Variceal Bleeding**Grace L. Su (Univ. of Michigan, USA), June Sung Lee (Inje Univ.)*

- 08:00-08:15 Case and Topic Presentation  
*Eun Sun Jang (Seoul National Univ.)*
- 08:15-08:30 Better  
*Guadalupe Garcia-Tsao (Yale Univ., USA)*
- 08:30-08:45 Worse  
*Yeon Seok Seo (Korea Univ.)*
- 08:45-09:00 Discussion

## ROOM 4 / WALKER II

**KAHBPS Symposium 1** **08:00-09:00** *Technical Advances in Minimally Invasive Liver Surgery**Young Seok Han (Daegu Catholic Univ.), Hae Won Lee (Seoul National Univ.)*

- 08:00-08:15 Considerations and Outcomes in Robotic Hepatectomy for Anatomically Challenging Hepatic Tumors  
*Nuri Lee (Veterans Health Care Medical Center)*
- 08:15-08:30 Hepatic Vein-Guided Anatomical Liver Resection  
*Wipusit Taesombat (Chulalongkorn Univ., Thailand)*
- 08:30-08:45 Pre-Reconstructed 3D Images Using AI Model for Liver Resection  
*Jinsoo Rhu (Sungkyunkwan Univ.)*
- 08:45-09:00 Overcoming Difficult Anatomical Variations of Minimal Invasive Donor Hepatectomy  
*Ho Joong Choi (The Catholic Univ. of Korea)*

## ROOM 5 / GRAND IV

Pathology Seminar 

**08:00-09:00** *Bridging Pathology and Clinical Practice in Liver Disease*  
 Young Nyun Park (Yonsei Univ.), Xiong Ma (Shanghai Jiao Tong Univ., China)

08:00-08:20 Challenges in the Diagnosis and Care of AIH, DILI, and DI-ALH:  
 A Pathologist's Perspective  
 Haeryoung Kim (Seoul National Univ.)

08:20-08:40 Challenges in the Diagnosis and Care of AIH, DILI, and DI-ALH:  
 A Clinician's Perspective  
 Kyung-Ah Kim (Inje Univ.)

08:40-09:00 Computational Pathology in Liver Diseases  
 Sung Hak Lee (The Catholic Univ. of Korea)

## ROOM 6 / GRAND V

Basic Research 2 

**08:00-09:00** *Molecular and Cellular Dynamics in Liver Fibrosis and Cancer*  
 Kyun-Hwan Kim (Sungkyunkwan Univ.), Kang Mo Kim (Univ. of Ulsan)

08:00-08:20 Drug Discovery for Liver Fibrosis through Employing Functional  
 Morphometry in Multicellular Hepatic Spheroid (MCHS)  
 Haeng Ran Seo (Institut Pasteur Korea)

08:20-08:40 Role of Protein Phosphatase in the Development and Treatment of HCC  
 Chang-Woo Lee (Sungkyunkwan Univ.)

08:40-09:00 Circulating Extracellular Vesicles as a Promising Source of  
 Biomarkers of HCC  
 Soon Sun Kim (Ajou Univ.)

## ROOM 1 / VISTA I+II

**KASL Symposium 4****09:10-10:30 Portal Hypertension and Its Repercussions in Hepatic Care**

*Chang Wook Kim (The Catholic Univ. of Korea),  
Jongman Kim (Sungkyunkwan Univ.)*

- 09:10-09:30 Personalized Approach to Albumin Replacement in Decompensated Cirrhosis  
*Rakhi Maiwall (Institute of Liver and Biliary Sciences, India)*
- 09:30-09:50 Correction and Prevention of Hyponatremia in Cirrhotic Patients with Ascites  
*Sejoong Kim (Seoul National Univ.)*
- 09:50-10:10 Diagnostic Test and Available Therapy for Covert vs. Overt Hepatic Encephalopathy  
*Elliot B. Tapper (Univ. of Michigan, USA)*
- 10:10-10:30 Blood Products and Pharmacologic Agents and Their Indications for Hepatic Coagulopathy  
*Eileen L. Yoon (Hanyang Univ.)*

## ROOM 2 / VISTA III

**KLCA-TLCA Joint Symposium****09:10-10:30 East Meets Excellence: Exploring HCC Guidelines of Korea and Taiwan**

*Jong Young Choi (The Catholic Univ. of Korea),  
Yi-Hsiang Huang (National Yang Ming Chiao Tung Univ., Taiwan)*

- 09:10-09:25 Biomarkers-Guided Liver Transplantation for Advanced HCC in Korea  
*YoungRok Choi (Seoul National Univ.)*
- 09:25-09:40 AI Research of HCC in Taiwan  
*Yi-Hsiang Huang (National Yang Ming Chiao Tung Univ., Taiwan)*
- 09:40-09:55 Dissecting the Divergence: A Comparative Analysis of Stage-Specific HCC Treatment Approaches in Korea  
*Ji Hoon Kim (Korea Univ.)*
- 09:55-10:10 Dissecting the Divergence: A Comparative Analysis of Stage-Specific HCC Treatment Approaches in Taiwan  
*I-Cheng Lee (National Yang Ming Chiao Tung Univ., Taiwan)*
- 10:10-10:30 Discussion

**ROOM 3 / WALKER I**

**Special Symposium 2**

**09:10-10:30** *The MASH-HCC Nexus: From Epidemiology to Clinical Outcomes*

*Jung-Hwan Yoon (Seoul National Univ.),  
Pierce Chow (National Cancer Centre Singapore, Singapore)*

09:10-09:30 *Changing HCC Epidemiology: Shifting from Non-MASH to MASH-HCC*  
*Jeong-Ju Yoo (Soonchunhyang Univ.)*

09:30-09:50 *Immune and Molecular Pathophysiology of MASH-HCC*  
*Tim F. Greten (National Cancer Institute, USA)*

09:50-10:10 *Strategies for Surveillance and Diagnosis in MASH-HCC*  
*Bo Hyun Kim (National Cancer Center)*

10:10-10:30 *The Future Landscape of Personalized Medicine for Immunotherapies  
in MASH-HCC*  
*Yun Bin Lee (Seoul National Univ.)*

**ROOM 4 / WALKER II**

**KAHBPS Symposium 2**

**09:10-10:30** *Biliary Pancreatic Disease in Cirrhotic Patients*

*Sung Su Yun (Yeungnam Univ.), Hyeyoung Kim (Soonchunhyang Univ.)*

09:10-09:30 *Management of Acute Cholecystitis*  
*Shang-Yu Wang (Chang Gung Memorial Hospital, Taiwan)*

09:30-09:50 *Non-Operative Management of Acute Cholecystitis*  
*Yun Nah Lee (Soonchunhyang Univ.)*

09:50-10:10 *Pancreatic Surgery in Cirrhotic Patients*  
*Young-Dong Yu (Korea Univ.)*

10:10-10:30 *Perihilar Cholangiocarcinoma in Cirrhotic Patients*  
*Min-Su Park (Kyung Hee Univ.)*



## ROOM 8 / ART

**09:10-10:30 Clinical Hepatology ***Joon Hyeok Lee (Sungkyunkwan Univ.), Chang Hyeong Lee (Daegu Catholic Univ.)*

- 09:10-09:30 Sarcopenia, Malnutrition, and Frailty in Patients with Liver Cirrhosis  
*Tae Hyung Kim (Hallym Univ.)*
- 09:30-09:50 Management of Liver Disease in Pregnancy and Pregnancy-Associated Liver Disease  
*Sung-Eun Kim (Hallym Univ.)*
- 09:50-10:10 Guidance for Managing the Long-Term Side Effects of Chronic Hepatitis B Antivirals  
*Jung Hwan Yu (Inha Univ.)*
- 10:10-10:30 Management and Rechallenge after Immune-Related Adverse Events of Immune Checkpoint Inhibitors  
*Wonseok Kang (Sungkyunkwan Univ.)*

ROOM 1 / VISTA I+II ROOM 2 / VISTA III  Live

**10:50-11:20 State-of-the-Art Lecture**

*Joo Hyun Sohn (Hanyang Univ.)*

10:50-11:20 Advances in Non-Invasive Assessment of MASH  
*Rohit Loomba (Univ. of California San Diego, USA)*



**Plenary Presentation 2**

**11:20-12:20** *Jin Sub Choi (Yonsei Univ.), Hee Chul Yu (Jeonbuk National Univ.), Hyung Joon Yim (Korea Univ.)*

11:20-11:35 [PP 2-1] Merlin-TAZ Pathway by miR-4449 Regulates Fibrosis Progression in MASH  
*Eunho Choi (Korea Univ.)*

11:35-11:50 [PP 2-2] Cardiovascular Risk from Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes  
*Han Ah Lee (Chung-Ang Univ.)*

11:50-12:05 [PP 2-3] AI-Assisted Intraoperative Navigation for Safe Right Liver Mobilization during Pure Laparoscopic Donor Right Hepatectomy  
*Namkee Oh (Sungkyunkwan Univ.)*

12:05-12:20 [PP 2-4] EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization (TACE) Combined with Durvalumab (D) with or without Bevacizumab (B) in Participants with Unresectable Hepatocellular Carcinoma (uHCC) Eligible for Embolization  
*Jeong Heo (Pusan National Univ.)*

ROOM 5 / GRAND IV

**12:20-13:10 KAHBPS Town Hall Meeting  **

ROOM 1 / VISTA I+II

**13:10-13:40 President's Choice Lecture**

*Yoon Jun Kim (Seoul National Univ.)*

13:10-13:40 Innovative Immunotherapy Concepts for Liver Cancer  
*Tim F. Greten (National Cancer Institute, USA)*

## ROOM 1 / VISTA I+II

**KASL Symposium 5****13:40-15:00***Personalized Approaches to Liver Disease**Byung-Cheol Song (Jeju National Univ.),  
Mark Muthiah (National Univ. Hospital, Singapore)*

13:40-14:00

Effectiveness and Challenges of Etiology-Based Surveillance Approaches for HCC

*Won Sohn (Sungkyunkwan Univ.)*

14:00-14:20

Virologic and Immunologic Biomarkers to Guide Treatment of Chronic Hepatitis B

*Wai-Kay Seto (The Univ. of Hong Kong, Hong Kong)*

14:20-14:40

Role of Combination Therapy in Hepatic Encephalopathy

*Barjesh Chander Sharma (Govind Ballabh Pant Hospital, India)*

14:40-15:00

Molecular-Based Strategy for Atezo/Bev-Failed HCC:

The 2025 French Medicine Genomic Program  
*Jean-Charles Nault (Sorbonne Université, France)*

## ROOM 2 / VISTA III

**KLCA-KASL Joint Symposium****13:40-15:00***We Are Not Alone: Pioneering Combinational Approaches in HCC**Kyung Sik Kim (Yonsei Univ.), Han Chu Lee (Univ. of Ulsan)*

13:40-14:00

Maximizing Early-Stage HCC Outcomes through Neoadjuvant and Adjuvant Strategies

*Andrea Casadei Gardini (Vita-Salute San Raffaele Univ., Italy)*

14:00-14:20

Combination of Loco-Regional Therapy and Systemic Treatments for Intermediate-Stage HCC

*Jin Woo Choi (Seoul National Univ.)*

14:20-14:40

The Synergistic Role of Radiotherapy in Multimodal HCC Management

*Sang Min Yoon (Univ. of Ulsan)*

14:40-15:00

Navigating Future Prospects for Triple Systemic Therapies in HCC

*Richard S. Finn (Univ. of California Los Angeles, USA)*

**ROOM 3 / WALKER I**

**Special Symposium 3**

**13:40-15:00 Predictive Analytics and Risk Assessment**

*Won Young Tak (Kyungpook National Univ.), Moon Seok Choi (Sungkyunkwan Univ.)*

- 13:40-14:00 Statistical Strategies and Common Pitfalls for Risk Calculators  
*Sangwook Kang (Yonsei Univ.)*
- 14:00-14:20 The Evolution and Implications of MELD Score: Version 3.0  
*W. Ray Kim (Stanford Univ., USA)*
- 14:20-14:40 Analytic Morphomics for Predicting Outcomes of Liver Disease  
*Grace L. Su (Univ. of Michigan, USA)*
- 14:40-15:00 HCC Prediction Models Specific to Underlying Liver Disease  
*Minjong Lee (Ewha Womans Univ.)*

**ROOM 4 / WALKER II**

**KAHBPS Symposium 3**

**13:40-15:00 Surgical Liver Resection of HCC in Various Conditions**

*Yang-Seok Koh (Chonnam National Univ.), Bong-Wan Kim (Ajou Univ.)*

- 13:40-14:00 Management and Prognosis of Ruptured HCC  
*Jae Hyun Kwon (Hallym Univ.)*
- 14:00-14:20 Overcoming Small Estimated Future Remnant Liver Volume  
*Alfred Kow (National Univ. of Singapore, Singapore)*
- 14:20-14:40 Large HCC in Surgical Resection Era  
*Sang Jin Kim (Korea Univ.)*
- 14:40-15:00 Liver Resection in Elderly HCC Patients  
*Boram Lee (Seoul National Univ.)*

## ROOM 6 / GRAND V

**Special Interest Group 2****13:40-15:00 Advancing and Discovering Cures for Rare Liver Disease***Sook-Hyang Jeong (Seoul National Univ.), Ja Kyung Kim (Yonsei Univ.)*

- 13:40-14:00 Emerging Diagnostic and Therapeutic Approaches for Wilson's Disease  
*Beom Hee Lee (Univ. of Ulsan)*
- 14:00-14:20 Overlap Syndrome: The Difference between Autoimmune Hepatitis and Primary Biliary Cholangitis  
*Xiong Ma (Shanghai Jiao Tong Univ., China)*
- 14:20-14:40 Second-Line Pharmacotherapies for Hard-to-Treat Autoimmune Hepatitis and Primary Biliary Cholangitis  
*Atsumasa Komori (Nagasaki Univ., Japan)*
- 14:40-15:00 Discussion

## ROOM 8 / ART

**Special Interest Group 3****13:40-15:00 Navigating the Path to Hepatitis B Virus Eradication: Targets and Trials***Jin-Wook Kim (Seoul National Univ.),  
Tatsuya Kanto (National Center for Global Health and Medicine, Japan)*


- 13:40-14:00 Experimental in Vitro and in Vivo Models for Hepatitis B Virus Cure Research  
*Wenhui Li (Tsinghua Univ., China)*
- 14:00-14:20 Treatment Endpoints and Study Design to Cure Hepatitis B Virus  
*Sang Hoon Ahn (Yonsei Univ.)*
- 14:20-14:40 Promising Results for Curing Hepatitis B Virus: Viral and Immune Targets  
*Man-Fung Yuen (The Univ. of Hong Kong, Hong Kong)*
- 14:40-15:00 Discussion

ROOM 1 / VISTA I+II

**The Liver Week 2024 Debrief Session**

**15:20-16:20** Ju Hyun Shim (KASL), Jongman Kim (KAHBPS), Su Jong Yu (KLCA),  
Hae Won Lee (KLTS)

15:20-15:35  KASL  
Moon Haeng Hur (Seoul National Univ.)

15:35-15:50  KAHBPS  
Jinsoo Rhu (Sungkyunkwan Univ.)

15:50-16:05  KLCA  
Hye Won Lee (Yonsei Univ.)

16:05-16:20  KLTS  
Jae Geun Lee (Yonsei Univ.)

**16:20-16:40 Closing & Award Ceremony**



The Liver Week 2020  
August 13-14, 2020  
VIRTUAL CONFERENCE


The Liver Week 2021  
May 13-15, 2021  
VIRTUAL CONFERENCE

ABSTRACT  
PRESENTATION

\* 3대 피라미드가 담고 있는 완벽한 황금비율처럼  
 아토바미브®에이정은 Atorvastatin+Ezetimibe+Amlodipine  
 3제 조합으로 고혈압·이상지질혈증 치료의 Data를 쌓아 가겠습니다.

# GREAT A PROJECT

A more powerful A-combination



## 아토바미브®에이정은

- ▲. 국내 최초<sup>1</sup> Atorvastatin+Ezetimibe+Amlodipine 조합의 3제 복합제<sup>1</sup>
- ▲. 이상지질혈증과 고혈압 동시 개선 효과와 함께 높은 복용 편의성<sup>1-3</sup>
- ▲. 다양한 용량으로 환자 상태에 맞는 처방 용이성<sup>1</sup>

※ QR 코드를 통해 상세 제품정보를 참조하여 주시기 바랍니다.<sup>1</sup>



아토바미브®에이  
10/10 5mg



아토바미브®에이  
10/10 10mg



아토바미브®에이  
10/20 5mg



아토바미브®에이  
10/20 10mg

- 아토바미브®에이정의 실제 성분 별 용량은 Ezetimibe+Atorvastatin+Amlodipine 순으로 확인하십시오.

<sup>1</sup> 국내 허가일 기준(2024.01.12)

### References)

1. 아토바미브®에이정 제품 허가서 (Available at <https://medrug.mfds.go.kr> Accessed 08 Apr 2024)
2. B. Weisser, et al. High Blood Pressure & Cardiovascular Prevention, 2020;27(2):157 - 164.
3. Simons LA et al. Med J Aust, 2011;195(3):134 - 137.



유한양행

본사 서울 동대구 노원로본길 4 • 공장 충청남도 청주시 청원구 오창읍 영구대로 219  
 홈페이지: www.yuhin.co.kr • 소비자상담실: 080-024-1188 (수신시간 있음)



아토바미브®에이정  
 아토르바스타틴 + 에제티미브 + 암로디핀 정

KCP-AE-A-2400001



# Free Paper Presentation

Friday, June 28, 2024

## 1. MASLD, Clinical

09:10-10:30

Jin-Woo Lee (Inha Univ.), Ja Kyung Kim (Yonsei Univ.)

FP-1 09:10-09:23	Characteristics and Outcomes of Hepatocellular Carcinoma Related to MASLD versus NAFLD <i>Sung Won Chung (Univ. of Ulsan)</i>
FP-2 09:23-09:36	Impact of Cardiometabolic Risk Factors and Alcohol Consumption on Mortality in Steatotic Liver Diseases: A Comparative Analysis of MASLD and MetALD <i>Young Chang (Soonchunhyang Univ.)</i>
FP-3 09:36-09:49	Skeletal Muscle Mass Loss According to Sub-Classification of Steatotic Liver Disease: Insights from a Longitudinal Cohort Study <i>Aryoung Kim (Inje Univ.)</i>
FP-4 09:49-10:02	Comparison of Dipeptidyl Peptidase-4 Inhibitor and Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic Patients with Steatotic Liver Disease <i>Yunmi Ko (Seoul National Univ.)</i>
FP-5 10:02-10:15	Sequential Approach Using Combination of Newly Developed HOMA2-IR-ALT-TE-MASH (HALT-M) Score and Magnetic Resonance Elastography for Non-Invasive Identifying At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Obese Subjects <i>Yoonseok Lee (Gachon Univ.)</i>
FP-6 10:15-10:28	Protective Effects of MASLD in Chronic Hepatitis B Patients on the Risk for Hepatocellular Carcinoma, Hepatic Decompensation, and Mortality <i>Kunhee Kim (Yonsei Univ.)</i>

## 2. HCC, Clinical 1

13:30-14:50

Bo Hyun Kim (National Cancer Center), Geun Hong (Ewha Womans Univ.)

FP-7 13:30-13:43	Atezolizumab Plus Bevacizumab versus Lenvatinib for BCLC-B Stage of Patients with Hepatocellular Carcinoma: A Large Real-Life Worldwide Population <i>Francesco Vitiello (Vita-Salute San Raffaele Univ., Italy)</i>
FP-8 13:43-13:56	An Early Increase in IL-10 and TNF- $\alpha$ Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced HCC Patients <i>Soon Kyu Lee (The Catholic Univ. of Korea)</i>

## 2. HCC, Clinical 1

<b>FP-9</b> 13:56-14:09	Long-Term Survival Outcomes of Surgical Resection versus Radiofrequency Ablation for Solitary Hepatocellular Carcinoma Less Than 3cm: A Systematic Review and Meta-Analysis <i>Do Young Lee (Univ. of Ulsan)</i>
<b>FP-10</b> 14:09-14:22	Lenvatinib (L) versus Sorafenib (S) Second-Line Therapy in Hepatocellular Carcinoma (HCC) Patients (P) Progressed to Atezolizumab Plus Bevacizumab (AB) <i>Mara Persano (AOU Cagliari, Italy)</i>
<b>FP-11</b> 14:22-14:35	Transarterial Radioembolization versus Transarterial Chemoembolization Plus External Beam Radiotherapy in Hepatocellular Carcinoma with Portal Vein Thrombosis <i>Jae Woong Yoon (Seoul National Univ.)</i>
<b>FP-12</b> 14:35-14:48	Comprehensive Multi-Omics Analysis for Resectable Hepatocellular Carcinoma Uncovers Biomarkers to Predict Microvascular Invasion <i>Incheon Kang (CHA Univ.)</i>

## 3. LC and Others, Basic

<b>09:10-10:30</b> <i>Jung Il Lee (Yonsei Univ.), Moon Young Kim (Yonsei Univ. Wonju)</i>	
<b>FP-13</b> 09:10-09:23	The Hepatic Recovery Effects of Exosomes Derived from Human Chemically Derived Hepatic Progenitor Cells (hCdHs) <i>Min Kim (Hanyang Univ.)</i>
<b>FP-14</b> 09:23-09:36	Catecholamine Induces Hepatocyte Proliferation by Beta-2 Adrenergic Receptor-Mediated YAP Activation in Partial Hepatectomy <i>Katherine Po Sin Chung (KAIST)</i>
<b>FP-15</b> 09:36-09:49	Development of Mesenchymal Stem Cell-Derived Exosomes Targeting Liver Sinusoid Endothelial Cells for the Treatment of Chronic Liver Disease <i>Seul Ki Han (Yonsei Univ. Wonju)</i>
<b>FP-16</b> 09:49-10:02	Mechanisms of Liver Cirrhosis through the Regulation by MCRS1 <i>Eunjeong Kim (Kyungpook National Univ.)</i>

### 3. LC and Others, Basic

<b>FP-17</b> 10:02-10:15	Akkermansia Muciniphila Improve Cognitive Dysfunction by Regulating BDNF and Serotonin Pathway in Gut-Liver-Brain Axis <i>Goo Hyun Kwon (Hallym Univ.)</i>
<b>FP-18</b> 10:15-10:28	Quasi-Spatial Single-Cell Transcriptome Based on Physical Properties Defines Early Aging Associated Niche in Liver Tissue <i>Kwon Yong Tak (KAIST)</i>

### 4. Surgery, Technical Issues

13:30-14:50

*Gi Hong Choi (Yonsei Univ.), Juik Moon (Konyang Univ.)*

<b>FP-19</b> 13:30-13:43	Artificial Intelligence-Based Analysis Using Surface-Enhanced Raman Spectroscopy Profiles of Plasma Extracellular Vesicles to Develop an Early Diagnosis Method for Cholangiocarcinoma <i>Sehyeon Yu (Korea Univ.)</i>
<b>FP-20</b> 13:43-13:56	Initial Experience of Minimal Invasive Living Donor Liver Transplantation: From Hybrid Surgery to Totally Laparoscopic Approach <i>Jinsoo Rhu (Sungkyunkwan Univ.)</i>
<b>FP-21</b> 13:56-14:09	Development and Validation of a Novel Model for Surgical Instrument Recognition during Laparoscopic Cholecystectomy Using AI-Based Automated Surgical Instrument Detection System <i>Jae Hyun Kwon (Hallym Univ.)</i>
<b>FP-22</b> 14:09-14:22	From Ideas to Clinical Application of Tunnel Technique in Laparoscopic-Endoscopic Cooperative Surgery for Biliary and Pancreatic Stones <i>Thi The Trinh Nguyen (Vin Univ., Vietnam)</i>
<b>FP-23</b> 14:22-14:35	Resectability as a Prognostic Indicator in BCLC Stage B Hepatocellular Carcinoma: Challenging Current Treatment Paradigms <i>YoungRok Choi (Seoul National Univ.)</i>
<b>FP-24</b> 14:35-14:48	Minimally Invasive Hepatopancreatoduodenectomy for Locally Advanced Gallbladder Cancer <i>Kalayarasan Raja (JIPMER, India)</i>

## 5. HCC, Basic

14:50-16:10

Say-June Kim (The Catholic Univ. of Korea), Su Jong Yu (Seoul National Univ.)

FP-25

14:50-15:03

Exosomal miRNA as a Useful Biomarker for Predicting the Response of Atezolizumab and Bevacizumab Combination Therapy in Patients with Advanced Hepatocellular Carcinoma

*Eunho Choi (Korea Univ.)*

FP-26

15:03-15:16

NOX2 Regulates EMT Signaling through SREBP2 and Induces HCC Development

*Hei Gwon Choi (Chungnam National Univ.)*

FP-27

15:16-15:29

Application of CRISPR/Cas9 Technology for Constructing a Hepatocellular Carcinoma Model Using Human Chemically Derived Hepatocytes

*Michael Girma Mamo (Hanyang Univ.)*

FP-28

15:29-15:42

Identification and Functional Evaluation of LINC01446 and AK7 in Hepatocellular Carcinoma Progression and Metastasis

*Min Ji Kang (Ajou Univ.)*

FP-29

15:42-15:55

Landscape of Circulating Immune Cells after Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma

*Young-Sun Lee (Korea Univ.)*

FP-30

15:55-16:08

Transcobalamin 1 (TCN1) Regulated Hypoxia-Driven Cancer Stemness via ITGA3-Mediated Notch Signaling Pathway in Hepatocellular Carcinoma

*Gregory Kenneth Muliawan (The Hong Kong Polytechnic Univ., Hong Kong)*

## 6. Drug and Toxic Injury

09:10-10:30

Chang Wook Kim (The Catholic Univ. of Korea)

In Hee Kim (Jeonbuk National Univ.)

FP-31

09:10-09:23

Personalized Prediction of Drug-Induced Liver Injury Using the Transformer Architecture

*Harim Kim (Handong Global Univ.)*

FP-32

09:23-09:36

Evaluation of Hepatoprotective and Antioxidant Properties of Phytosterols against Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice

*Gireesh Dayma (Manipal Univ., India)*

## 6. Drug and Toxic Injury

<b>FP-33</b> 09:36-09:49	Understanding of the Underlying Mechanisms of CXCL1-Associated Neutrophil Migration in APAP-Induced Liver Injury <i>Jisoo Kang (Ewha Womans Univ.)</i>
<b>FP-34</b> 09:49-10:02	Ameliorative Effects of Punica Granatum (Pomegranate) Seed Oil Extract on Ethanol-Induced Gastric and Hepatic Disorders in Animal Models <i>Assiya Karaltayeva (Al-Farabi Kazakh National Univ., Kazakhstan)</i>
<b>FP-35</b> 10:02-10:15	Analysis of Drug Inducing Liver Injury: A Graph-Based Machine Learning Approach <i>Geonyeong Choi (Handong Global Univ.)</i>
<b>FP-36</b> 10:15-10:28	Pre-Clinical Evaluation of Hepatoprotective Effects of Lutein Against DMBA-Induced Hepatotoxicity in Experimental Rats <i>Yogesh Dayma (Jawaharlal Nehru Univ., India)</i>

## 7. ALD and Genetics

13:30-14:50

Jae Young Jang (Soonchunhyang Univ.)  
Soo Young Park (Kyungpook National Univ.)

<b>FP-37</b> 13:30-13:43	Expansion of Effector Regulatory T Cells in Steroid Responders of Severe Alcohol-Associated Hepatitis <i>Min Woo Kang (The Catholic Univ. of Korea)</i>
<b>FP-38</b> 13:43-13:56	Dysbiotic Change in Intestinal Microbiome in Korean Alcoholic Liver Disease Patients <i>Young Youn Cho (Chung-Ang Univ.)</i>
<b>FP-39</b> 13:56-14:09	Effect of Diabetes on Mortality and Liver Transplantation in Patients with Alcoholic Liver Cirrhosis <i>Jihye Lim (The Catholic Univ. of Korea)</i>
<b>FP-40</b> 14:09-14:22	Anthraquinone Analogues for Alcoholic-Induced Liver Fibrosis Therapy Targeting TGF- $\beta$ Receptor: Bibliometric and Molecular Docking Evidence <i>Amanda Natania Gracia (Universitas Palangka Raya, Indonesia)</i>
<b>FP-41</b> 14:22-14:35	The Prognostic Impact of Psychiatric Intervention on Alcohol-Associated Liver Disease: A Prospective Study of the UK Biobank Cohort <i>Keungmo Yang (The Catholic Univ. of Korea)</i>

## 7. ALD and Genetics

FP-42  
14:35-14:48

The Causal Linkage between Telomere Attrition and Cirrhosis:  
A Mendelian Randomization Study

*Hyunjae Shin (National Cancer Center)*

## 8. Autoimmune Disease

14:50-16:10

*Sook-Hyang Jeong (Seoul National Univ.), Sung Jae Park (Inje Univ.)*

FP-43  
14:50-15:03

Risk Factors Affecting Non-Response and Biochemical Response in  
Autoimmune Hepatitis: A Multicenter Cohort Study

*Soon Kyu Lee (The Catholic Univ. of Korea)*

FP-44  
15:03-15:16

Risk of Extrahepatic Malignancies in Patients with Autoimmune Hepatitis:  
A Nationwide Cohort Study

*Sung Won Chung (Univ. of Ulsan)*

FP-45  
15:16-15:29

Decoding the Role of Long Non-Coding RNAs in Autoimmune Hepatitis  
Progression: A Machine Learning Approach

*Rifaldy Fajar (Karlstad Univ., Sweden)*

FP-46  
15:29-15:42

Development of a Nomogram for Predicting Survival in Patients with  
Autoimmune Hepatitis: A Multicenter Cohort Study

*Soon Kyu Lee (The Catholic Univ. of Korea)*

FP-47  
15:42-15:55

Vibration-Controlled Transient Elastography-Based Scores in Autoimmune  
Hepatitis for Predicting Liver Fibrosis Stage and Liver-Related Events

*Kunhee Kim (Yonsei Univ.)*

FP-48  
15:55-16:08

Multicenter Study on Incidence and Risk Factors of Hepatocellular  
Carcinoma in Patients with Autoimmune Hepatitis

*Jiwon Yang (Univ. of Ulsan)*

# Free Paper Presentation

Saturday, June 29, 2024

## 9. HBV

09:10-10:30

Jung Woo Shin (Univ. of Ulsan), Jae Yoon Jeong (Ewha Womans Univ.)

FP-49

09:10-09:23

Impact of Maternal Chronic HBV Infection on the Neurodevelopment of Children: A Comprehensive Korean Cohort Study

Yewan Park (Kyung Hee Univ.)

FP-50

09:23-09:36

A Machine Learning Model to Predict Liver-Related Outcomes after the Functional Cure of Chronic Hepatitis B

Moon Haeng Hur (Seoul National Univ.)

FP-51

09:36-09:49

A Nationwide Seroepidemiology Study of Hepatitis D Virus Infection in South Korea

Sung Won Lee (The Catholic Univ. of Korea)

FP-52

09:49-10:02

Effectiveness of Solanum Procumbens Combined with Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B

Le Thi Thu Hien (Thai Nguyen Univ., Vietnam)

FP-53

10:02-10:15

Factors Predictive of Improvement of Renal Function after Switching to Tenofovir Alafenamide from Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B

Hyeyeon Hong (Univ. of Ulsan)

FP-54

10:15-10:28

Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: Liver-Related Clinical Outcomes and Subgroup Analysis by Liver Cirrhosis Status

Soon Sun Kim (Ajou Univ.)

## 10. HCC, Clinical 2

13:40-15:00

Gi Hong Choi (Yonsei Univ.), Hyun Phil Shin (Kyung Hee Univ.)

FP-55

13:40-13:53

Peripheral Blood Inflammatory Score Using a Cytokine Multiplex Assay Predicts Clinical Outcomes in Unresectable HCC Patients Treated with Atezolizumab/Bevacizumab

Hee Sun Cho (The Catholic Univ. of Korea)

FP-56

13:53-14:06

Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population

Mara Persano (AOU Cagliari, Italy)

## 10. HCC, Clinical 2

<b>FP-57</b> 14:06-14:19	Increased Variceal Bleeding Risk Associated with Atezolizumab Plus Bevacizumab Dose Not Affect Survival Outcomes in Unresectable Hepatocellular Carcinoma: Concurrent Endoscopy and Computed Tomography Screening <i>Jeayeon Park (Seoul National Univ.)</i>
<b>FP-58</b> 14:19-14:32	A Machine Learning Model to Predict De Novo Hepatocellular Carcinoma Beyond Year 5 of Antiviral Therapy <i>Yeonjung Ha (CHA Univ.)</i>
<b>FP-59</b> 14:32-14:45	Effect of Preoperative Transarterial Chemoembolization for Resectable Single Hepatocellular Carcinoma: A Single-Center Cohort Study <i>Sang-Hoon Kim (Univ. of Ulsan)</i>
<b>FP-60</b> 14:45-14:58	Geriatric Nutritional Risk Index as a Prognostic Factor in Patients with Hepatocellular Carcinoma: Based on Korea Nationwide Cancer Registry <i>Heechul Nam (The Catholic Univ. of Korea)</i>

## 11. Liver Transplantation 1

**09:10-10:30** Dong-Hwan Jung (Univ. of Ulsan), Young Chul Yoon (The Catholic Univ. of Korea)

<b>FP-61</b> 09:10-09:23	Long-Term Outcomes of Liver Replantation: A 31-Year Korean Single-Center Experiences <i>Sang-Hoon Kim (Univ. of Ulsan)</i>
<b>FP-62</b> 09:23-09:36	3D Auto-Segmentation of Biliary Structure of Living Liver Donors Using Magnetic Resonance Cholangiopancreatography <i>Jinsoo Rhu (Sungkyunkwan Univ.)</i>
<b>FP-63</b> 09:36-09:49	Oxygen Delivery And Consumption during Hypothermic Oxygenated Machine Perfusion and Their Impact on Post-Liver Transplant Outcome <i>Luca Del Prete (Policlinico di Milano, Italy)</i>
<b>FP-64</b> 09:49-10:02	Anatomical Study of the Paracaval Branch of Caudate Lobe: Implication of Caudate Preserving Right Hepatectomy for Donors with Marginal Remnant Liver Volume (with Video) <i>Na Reum Kim (Yonsei Univ.)</i>



## 11. Liver Transplantation 1

<b>FP-65</b> <small>10:02-10:15</small>	<p>The Impact of Tacrolimus Level and Its Inpatient Variability on the Development of Chronic Kidney Disease Following Liver Transplantation</p> <p><i>Soon Kyu Lee (The Catholic Univ. of Korea)</i></p>
<b>FP-66</b> <small>10:15-10:28</small>	<p>Attenuation of Hepatic Ischemia-Reperfusion Injury Associated with Liver Transplantation by Curcumin in Rodents via Anti-Inflammatory Action</p> <p><i>Ekta Yadav (Shalom Institute of Health and Allied Sciences, India)</i></p>

## 12. MASLD, Basic

<b>09:10-10:30</b>		<i>Jong Eun Yeon (Korea Univ.), Byoung Kuk Jang (Keimyung Univ.)</i>
<b>FP-67</b> <small>09:10-09:23</small>	<p>Omentin-1 in Visceral Adipose Tissue: Implications on Its Role in Diabetes and Metabolic Dysfunction- Associated Steatotic Liver Disease</p> <p><i>Noel Salvoza (Philippine Council for the Health Research and Development, Philippines)</i></p>	
<b>FP-68</b> <small>09:23-09:36</small>	<p>The Genome-Wide Association Study of Metabolic Dysfunction-Associated Steatotic Liver Disease in Korean Large Population Cohort</p> <p><i>Hayoung Oh (CHA Univ.)</i></p>	
<b>FP-69</b> <small>09:36-09:49</small>	<p>Nintedanib Alleviates Metabolic-Associated Fatty Liver Disease in Mice by Elimination of Activated Fibroblasts</p> <p><i>Sung Woo Cho (The Catholic Univ. of Korea)</i></p>	
<b>FP-70</b> <small>09:49-10:02</small>	<p>Identification of Causal Genes for Nonalcoholic Fatty Liver Disease Using Single-Cell eQTL Analysis</p> <p><i>Sung Eun Hong (Seoul National Univ.)</i></p>	
<b>FP-71</b> <small>10:02-10:15</small>	<p>Knockout of LPS Inactivator Ameliorates NASH Progression in Mice Model</p> <p><i>So-Jin Sim (Kangwon National Univ.)</i></p>	
<b>FP-72</b> <small>10:15-10:28</small>	<p>Therapeutic Potential of miR-660-5p and miR-125a-5p Antagonists in Attenuating Liver Fibrosis: Insights from Next-Generation Sequencing and Experimental Validation</p> <p><i>Young Chang (Soonchunhyang Univ.)</i></p>	

## 13. HBV and HCV

13:40-15:00

Won Hyeok Choe (Konkuk Univ.), Eun Young Cho (Wonkwang Univ.)

<b>FP-73</b> 13:40-13:53	Analysis of a Machine Learning-Based Predictive Model for Hepatocellular Carcinoma in Chronic Hepatitis B Patients <i>Ye Jun Kim (Handong Global Univ.)</i>
<b>FP-74</b> 13:53-14:06	Association between Viral Replication Activity and Recurrence of HBV-Associated Hepatocellular Carcinoma after Curative Resection <i>Won-Mook Choi (Univ. of Ulsan)</i>
<b>FP-75</b> 14:06-14:19	Diagnostic Impact of Circulating Tumor DNA for the Early Stage of HBV Induced HCC with Profiling Fragmentation and DNA Methylation <i>Tom Ryu (Soonchunhyang Univ.)</i>
<b>FP-76</b> 14:19-14:32	The Effect of SRC1 Inhibitors in Hepatitis B-Related Liver Cancer <i>Agustiningsih Agustiningsih (Eijkman Research Center for Molecular Biology, Indonesia)</i>
<b>FP-77</b> 14:32-14:45	Post-Marketing Surveillance of the Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C <i>Jeong Heo (Pusan National Univ.)</i>
<b>FP-78</b> 14:45-14:58	Epidemiological Insights into Hepatitis C through Blood Samples from the Korea National Health and Nutrition Examination Survey (2016-2020) <i>Chang Hun Lee (Jeonbuk National Univ.)</i>

## 14. LC, Clinical and Liver Failure

09:10-10:15

Sang Youn Hwang (Dongnam Institute of Radiological & Medical Sciences)  
Do Seon Song (The Catholic Univ. of Korea)

<b>FP-79</b> 09:10-09:23	Inhibition of Sodium-Glucose Cotransporter-2 and Liver-Related Complications in Individuals with Diabetes: A Mendelian Randomization and Population-Based Cohort Study <i>Hyunjae Shin (National Cancer Center)</i>
<b>FP-80</b> 09:23-09:36	Development and External Validation of Global Leadership Initiative on Malnutrition-Dictated Nomograms Predicting Long-Term Mortality in Hospitalized Cirrhosis <i>Chao Sun (Tianjin Medical Univ. General Hospital, China)</i>

## 14. LC, Clinical and Liver Failure

<b>FP-81</b> 09:36-09:49	Impact of Spontaneous Portosystemic Shunts on the Risk of Hepatic Decompensation in Patients with Cirrhosis <i>Sung Won Chung (Univ. of Ulsan)</i>
<b>FP-82</b> 09:49-10:02	The Effects of Captopril on Portal Vein Thickness and Transforming Growth Factor Beta 1 (TGF- $\beta$ 1) Levels in Patients with Liver Cirrhosis: An Experimental Double-Blind Randomized Controlled Trial <i>Muhammad Ilham Malda (Sebelas Maret Univ., Indonesia)</i>
<b>FP-83</b> 10:02-10:15	Development of an Artificial Intelligence-Based Predictive Model and Treatment Decision System Using the Korean Acute-on-Chronic Liver Failure Cohort (KACLIF) <i>Seong Hee Kang (Korea Univ.)</i>

## 15. Liver Transplantation 2

13:40-15:00

*Tae-Seok Kim (Keimyung Univ.), Cheon Soo Park (The Catholic Univ. of Korea)*

<b>FP-84</b> 13:40-13:53	Outcomes of 6000 Living Donor Liver Transplantation: A 30-Year Journey in a High-Volume Single Center <i>Young-In Yoon (Univ. of Ulsan)</i>
<b>FP-85</b> 13:53-14:06	Advancing Graft Failure Prediction Post-Liver Transplantation: External Validation of a Model Using Aspartate Aminotransferase, Total Bilirubin, and Coagulation Factors <i>Sunghyo An (Sungkyunkwan Univ.)</i>
<b>FP-86</b> 14:06-14:19	Beyond Transplant Criteria: The Prognostic Impact of Macrotrabecular-Massive Hepatocellular Carcinoma in Liver Transplantation <i>Eun-Ki Min (Yonsei Univ.)</i>
<b>FP-87</b> 14:19-14:32	Survival Benefits in Living-Donor Liver Transplantation: A Nested Case-control Analysis Based on the MELD Score Trajectories from the Waitlist <i>Seung Hyuk Yim (Yonsei Univ.)</i>
<b>FP-88</b> 14:32-14:45	Impact of Liver Graft Complexity on Long-Term Survival Outcomes in Living Donor Liver Transplantation <i>Deok-Gie Kim (Yonsei Univ.)</i>

Free Paper Presentation | Saturday, June 29, 2024

---

## 15. Liver Transplantation 2

FP-89  
14:45-14:58

Living Donor Liver Transplant (LDLT): Analysis in Asia's Case of Liver Transplant

*Vivi Usmayanti (Economics Faculty, Universitas Sriwijaya, Indonesia)*

---



# Oral Poster Presentation

Friday, June 28, 2024 | Exhibition Hall

## 1. HBV 1

16:30-17:30

Jeong Han Kim (Konkuk Univ.), Sae Hwan Lee (Soonchunhyang Univ.)

OP-1 16:30-16:40	Effect of Diabetes on the Risk of Fibrosis Progression in Patients with Chronic Hepatitis B <i>Mi Na Kim (Yonsei Univ.)</i>
OP-2 16:40-16:50	Lack of Association between Early On-Treatment HBeAg-Seroclearance and Development of Hepatocellular Carcinoma or Decompensated Liver Cirrhosis <i>Gyung Sun Lim (National Cancer Center)</i>
OP-3 16:50-17:00	Stratification of HBeAg-Negative Chronic Hepatitis B Patients through Longitudinal Monitoring of HBV DNA Levels <i>Hae Lim Lee (The Catholic Univ. of Korea)</i>
OP-4 17:00-17:10	Comparison of Denosumab and Bisphosphonates for Tenofovir-Induced Osteoporosis in Patients with Chronic Hepatitis B <i>Yunmi Ko (Seoul National Univ.)</i>
OP-5 17:10-17:20	Cost-Effectiveness of Antiviral Therapy in Patients with Chronic Hepatitis B in the High Viremic Gray Zone <i>Won-Mook Choi (Univ. of Ulsan)</i>
OP-6 17:20-17:30	Comparable Outcomes between Besifovir and Other Antiviral Therapies in Hepatocellular Carcinoma Development Among Patients with Chronic Hepatitis B <i>Jae Seung Lee (Yonsei Univ.)</i>

## 2. MASLD, Basic

16:30-17:30

Won Kim (Seoul National Univ.), Won-Il Jeong (KAIST)

OP-7 16:30-16:40	Quercetin and Resveratrol Ameliorates Diabetic Induced NAFLD by Inhibiting Proprotein Convertase Subtilisin/Kexin Type 9 and Dipeptidyl Peptidase-IV <i>Anand Krishna Singh (Shri Vaishnav Vidyapeeth Vishwavidyalaya, India)</i>
OP-8 16:40-16:50	Translational Investigation of Non-Alcoholic Fatty Liver Disease in a Rat Model for Hepatocyte Transplantation <i>Cheng-Maw Ho (National Taiwan Univ., Taiwan)</i>

## Oral Poster Presentation | Friday, June 28, 2024

### 2. MASLD, Basic

<b>OP-9</b> 16:50-17:00	Intrahepatic IgA-Fibroblast Interaction and Its Impact on Inflammation in Steatotic Liver Diseases <i>Jong Geun Park (The Catholic Univ. of Korea)</i>
<b>OP-10</b> 17:00-17:10	Bacteroides Eggerthii as a Potential Treatment Strategy for NAFLD and Obesity <i>Ji Yi Choi (Ajou Univ.)</i>
<b>OP-11</b> 17:10-17:20	Laminarin Ameliorates Hepatic Steatosis and Upregulates Hepatic SMP-30 Expression in High-Fat Diet Mouse Models of Non-Alcoholic Fatty Liver Disease <i>Ji-Won Park (Hallym Univ.)</i>
<b>OP-12</b> 17:20-17:30	sQTL Analysis Reveals Splicing-Mediated Regulation of MASLD Pathogenesis <i>Bo-Yeong Jin (Seoul National Univ.)</i>

### 3. MASLD, Clinical 1

<b>16:30-17:20</b>	<i>Byung Seok Lee (Chungnam National Univ.)</i> <i>Byung Seok Kim (Daegu Catholic Univ.)</i>
<b>OP-13</b> 16:30-16:40	Analysis for the Association between Body Weight, Waist Circumference Change and Cardio-Cerebrovascular Risk among Nonalcoholic Fatty Liver Disease Patients <i>Se Young Jang (Kyungpook National Univ.)</i>
<b>OP-14</b> 16:40-16:50	A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Based on Bioimpedance Analysis with Machine Learning Algorithms <i>Jeayeon Park (Seoul National Univ.)</i>
<b>OP-15</b> 16:50-17:00	The Number of Meeting Cardiometabolic Criteria in Metabolic-Dysfunction Associated Steatotic Liver Disease Is Associated with Prognosis of Hepatocellular Carcinoma <i>Tom Ryu (Soonchunhyang Univ.)</i>
<b>OP-16</b> 17:00-17:10	Association of the Duration of Comorbidities on the Development of Steatotic Liver Disease and Patient Survival <i>Ha Il Kim (Hanyang Univ.)</i>
<b>OP-17</b> 17:10-17:20	Differential Risk of Hepatocellular Carcinoma Based on Antidiabetics in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Han Ah Lee (Chung-Ang Univ.)</i>

## 4. LC, Clinical and Liver Failure 1

16:30-17:30

Hyung Joon Kim (Chung-Ang Univ.), Sang Gyune Kim (Soonchunhyang Univ.)

OP-18

16:30-16:40

Development and Validation of an Explainable Machine Learning Model for Predicting Multidimensional Frailty in Hospitalized Patients with Cirrhosis

Chao Sun (Tianjin Medical Univ., China)

OP-19

16:40-16:50

Does Senescent Change in Spleen Affect Splenomegaly in Elderly Patients with Liver Cirrhosis?

Yunjeong Lee (Seoul National Univ.)

OP-20

16:50-17:00

Prediction of Liver Cirrhosis Using Regular Health Check-Up Data: Development of Machine Learning Model and Cross-Country Validation

Yeonjung Ha (CHA Univ.)

OP-21

17:00-17:10

Evaluation and Comparative Study of Machine Learning-Based Models to Determine the Seropositivity of Hepatitis B Virus (HBV)

Deepika Singh (SHUATS, India)

OP-22

17:10-17:20

A Deep Learning Approach to Predict Liver Fibrosis from Laparoscopic Videos: Intraoperative Liver Resection Decision Support

Namkee Oh (Sungkyunkwan Univ.)

OP-23

17:20-17:30

An Approach Using Non-Invasive Parameters of Machine Learning Techniques for Predicting Portal Hypertension

Seul Ki Han (Yonsei Univ. Wonju)

## 5. Liver Transplantation 1

16:30-17:30

Gyu-seong Choi (Sungkyunkwan Univ.)  
Young Chul Yoon (The Catholic Univ. of Korea)

OP-24

16:30-16:40

Metformin Modulates Regulatory T and B Cells and Suppresses Th17 Cells through Various Pathways, Including Gut Microbiome, in Liver Transplantation

Soon Kyu Lee (The Catholic Univ. of Korea)

OP-25

16:40-16:50

Performance of the LI-RADS-Based Milan Criteria and Its Prognostic Implication in Potential Transplant Candidates with Hepatocellular Carcinoma

Yeong Seok Hwang (Univ. of Ulsan)

## Oral Poster Presentation | Friday, June 28, 2024

### 5. Liver Transplantation 1

<b>OP-26</b> 16:50-17:00	Impact of Pre-Liver Transplant Treatments on Imaging Accuracy of HCC Staging and Their Influence on Outcome <i>Eloisa Franchi (Policlinico di Milano, Italy)</i>
<b>OP-27</b> 17:00-17:10	Validation of Sundaram ACLF-LT-Mortality (SALT-M) Score in Korean Patients with Acute-on-Chronic Liver Failure <i>Deok-Gie Kim (Yonsei Univ.)</i>
<b>OP-28</b> 17:10-17:20	Selection of Safe Donors for Living Donor Liver Transplant Using Extended Right Lobe Graft <i>Sung Yeon Hong (Ajou Univ.)</i>
<b>OP-29</b> 17:20-17:30	Adult-to-Adult Right Lobe Graft Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure: An Initial Single-Center Experience in Vietnam <i>Thang Tran Manh (Vin Univ., Vietnam)</i>

### 6. HCC, Basic 1

**16:30-17:20** *Su Cheol Park (Korea Cancer Center Hospital), Wonhyo Seo (Ewha Womans Univ.)*

<b>OP-30</b> 16:30-16:40	Lipophilic Statin Increases Sensitivity for Lenvatinib by Suppressing YAP/TAZ in Hepatocellular Carcinoma Cell Lines and Patient-Derived Organoids <i>Jae Seung Lee (Yonsei Univ.)</i>
<b>OP-31</b> 16:40-16:50	Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma <i>Ji Won Han (The Catholic Univ. of Korea)</i>
<b>OP-32</b> 16:50-17:00	A Platinum Complex of 2-Benzoylpyridine Induce Mitochondria-Mediated Apoptosis via ROS-Dependent and p53-Independent Pathway in HepG2 Cells <i>Yuntao Bao (Guangxi Medical Univ., China)</i>
<b>OP-33</b> 17:00-17:10	Circulating Small Extracellular Vesicle-Derived Splicing Factor 3B Subunit 4 as a Non-Invasive Diagnostic Biomarker of Early Hepatocellular Carcinoma <i>Soon Sun Kim (Ajou Univ.)</i>
<b>OP-34</b> 17:10-17:20	Telomere Length and Liver Inflammation: Implications for Disease Progression and Hepatocarcinogenesis <i>Jung Eun Jang (The Catholic Univ. of Korea)</i>



## 7. HCC, Clinical 1

**16:30-17:20** Yang-Seok Koh (Chonnam National Univ.), Yong Jin Jung (Seoul National Univ.)

<b>OP-35</b> 16:30-16:40	The Prognostic Effect of Regular Surveillance for Recurrence Following Curative Resection for Hepatocellular Carcinoma: A Large Multicentre Analysis <i>Tian Yang (Jilin Univ., China)</i>
<b>OP-36</b> 16:40-16:50	Survival Comparison of Patients with BCLC Stage B Hepatocellular Carcinoma Initially Treated by Surgical Resection and TACE: A Nationwide Multicenter Study <i>Yung Kil Kim (Soonchunhyang Univ.)</i>
<b>OP-37</b> 16:50-17:00	Korean Multicenter Prospective Observational Study on Efficacy of Y90 for HCC (KURE-YTT-HCC): Interim Results <i>Dongho Hyun (Sungkyunkwan Univ.)</i>
<b>OP-38</b> 17:00-17:10	Higher Risk of Proteinuria in Atezolizumab Plus Bevacizumab Than Lenvatinib as a First-Line Systemic Treatment in Unresectable Hepatocellular Carcinoma <i>Jiwon Yang (Univ. of Ulsan)</i>
<b>OP-39</b> 17:10-17:20	Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1 $\alpha$ Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma <i>Sung Won Chung (Univ. of Ulsan)</i>

## 8. HCC, Clinical 2

**16:30-17:30** Tae Hyun Kim (National Cancer Center), Pyoung Jae Park (Korea Univ.)

<b>OP-40</b> 16:30-16:40	SGLT2i Impact on HCC Incidence in Patients with Fatty Liver Disease and Diabetes: A Nation-Wide Cohort Study in South Korea <i>Hyo Jung Cho (Ajou Univ.)</i>
<b>OP-41</b> 16:40-16:50	To Combine Local or Systemic Therapy? That Is the Question in HCC with MVI <i>Hyunki Park (Sungkyunkwan Univ.)</i>
<b>OP-42</b> 16:50-17:00	Beneficial Effect of Combined Radiation Therapy in Atezolizumab Plus Bevacizumab Treatment of Hepatocellular Carcinoma Patients with Main Portal Vein Tumor Thrombosis <i>Hyun Young Woo (Pusan National Univ.)</i>

## 8. HCC, Clinical 2

<b>OP-43</b> 17:00-17:10	A Risk Prediction Model for Hepatocellular Carcinoma in General Population without Traditional Risk Factors for Liver Disease <i>Byeong Geun Song (Sungkyunkwan Univ.)</i>
<b>OP-44</b> 17:10-17:20	Temporal Trends and Long-Term Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma within the Milan Criteria <i>Se Young Jang (Kyungpook National Univ.)</i>
<b>OP-45</b> 17:20-17:30	A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma <i>Ji Won Han (The Catholic Univ. of Korea)</i>

## 9. Surgery, Technical Issues

<b>16:30-17:20</b> <i>Sae Byeol Choi (Korea Univ.), Young-Il Choi (Kosin Univ.)</i>	
<b>OP-46</b> 16:30-16:40	Indocyanine Green Fluorescence Navigation in Laparoscopic Hepatobiliary Surgery from Cholecystectomy to Living Donor Right Hepatectomy: A Retrospective Single-Center Study in Vietnam <i>Anh Nguyen Hoang Ngoc (108 Military Central Hospital, Vietnam)</i>
<b>OP-47</b> 16:40-16:50	Outcomes of Laparoscopic Choledochotomy Using Cholangioscopy via Percutaneous-Choledochal Tube for Treatment of Hepatolithiasis and Choledocholithiasis: A Preliminary Vietnamese Study <i>Thang Tran Manh (Vin Univ., Vietnam)</i>
<b>OP-48</b> 16:50-17:00	Laparoscopic Liver Resection in Fledgling Medical Center with Novice Surgeon: Comparison with Open Resection <i>Seoung Yoon Rho (Yonsei Univ.)</i>
<b>OP-49</b> 17:00-17:10	Learning Curves for Laparoscopic Hepatectomy According to Iwate Difficulty Score Using CUSUM Analysis <i>Sehyeon Yu (Korea Univ.)</i>
<b>OP-50</b> 17:10-17:20	Disposable Bipolar Irrigated Sealer (Aquamantys®) Should Be Used with Caution during Liver Resection <i>Tae-Seok Kim (Keimyung Univ.)</i>

## 10. Autoimmune Disease

16:30-17:30

Woo Jin Chung (Keimyung Univ.), Sung-Eun Kim (Hallym Univ.)

OP-51

16:30-16:40

AMPK Activation and Hepatoprotective Effects of 1,5-Benzothiazepine Derivatives in Autoimmune Hepatitis: Docking and ADMET Analysis

Rizki Rachmad Saputra (Universitas Palangka Raya, Indonesia)

OP-52

16:40-16:50

TNF  $\alpha$  308 G/A Gene Polymorphism with Risk of Autoimmune Liver Disease: An Updated Meta-Analysis

Jin Hee Cha (St. Carolus Hospital, Indonesia)

OP-53

16:50-17:00

Advanced Fibrosis and Low Platelet Counts Are Associated with the Development of Liver Cirrhosis in Patients with Autoimmune Hepatitis: A Multicenter Cohort Study

Soon Kyu Lee (The Catholic Univ. of Korea)

OP-54

17:00-17:10

The Effectiveness of Fenofibrate Use in the Treatment of Primary Biliary Cholangitis with Incomplete Response to Ursodeoxycholic Acid

Madina Yerezhpebayeva (Nazarbayev Univ., Kazakhstan)

OP-55

17:10-17:20

In Treatment-Naive Autoimmune Hepatitis, Serum Ferritin Levels Are Linked to Progressive Liver Fibrosis

Ashok Kumar Sah (Galgotias Univ., India)

OP-56

17:20-17:30

Seropositive versus Seronegative Autoimmune Hepatitis (AIH): Comparative Analyses of Histomorphological Characteristics in Liver Biopsies of AIH Patients

Rimlee Dutta (All India Institute of Medical Sciences, India)

## 11. Others

16:30-17:20

Ki Tae Suk (Hallym Univ.), Hyun Phil Shin (Kyung Hee Univ.)

OP-57

16:30-16:40

A Multicenter Study on Hepatocellular Adenomas in Korea: Clinicopathological and Imaging Features

Subin Heo (Univ. of Ulsan)

OP-58

16:40-16:50

Epidemiology and Clinico-Epidemiologic Characteristics of Acute Viral Hepatitis in South Korea: A Prospective, Nationwide Multicenter Study

Chang Hun Lee (Jeonbuk National Univ.)



# Oral Poster Presentation

Saturday, June 29, 2024

## 12. HBV 2

09:30-10:30

Nae-Yun Heo (Inje Univ.), Seung Kak Shin (Gachon Univ.)

OP-62 09:30-09:40	Non-Linear Association between Liver Fibrosis Scores and Viral Load in Patients with Chronic Hepatitis B <i>Seung Won Choi (Univ. of Ulsan)</i>
OP-63 09:40-09:50	Seroprevalence of Sexually Transmitted Diseases among Overseas Job Seekers in Nepal <i>Arun Bahadur Chand (Kist Medical College &amp; Teaching Hospital, Nepal)</i>
OP-64 09:50-10:00	The Impact of Alanine Aminotransferase Fluctuation on the Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients <i>Youngsu Park (Seoul National Univ.)</i>
OP-65 10:00-10:10	Multi-Method Analysis Identifies Genotypes in All Evaluated Participants on-NA, B-Together Study <i>Jeong Heo (Pusan National Univ.)</i>
OP-66 10:10-10:20	HBV Mother-to-Child Transmission in Infants Born to Chronic HBV Mothers with or without Tenofovir Therapy During Pregnancy <i>Ha Linh (103 Cam Khe Clinic, Vietnam)</i>
OP-67 10:20-10:30	Impact of Maternal Hepatitis B Virus Infection on Congenital Heart Disease Risk in Offspring: A National Cohort Study <i>Yewan Park (Kyung Hee Univ.)</i>

## 13. HCV

09:30-10:30

Suk Bae Kim (Dankook Univ.), Ki Tae Yoon (Pusan National Univ.)

OP-68 09:30-09:40	Prognosis after Sustained Virologic Response of Chronic Hepatitis C Patients Treated with Sofosbuvir Based Treatment; A Multicenter Prospective Observational Study <i>Jeong Han Kim (Konkuk Univ.)</i>
OP-69 09:40-09:50	Treatment Efficacy and Safety Profile of Sofosbuvir and Velpastavir Based Treatment in South Korea: Multi-Institutional Prospective Study <i>Jae Hyun Yoon (Chonnam National Univ.)</i>

## Oral Poster Presentation | Saturday, June 29, 2024

### 13. HCV

<b>OP-70</b> 09:50-10:00	Unveiling Potential Antiviral siRNAs Targeting Hepatitis C Virus Genotype 1 for Therapeutic Breakthroughs <i>Rian Ka Praja (Universitas Palangka Raya, Indonesia)</i>
<b>OP-71</b> 10:00-10:10	Real-World Experience on the Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Patients with Chronic Hepatitis C Who Have Failed Previous Treatments with Direct Acting Antivirals in Korea: A Multi-Center Study <i>Sangdeok Shin (Sungkyunkwan Univ.)</i>
<b>OP-72</b> 10:10-10:20	Development of Diagnostic/Prognostic Marker and Therapeutic Target for HCV-Mono- and HIV/HCV-Co-Infection-Mediated Liver Diseases <i>Pankaj Chaudhary (Univ. of North Texas Health Science Center, USA)</i>
<b>OP-73</b> 10:20-10:30	Implementation of an Electronic Medical Record-Based Automatic Alert System for the Care Cascade of Hepatitis-C-Virus Infection in Patients Undergoing Elective Surgery <i>Jae Seung Lee (Yonsei Univ.)</i>

### 14. MASLD, Clinical 2

<b>09:30-10:20</b> <i>Tae-Hee Lee (Konyang Univ.), Jeong Il Yu (Sungkyunkwan Univ.)</i>	
<b>OP-74</b> 09:30-09:40	Bariatric Surgery Improves MRI-Determined Hepatic Proton Density Fat Fraction and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Obesity: A Systematic Review and Meta-Analysis <i>Hyeyoung Hwang (National Cancer Center)</i>
<b>OP-75</b> 09:40-09:50	Changes in Liver Stiffness and Controlled Attenuation Parameters of Transient Elastography According to Weight Change in Non-Alcoholic Fatty Liver Patients <i>Seong Kyun Na (Inje Univ.)</i>
<b>OP-76</b> 09:50-10:00	Mobile Lifestyle Intervention with Partial Meal Replacements Improves Liver Functions in Metabolic Dysfunction Associated Steatotic Liver Disease: A Randomized Controlled Trial <i>Ju Young Kim (Bionutrition)</i>
<b>OP-77</b> 10:00-10:10	Sequential Diagnostic Approach by Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic-Associated Steatotic Liver Disease <i>Yeowool Kang (Dong-A Univ.)</i>

## 14. MASLD, Clinical 2

<b>OP-78</b> 10:10-10:20	Effect of Thyroid Hormones on the Progression of NAFLD in a Prospective Cohort <i>Sae Kyung Joo (Seoul National Univ.)</i>
-----------------------------	---

## 15. LC and Others, Basic

<b>09:30-10:20</b>	<i>Jaeyoun Cheong (Ajou Univ.), Young-Sun Lee (Korea Univ.)</i>
<b>OP-79</b> 09:30-09:40	Verification of Liver Regeneration Using Vascularized Hepatic Microtissue Spheroids Fabricated by Bioprinting <i>Jiyoon Byeon (Hanyang Univ.)</i>
<b>OP-80</b> 09:40-09:50	Clusterin Deficiency Exacerbates Cholestatic Liver Disease through ER Stress and NLRP3 Inflammasome Activation <i>Hye-Young Seo (Keimyung Univ.)</i>
<b>OP-81</b> 09:50-10:00	Characterizing the Exhausted CD8 T Cell Subset in Liver Fibrosis <i>Jeong-Hyuk Yoon (Kangwon National Univ.)</i>
<b>OP-82</b> 10:00-10:10	Characterization and Establishment of Autologous Hepatic Progenitors for the Development of Maple Syrup Urine Disease Treatment <i>Soyoung Jeon (Hanyang Univ.)</i>
<b>OP-83</b> 10:10-10:20	Differentiation of Human Chemically Derived Hepatic Progenitor Cells to Cholangiocytes on 3D Printed Silicone Stents for Preventing Biliary Complications <i>Haerin Jeon (Hanyang Univ.)</i>

## 16. LC, Clinical and Liver Failure 2

09:30-10:30		Soon Woo Nam (The Catholic Univ. of Korea) Soung Won Jeong (Soonchunhyang Univ.)
OP-84 09:30-09:40	Non-Cirrhotic Portal Hypertension(NCPH): Demographic, Clinicopathological, Short and Long Term Outcome of Shunt Surgery – PSRS- A Tertiary Care Hospital Experience in Eastern India (Odisha)	Swamy Rajesh Hudugur (IMS & SUM Hospital, India)
OP-85 09:40-09:50	Prognostic Value of Geriatric Nutritional Index in Patients with Decompensated Cirrhosis: A Single-Center Cohort Study	Heechul Nam (The Catholic Univ. of Korea)
OP-86 09:50-10:00	Sarcopenia as an Independent Factor for Mortality in Liver Cirrhosis Patients with Spontaneous Bacterial Peritonitis	Koo Hwan Oh (Jeonbuk National Univ.)
OP-87 10:00-10:10	Wearable Technology for the Management of Liver Cirrhosis and Hypertension: A New Tool	Deepika Singh (SHUATS, India)
OP-88 10:10-10:20	Risk of Serious Infection in Patients with Chronic Liver Disease: A Nationwide Population-Based Cohort Study	Won Sohn (Sungkyunkwan Univ.)
OP-89 10:20-10:30	Terlipressin Given by Continuous Intravenous Infusion versus Intravenous Boluses in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis	Bea Regine Panganiban (Philippine General Hospital, Philippines)

## 17. DILI and Infection

09:30-10:30		JooHo Lee (CHA Univ.), Hyun Woong Lee (Yonsei Univ.)
OP-90 09:30-09:40	Thromboembolic Event Risk Factors in Patients with Liver Abscesses: Development of a Predictive Nomogram	Jaeeun Lee (The Catholic Univ. of Korea)
OP-91 09:40-09:50	Modulation of Endoplasmic Reticulum Stress by Synergetic Effect of Kaempferol and Resveratrol to Enhances Improvement in Liver Disease	Neha Sharma (Devi Ahilya Univ., India)



## 17. DILI and Infection

<p><b>OP-92</b> 09:50-10:00</p>	<p>Pterostilbene Loaded Lipid Polymer Hybrid Nanoparticles Protect against Hepatic Ischemia-Reperfusion Injury in Rats via Alteration of Bcl-2/Bax and NF-κB/SMAD-4 Pathways</p> <p><i>V Kumar (SHUATS, India)</i></p>
<p><b>OP-93</b> 10:00-10:10</p>	<p>Antihyperlipidemic and Anti-Obesity Effects of Germinated Chickpea (Cicer Arietinum) Sprouts Flour Supplementation on Liver Function and Glucose Metabolism in Wistar Male Rats</p> <p><i>Yogesh Dayma (Jawaharlal Nehru Univ., India)</i></p>
<p><b>OP-94</b> 10:10-10:20</p>	<p>Enhancing Liver Health in Type 2 Diabetes: CD26 Inhibitors &amp; Glycine Max Antioxidants Synergy</p> <p><i>Anand Krishna Singh (Shri Vaishnav Vidyapeeth Vishwavidyalaya, India)</i></p>
<p><b>OP-95</b> 10:20-10:30</p>	<p>Association between Ursodeoxycholic Acid Use and COVID-19 in Individuals with Chronic Liver Disease in South Korea</p> <p><i>Sang Yi Moon (Dong-A Univ.)</i></p>

## 18. ALD and Genetics

**09:30-10:20**

*Moon Young Kim (Yonsei Univ. Wonju), Young Kul Jung (Korea Univ.)*

<p><b>OP-96</b> 09:30-09:40</p>	<p>Protective Effect of Hepatic Stellate Cell-Derived Retinoids in Alcohol-Induced Steatotic Liver Disease</p> <p><i>Sung Eun Choi (KAIST)</i></p>
<p><b>OP-97</b> 09:40-09:50</p>	<p>Gut Microbiota Dysbiosis in Alcoholic Liver Disease Progression: Therapeutic Insights via Gut-Liver Axis</p> <p><i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i></p>
<p><b>OP-98</b> 09:50-10:00</p>	<p>Psyllium Fiber Improves Hangovers and Inflammatory Liver Injury by Inhibiting Intestinal Drinking</p> <p><i>Keungmo Yang (The Catholic Univ. of Korea)</i></p>
<p><b>OP-99</b> 10:00-10:10</p>	<p>Genome-Wide Association Study Identifies PTPRD Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease in South Korea</p> <p><i>Dong Yun Kim (Yonsei Univ.)</i></p>

## 18. ALD and Genetics

<b>OP-100</b> 10:10-10:20	Identification of Alcoholic Hepatitis-Related and Mesenchymal Stem Cell Treatment Target Genes <i>Seul Ki Han (Yonsei Univ. Wonju)</i>
------------------------------	---

## 19. Liver Transplantation 2

<b>09:30-10:30</b> <i>Doojin Kim (Gachon Univ.), Kwangho Yang (Pusan National Univ.)</i>	
<b>OP-101</b> 09:30-09:40	A 9-Year Single-Center Experience of 310 Cases of Pure Laparoscopic Donor Right Hepatectomy <i>Hyo Jung Ko (Univ. of Ulsan)</i>
<b>OP-102</b> 09:40-09:50	Evaluating the Most Suitable EGFR Equations for Predicting the Risk of End-Stage Renal Disease in Liver Transplant Recipients <i>Jae Geun Lee (Yonsei Univ.)</i>
<b>OP-103</b> 09:50-10:00	Economics Analysis of Liver Transplantation in Asia <i>Pisi Bethania Titalessy (Universitas Cenderawasih, Indonesia)</i>
<b>OP-104</b> 10:00-10:10	Impact of Non-Stenting Eversion Technique in Biliary Stricture Incidence Post-LDLT: A Critical Analysis <i>Ju-Eun Shim (Chungnam National Univ.)</i>
<b>OP-105</b> 10:10-10:20	The Modified APOLT in LDLT with Small-for-Size Graft in Cirrhotic Patient by NAFLD <i>JaRyung Han (Daegu Catholic Univ.)</i>
<b>OP-106</b> 10:20-10:30	The Comparison between Duct-to-Duct(DTD) and Choledochoduodenostomy (CDD) in Deceased Donor Liver Transplant; Should the Main Technique Be Changed? <i>Patharat Singthong (Khonkaen Univ., Thailand)</i>

## 20. HCC, Basic 2

09:30-10:30

Eunyoung Tak (Univ. of Ulsan), Jihyun An (Hanyang Univ.)

OP-107 09:30-09:40	Elucidating the Role of Liquid-Liquid Phase Separation in Hepatocellular Carcinoma: From Single-Cell Analysis to Prognostic Biomarkers <i>Rui Luo (Southwest Medical Univ., China)</i>
OP-108 09:40-09:50	Exploring Biflavonoid Derivatives as Promising PD-L1 Inhibitors for Immune Checkpoint Therapy in Hepatocellular Carcinoma by Virtual Screening, and Molecular Interaction Analysis <i>Reny Rosalina (Universitas Palangka Raya, Indonesia)</i>
OP-109 09:50-10:00	Circulating exoPD-L1 Predicts the Outcome of Patients with HCC Who Received Atezolizumab-Bevacizumab <i>Yu Rim Lee (Kyungpook National Univ.)</i>
OP-110 10:00-10:10	Glypican-3 Peptide-Linked Chimeric Antigen Receptor-Macrophages (pCAR-M): A Novel Therapeutic Strategy for Hepatocellular Carcinoma (HCC) <i>Rainbow Wing Hei Leung (The Hong Kong Polytechnic Univ., Hong Kong)</i>
OP-111 10:10-10:20	Unraveling Immune-Activated Tumor Microenvironment Correlated with Clinical Response to Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma <i>Myung Ji Goh (Sungkyunkwan Univ.)</i>
OP-112 10:20-10:30	A Novel Mitochondrial Micropeptide HRMM Interacts with ATP5B to Promote Energy Metabolism and Hepatocellular Carcinoma Progression <i>Wenli Xu (Guangxi Medical Univ., China)</i>

## 21. HCC, Clinical 3

09:30-10:30

Tae Hun Kim (Ewha Womans Univ.), Sung Hwan Lee (CHA Univ.)

OP-113 09:30-09:40	Impact of Virtual Reality Education on Disease-specific Knowledge and Anxiety for Hepatocellular Carcinoma Patient Scheduled for Liver Resection: A Randomized Controlled Study <i>Jaehun Yang (Gachon Univ.)</i>
OP-114 09:40-09:50	Clinical Course and Prognosis of Long-Term Survivors of Hepatocellular Carcinoma <i>Soon Sun Kim (Ajou Univ.)</i>

## 21. HCC, Clinical 3

<b>OP-115</b> 09:50-10:00	Heavy Smoking Increases Early Mortality Risk in Patients with Hepatocellular Carcinoma after Curative Treatment <i>Jaejun Lee (The Catholic Univ. of Korea)</i>
<b>OP-116</b> 10:00-10:10	Efficacy and Safety of First-line Systemic Therapy in Child-Turcotte-Pugh B, Unresectable Hepatocellular Carcinoma Patients: Atezolizumab Plus Bevacizumab vs. Sorafenib <i>Aryoung Kim (Inje Univ.)</i>
<b>OP-117</b> 10:10-10:20	Failure to Achieve Textbook Outcomes: Stratifying Risk among Patients Undergoing Hepatectomy for Hepatocellular Carcinoma <i>Tian Yang (Jilin Univ., China)</i>
<b>OP-118</b> 10:20-10:30	Identification of Plasma Protein Biomarkers Associated with Tyrosine Kinase Inhibitor Resistance in Hepatocellular Carcinoma Patients <i>Su Jin Kim (Ajou Univ.)</i>

## 22. Biliary and Pancreatic Disease

<b>09:30-10:30</b> <i>Nam Kyu Choi (Chosun Univ.), Seung Eun Lee (Chung-Ang Univ.)</i>	
<b>OP-119</b> 09:30-09:40	Role of Procalcitonin in Guiding Antimicrobial Usage in Acute Pancreatitis – A Randomized Clinical Trial <i>Raj Kumar Nagarajan (JIPMER, India)</i>
<b>OP-120</b> 09:40-09:50	Endoscopic Ultrasonography (Eus) Hepaticogastrostomy (Hgs) versus Choledochoduodenostomy (Cds) in Ercp-Failed Malignant Biliary Obstruction: A Systematic Review and Meta-Analysis <i>Syifa Mustika (Universitas Brawijaya, Indonesia)</i>
<b>OP-121</b> 09:50-10:00	Impact of Sarcopenia on Surgical Outcomes in Patients Undergoing Pancreaticoduodenectomy (PD): A Tertiary Care Center Experience in ODISHA- INDIA <i>Swamy Rajesh Hudugur (IMS &amp; SUM Hospital, India)</i>
<b>OP-122</b> 10:00-10:10	Perineural Invasion Signature from Spatiotemporal Transcriptomics Data Shows Distinct Tumor Biology with Therapeutic Resistance in Advanced Biliary Tract Cancer <i>Sung Hwan Lee (CHA Univ.)</i>



## HBV, Basic

PE-01	In Silico and in vitro Anti-Hepatitis B Virus Activity of Bioassay-Guided Compound Quercetin and Myricetin-3-O-Rhamnoside from Pistacia Lentiscus <i>Deepika Singh (SHUATS, India)</i>
PE-02	Hepatitis B and Hepatitis C Viruses as Aetiological Factors for Liver Cancer in Sri Lanka; A Narrative Overview <i>Baduge F.B.N.S (National Cancer Center)</i>
PE-03	Risk Factors for Mother-to-Child Transmission Using the National Hepatitis B Perinatal Transmission Prevention Program Database in Korea, 2002-2021 <i>Byung-Woo Kim (National Cancer Center)</i>
PE-04	COVID-19 Vaccination Outcomes in Living Donor Liver Transplant Recipients: Influence of Combined Immunosuppressant and HBV Antiviral Therapy <i>Ryunjin Lee (Univ. of Ulsan)</i>
PE-05	Targeting the X Gene of HBV Genotype B: Identification of Promising siRNA Antivirals <i>Qonita Sari Bustomi (Universitas Palangka Raya, Indonesia)</i>
PE-06	Current Issues of HBV Epidemiology in the Rural Province Ha Giang, Vietnam <i>Evgeniia Lichnaia (Saint-Petersburg Pasteur Institute, Russia)</i>
PE-07	Rapid Diagnostic Test (RDT) Hepatitis B Surface Antigen (HBsAg) for Pregnant Women in Indonesia <i>Putri Ayu (Andalas Univ., Indonesia)</i>
PE-08	Effectiveness of Counseling Using Video Media to Increase Knowledge about Hepatitis B <i>Hadi Saputra (Muhammadiyah Surakarta Univ., Indonesia)</i>
PE-09	Prevalence of Hepatitis B Virus Infection among Health Care Workers in a Secondary Health Center, Single-Center Study <i>Uranbaigali Dashnyam (Molor Clinic, Mongolia)</i>
PE-10	Risk Factors for Hepatitis B Incidence in Pregnant Women in Indonesia <i>Rinita Istiqomah (Yogyakarta State Univ., Indonesia)</i>

## HBV, Clinical

PE-01	<p>Efficacy and Safety of Switching Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Virologically Suppressed Chronic Hepatitis B Patients with Antiviral Resistance: Preliminary Data</p> <p><i>Jae Seung Lee (Yonsei Univ.)</i></p>
PE-02	<p>FIB-5 versus FIB-4 Index for Assessment of Hepatic Fibrosis in Chronic Hepatitis B Affected Patients</p> <p><i>Mohamed Abdel-Samiee (National Liver Institute, Egypt)</i></p>
PE-03	<p>Metabolic Dysfunction-Associated Steatotic Liver Disease Is Not Independently Associated with Complete Response to Oral Antiviral Treatment in Chronic Hepatitis B</p> <p><i>Juseok Lee (Daegu Catholic Univ.)</i></p>
PE-04	<p>Comparison of the Effects of Entecavir and Tenofovir Disoproxil Fumarate on Recurrence of Hepatocellular Carcinoma After Surgical Resection in Chronic Hepatitis B</p> <p><i>EunJee Lim (Seoul National Univ.)</i></p>
PE-05	<p>Association of Nucleos(T)ide Analog Therapy with Parkinson Disease in Patients with Chronic Hepatitis B Virus Infection: Preliminary Results of A Nationwide Cohort Study</p> <p><i>Ha Il Kim (Hanyang Univ.)</i></p>
PE-06	<p>Epidemiological Insights into Hepatitis B through Blood Samples from the 2020 Korea National Health and Nutrition Examination Survey</p> <p><i>Chang Hun Lee (Jeonbuk National Univ.)</i></p>
PE-07	<p>Tenofovir Is Associated with A Better Prognosis for Hepatitis B Virus-Related Hepatocellular Carcinoma Than Entecavir</p> <p><i>Sung Won Chung (Univ. of Ulsan)</i></p>
PE-08	<p>Genomic Landscape of Non-Hodgkin Lymphoma Patients with Current or Past Hepatitis B Virus Infections</p> <p><i>Moon Haeng Hur (Seoul National Univ.)</i></p>
PE-09	<p>A Multicenter Observational Study to Compare the Effects of Drug Convenience on Safety and Efficacy of Entecavir Tablet and ODT (Orally Disintegrating Tablet) in Patients with Chronic Hepatitis B</p> <p><i>Hyunkyung Lee (Chong Kun Dang Pharmaceutical Corp.)</i></p>

## HBV, Clinical

PE-10	Risk of Hepatocellular Carcinoma after Curative Treatment When Switching from Tenofovir Disoproxil Fumarate or Entecavir to Tenofovir Alafenamide: A Real-World Multicenter Cohort Study <i>Hyunjae Shin (National Cancer Center)</i>
PE-11	An Artificial Intelligence Model Utilizing Computed Tomography Auto-Segmentation to Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B <i>Hyunjae Shin (National Cancer Center)</i>
PE-12	The Changes in Plasma HBV-RNA Levels in The Patients with Chronic Hepatitis B are Treated with Tenofovir Alafenamide (TAF) <i>Ha Linh (103 Cam Khe Clinic, Vietnam)</i>
PE-13	Survey on the Change of HBcrAg in Patients with Chronic Hepatitis B before and after Treatment with Tenofovir Disoproxil Fumarate 300mg <i>Pham Thi Thuy (Bach Mai Hospital, Vietnam)</i>
PE-14	Impact of Antiretroviral Therapy on Liver Enzymes in HIV Patients in Western Regional Hospital, Nepal: A Pre-Post Study <i>Nim Bahadur Dangi (Pokhara Univ., Nepal)</i>
PE-15	Post-Vaccination Immunity Against Hepatitis B Among between the Ages 10 to 35 Years <i>Doljinsuren Enkhbayar (Yonsei Univ.)</i>
PE-16	DNA-Guided Hepatitis B Diagnosis, Viral Load Is Essential, But Not Sufficient <i>Surya Ram Duwal (Central Diagnostic Laboratory and Research Center, Nepal)</i>
PE-17	The Relationship between miR-146a, Platelet to Lymphocyte Ratio (PLR) and Liver Fibrosis in Hepatitis B <i>Najma Nusaibah (Sebelas Maret Univ., Indonesia)</i>

## HCV, Basic

PE-01	Interleukin-18 rs187238 Gene Polymorphism with Risk of Chronic Hepatitis C: An-Updated Meta-Analysis <i>Jin Hee Cha (St. Carolus Hospital, Indonesia)</i>
-------	--



## HCV, Basic

PE-02	Risk of Extrahepatic Cancers among Patients with Chronic Hepatitis C Virus in Korea: A Population-Based Retrospective Cohort Study using National Health Insurance Service Claim Data, 2002-2022 <i>Yoon Park (National Cancer Center)</i>
PE-03	A Multilevel Analysis of Factors Affecting the Prevalence of Hepatitis C Virus <i>Hwa Young Choi (National Cancer Center)</i>
PE-04	Trends in Prevalence and Survival Rates among Hepatitis C Patients and Substance Users in South Korea, 2002-2023 <i>Hwa Young Choi (National Cancer Center)</i>
PE-05	The Impact of Effect of Increased Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) on Bilirubin (BIL) in Hepatitis C Patients <i>Devi Yulia Rahmi (Universitas Andalas, Indonesia)</i>

## HCV, Clinical

PE-01	Association Between Hepatitis C, Autoimmune Hepatitis and Insulin Resistance, Results from NHANES (National Health and Nutrition Examination Survey) <i>Javad Alizargar (Kashan Univ. of Medical Sciences, Iran)</i>
PE-02	Glecaprevir/Pibrentasvir Improves Fibrosis after SVR and during Long-Term Follow-Up <i>Yang Jae Yoo (Korea Univ.)</i>
PE-03	Efficacy and Safety of Locally Developed and Imported Direct-Acting Antiviral Agents for Hepatitis C in China-A Systematic Review, Meta-Analysis <i>Zhitao Wang (Peking Union Medical College, China)</i>
PE-04	Prognosis after Sustained Virologic Response of Elderly Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals <i>Jeong Han Kim (Konkuk Univ.)</i>
PE-05	Prognosis after Sustained Virologic Response of Chronic Hepatitis C Patients with Cirrhosis Treated with Direct-Acting Antiviral Treatment <i>Jeong Han Kim (Konkuk Univ.)</i>

## HCV, Clinical

PE-06	Assessing Liver Fibrosis in Patients with Chronic Hepatitis C Genotype 6 Treated with Ledvir <i>Le Thi Thu Hien (Thai Nguyen Univ., Vietnam)</i>
PE-07	Real-World Data with Pangenotypic Direct-Acting Antivirals: Preliminary Results of the SVR10K Study <i>Sungshin Kwon (Gilead Sciences, Inc.)</i>
PE-08	Long-Term Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antivirals in Pediatric Patients with Hepatitis C Virus <i>Sungshin Kwon (Gilead Sciences, Inc.)</i>
PE-09	Improved Linkage of Care of Chronic Hepatitis C among People Who Use Drugs (PWUDs) with On-Site-Treatment Program: A Prospective, Multicenter Study <i>Gwang Hyeon Choi (Seoul National Univ.)</i>

## Alcoholic Liver Disease

PE-01	Comparison of the Effects of Medical Addiction Therapy on Liver Function in Alcohol Use Disorder: Retrospective Cohort Study <i>EunJee Lim (Seoul National Univ.)</i>
PE-02	The Impact of Psychiatric Intervention on Outcomes in Patients with Alcoholic Liver Disease: A Retrospective Cohort Study <i>Hyundam Gu (The Catholic Univ. of Korea)</i>

## Autoimmune Liver Disease

PE-01	Discordance between Biochemical Response and Histological Remission in Patients with Autoimmune Hepatitis <i>Jaehong Jeong (Daegu Catholic Univ.)</i>
PE-02	Retrospective Analysis of Autoimmune Hepatitis and Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndrome in a Tertiary Hospital <i>Sung Hwan Yoo (Yonsei Univ.)</i>
PE-03	Associations of Antinuclear Antibody with Mitochondrial Antibody and Smooth Muscle Antibody in Autoimmune Liver Diseases <i>Chen Ching Ju (Chi Mei Medical Center, Taiwan)</i>

## Cell Biology and Molecular Biology

PE-01	Exploring CD47 as a Prognostic Marker for Pancreatic Cancer and Its Association with Adverse Clinicopathologic Features <i>Eden Demere Amare (Hanyang Univ.)</i>
PE-02	Human PAH mRNA in vivo Screening for the Development of Phenylketonuria Treatment <i>Dayoung Kim (Hanyang Univ.)</i>
PE-03	Heat-Inactivated Bacteria: Potential Anti-Cancer Agents against Liver, Pancreatic, and Gallbladder Cancer Cell Lines <i>Ranbir Singh (Shakuntla Hospital and Research Center, India)</i>
PE-04	A Modern Approach for Transplanting Glucose-Sensitive Cells That Produce Insulin <i>Nodirjon Ruzimurodov (Institute of Immunology and Human Genomics, Uzbekistan)</i>
PE-05	Therapeutic Potential of Moringa Oleifera Leaves Ethanol Extract in Restoring Hepatic Enzyme Levels and Metabolic Functions in an Experimental Rat Model of Hypothyroidism <i>Assiya Karaltayeva (Al-Farabi Kazakh National Univ., Kazakhstan)</i>
PE-06	Organoid Technology as a Precise Prediction Platform of Systematic Treatment for Hepatocellular Carcinoma <i>Dong Hee Ryu (Chungbuk National Univ.)</i>
PE-07	Codon Usage and Possible Involvement of Genes Associated with Liver Cancer <i>Preeti Puranik (Oriental Univ., India)</i>
PE-08	Liver Biopsy Results for Diagnosis and Differential Diagnosis of Liver Disorders: A Retrospective Study at Intermed Hospital, Mongolia <i>Amarjargal Batdelger (Intermed Hospital, Mongolia)</i>

## Genetic

PE-01	Protein-Centric Omics Analysis Reveals Circulating Complements Linked to Non-Viral Liver Diseases as Potential Therapeutic Targets <i>Yingzhou Shi (Shandong Univ., China)</i>
-------	---

## Genetic

PE-02 Massively Parallel Reporter Assay for Fine-Mapping of NAFLD-Specific Expression Quantitative Trait Locus (NAFLD-eQTL)

*Hyungtai Sim (Seoul National Univ.)*

## Drug and Toxic Injury

PE-01 Double-Edged Sword? A Bibliometric Look at Antiretrovirals and Liver Injury in HIV Patients (2018-2024)

*Willy Febri (Universitas Muhammadiyah Palangka Raya, Indonesia)*

PE-02 Development of CA19-9-Targeting Chimeric Antigen Receptor-Expressing Cytotoxic Cells for the Treatment of Cholangiocarcinoma

*Deok Hwa Seo (The Catholic Univ. of Korea)*

PE-03 Risk of Dyslipidemia and Cardiovascular Events in Chronic Hepatitis B Patients Taking Tenofovir Alafenamide: A National Wide Data Analysis

*Jae Young Kim (Soonchunhyang Univ.)*

PE-04 Liver and Kidney Injury from Ethylene Glycol/Diethylene Glycol-Contaminated Cough Syrups in Children: A Literature Review

*Willy Febri (Universitas Muhammadiyah Palangka Raya, Indonesia)*

PE-05 Parenteral Nutrition-Induced Liver Function Complications: Incidence, Risk Factors, and Prognosis

*Jae Woo Park (Soonchunhyang Univ.)*

PE-06 Pharmacovigilance Study on Potential Interaction Aspects of Use in Inhibiting Covid-19 Virus in Indonesia

*Andi Nursanti (Andini Persada College of Health Sciences, Indonesia)*

PE-07 Unveiling the Concealed Risks of Using Bajakah Kalalawit Leaves (*Uncaria gambir Roxb.*) Through Toxicity Tests on Liver

*Decenly Decenly (Universitas Palangka Raya, Indonesia)*

## Liver Cirrhosis, Portal Hypertension with Cx. Basic

PE-01 Childhood Non-Hodgkin Lymphoma (NHL) and Myeloproliferative Neoplasm with Budd Chiari syndrome: A Rare Presentation

*Prachi Singh (Indraprastha Apollo Hospital, India)*

## Liver Cirrhosis, Portal Hypertension with Cx. Clinical

PE-01	<p>Predictive Performance Concerning Distinct SMI Cut-Offs of Sarcopenia for Mortality among Cirrhosis</p> <p><i>Chao Sun (Tianjin Medical Univ. General Hospital, China)</i></p>
PE-02	<p>Zinc Deficiency in Patients with Chronic Liver Disease: Single Center Study</p> <p><i>Lkhagvasuren Batbaatar (Mongolian Univ. of Science and Technology, Mongolia)</i></p>
PE-03	<p>Sarcopenia and Sarcopenic Obesity in Liver Cirrhosis in the Kazakh Population. Experience of the National Research Oncology Center</p> <p><i>Khalima Malgazdarova (National Research Oncology Center, Kazakhstan)</i></p>
PE-04	<p>Endoscopic Prophylaxis and Treatment of Portal-Genesis Oesophageal Haemorrhage</p> <p><i>Lugmar Svarov (Almaty City Emergency Hospital, Kazakhstan)</i></p>
PE-05	<p>Synchronous Splenectomy and Hepatectomy in the Management of Hepatocellular Carcinoma with Liver Cirrhosis and Hypersplenism: Assessing Indications and Outcomes</p> <p><i>Nguyen Minh Trong (National Hospital of Tropical Diseases, Vietnam)</i></p>
PE-06	<p>Combine Surgery and Interventional Radiologic Method to Achieve Curative Treatment for Patients with HCC and Clinically Significant Portal Hypertension</p> <p><i>Giang Truong Nguyen (National Hospital of Tropical Diseases, Vietnam)</i></p>
PE-07	<p>The Experience of Using a Modified Endoscopic Ligator for The Treatment of Bleeding from Esophageal Varicose Veins</p> <p><i>Halima Bebezova (Kyrgyz-Russian Slavic Univ., Kyrgyzstan)</i></p>
PE-08	<p>Fecal Calprotectin as a Potential Non-Invasive Diagnostic Biomarker for Hepatic Encephalopathy: A Meta-Analysis</p> <p><i>Rukesh Yadav (Tribhuvan Univ., Nepal)</i></p>
PE-09	<p>The Value of Platelet-Albumin-Bilirubin Score in Predicting Early Rebleeding and In-Hospital Mortality in Cirrhotic Patients with Acute Variceal Bleeding</p> <p><i>Le Thi Thu Hien (Thai Nguyen Univ., Vietnam)</i></p>
PE-10	<p>A Report of Lesions of Liver in Autopsy</p> <p><i>Harshita Dubey (All India Institute of Medical Sciences, India)</i></p>

## Liver Failure, Acute

PE-01	Exploring Self-Efficacy Levels Among Chronic Liver Disease Patients in Indonesia: Implications for Healthcare Support and Intervention <i>Pisi Bethania Titalessy (Universitas Cenderawasih, Indonesia)</i>
PE-02	Analysis of Conformational Changes in The Aromatic Residue Binding Site of FXa Using Molecular Simulations <i>Irsandi Dwi Oka Kurniawan (Institut Teknologi Sepuluh Nopember, Indonesia)</i>
PE-03	Formulating the Degenerative Changes are Associated with Acute Infective Viral Hepatitis Patients <i>Manju Rani (CHC Siyana, India)</i>

## Liver, Infectious Disease

PE-01	Prevalence and Associated Factors of Liver Disease in Indonesia: Analysis from the Indonesia Family Life Survey <i>Nadyatul Husna (Alumnus of Universitas Andalas, Indonesia)</i>
PE-02	Seroprevalence of Hepatitis A, E, and Human Immunodeficiency Virus in People Who Use Drugs in South Korea <i>Eun Sun Jang (Seoul National Univ.)</i>
PE-03	Humanized Mice Efficiently Engrafted with Primary Human Hepatocytes are Useful for Liver Disease Research <i>Hee Sun Byun (GHBIO)</i>
PE-04	Identification of Cytotoxic CD4+ Population among CD69(-) Liver-Infiltrating T-Cells <i>Eun Ji Jang (The Catholic Univ. of Korea)</i>
PE-05	Unveiling the Silent Invader: A Case of Hydatid Disease in a Filipino Male Presenting as Abdominal Pain <i>Natasha Bernadine A. Mapa (Makati Medical Center, Philippines)</i>
PE-06	Method of Transfistular Elimination of Cystobiliary Fistulas of The Residual Cavity after Echinococcectomy from the Liver <i>Farukh Mahmudzoda (Avicenna Tajik State Medical Univ., Tajikistan)</i>

## Liver, Infectious Disease

PE-07	Sequence of Choosing Tactics for Minimally Invasive Treatment of Obstructive Jaundice of Parasitic Genesis <i>Farukh Mahmudzoda (Avicenna Tajik State Medical Univ., Tajikistan)</i>
PE-08	Minimally Invasive Treatment of Liver Echinococcosis, Subdiaphragmatic Localization <i>Farukh Mahmudzoda (Avicenna Tajik State Medical Univ., Tajikistan)</i>
PE-09	Analysis of Socio-Economic and Mental Health Factors in Someone Affected by Liver Disease <i>Yusril Yusril (UIN Syeh M.Djamil Djambek Bukittinggi, Indonesia)</i>
PE-10	Pattern of Liver Function Tests Abnormality in Dengue Fever and Its Clinical Outcome <i>Saroj Pokhrel (Mediplus Hospital and Trauma Center, Nepal)</i>
PE-11	Liver Enzymes Alterations in Laboratory Confirmed Bacteremic Adult Patients <i>Deependra Hamal (Manipal College of Medical Sciences, Nepal)</i>
PE-12	Harmfulness Effects of Pedalium Murex L. Extract in Liver and Kidney Histopathological Examination in Mus Musculus <i>Ramesh Kumar Meena (Univ. of Rajasthan, India)</i>
PE-13	Urinary Tract Infection In Non-Hospitalized Patients with Cirrhosis and No Symptoms of Urinary Tract Infection: A Case Series Study <i>Zoljargal Badam (Dornod Univ., Mongolia)</i>
PE-14	Leishmania Donovanii: CD2 Biased Immune Response Skews the SAG Mediated Therapy for a Predominant Th1 Response in Experimental Infection <i>Sukrat Sinha (Sri Venkateswara College, India)</i>
PE-15	Deciphering the Antipathogenic Actions of Epigallocatechin-3-Gallate Against Coxiella Burnetii in Granulomatous Hepatitis: A Microbioinformatics Exploration <i>Astrid Ekklesia Saputri (Universitas Palangka Raya, Indonesia)</i>
PE-16	Burden of Viral Hepatitis and Syphilis Co-Infection among People Living with HIV in Nepal <i>Saroj Kumar Gupta (Pokhara Univ., Nepal)</i>

## MASLD, Basic

PE-01	Lactobacillus Acidophilus Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Jeong Ha Park (Hallym Univ.)</i>
PE-02	Streptococcus Salivarius Mitigates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating the NLRP3 Inflammasome Pathway <i>Jeong Su Kim (Hallym Univ.)</i>
PE-03	The Combination of Pterocarpus Marsupium Extract and Glibenclamide Leads to Significant Ultrastructural and Biochemical Alterations in a Liver of Non-Alcoholic Fatty Liver Disease <i>Neha Sharma (Devi Ahilya Univ., India)</i>
PE-04	Essential Adolescent Lifestyle: Coffee Drinking Habit Contributes to Liver Disease: Evidence from Asia <i>Vivi Usmayanti (Economics Faculty, Universitas Sriwijaya, Indonesia)</i>
PE-05	Psychosocial Problems and Coffee Consumption as Coping Strategy to Prevent Non-Alcoholic Fatty Liver Disease: An Observation <i>Vivi Usmayanti (Economics Faculty, Universitas Sriwijaya, Indonesia)</i>
PE-06	Analyzing the Role of Advanced Biomarker Kallistatin in NAFLD <i>Rajiv Nehra (Rani Durgavati Medical College, India)</i>
PE-07	CKD-01, a Novel Triple LOXL2/LOXL3/VAP-1 Inhibitor Effectively Mitigates Hepatic Fibrosis <i>Hyun-kyung Kim (Chong Kun Dang Pharmaceutical Corp.)</i>
PE-08	Effect of Combined Treatment with Statins and Ezetimibe in NASH Model: Inhibition of Macrophage via NF-kB Translocation and Activation <i>Seul Ki Han (Yonsei Univ. Wonju)</i>
PE-09	Solid Lipid Nanoparticle Ganodric Acid Ameliorates the High Fat Induced Nonalcoholic Fatty Liver Disease via Alteration Gut Microbiota and PI3K/AKT/mTOR Signaling Pathway <i>V Kumar (SIHAS, India)</i>
PE-10	Comprehensive of Non-Alcoholic Fatty Liver Disease: Study Based on Indian Railway Employee (NWR) <i>Rahul Kumar Meena (Indian Railway, India)</i>



## MASLD, Basic

PE-11	Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Metabolic Syndrome and Contribution of Metabolic Risk Factors in Non-Diabetic North Indian Males <i>Dharmveer Yadav (All India Institute of Medical Sciences, India)</i>
PE-12	Assessment of Nonalcoholic Fatty Liver Disease Knowledge Among Healthcare Workers in a Easter Province: A Cross-Sectional Pilot Study <i>Badam Bunguuzei (Dornod Univ., Mongolia)</i>
PE-13	Amelioration of HOMA-IR and Hepatoprotective Properties of Dipeptidyl Peptidase-IV Inhibitors Against Metabolic Associated Fatty Liver Disease in Type 2 Diabetic Mellitus <i>Purnima Tripathi (Shri Vaishnav Vidyapeeth Vishwavidyalaya, India)</i>
PE-14	Histopathological Analysis of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in Swiss Albino Mice after Exposure to Refined Diet <i>Gnanadesigan Ekambaram (Sankalchand Patel Univ., India)</i>
PE-15	Evaluation of Liver Function Test Results in Vegetarian and Non-Vegetarian Subjects <i>Sajina Paudel (Pokhara Univ., Nepal)</i>

## MASLD, Clinical

PE-01	Non-Invasive Diagnostic Tools for NAFLD: Meta-Analysis in Clinical Practice <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>
PE-02	Association between Sarcopenia and Coronary Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Yeonjung Ha (CHA Univ.)</i>
PE-03	Association of Metabolic Syndrome and Other Related Factors with Nonalcoholic Fatty Liver Disease (NAFLD) Severity <i>Javad Alizargar (Kashan Univ. of Medical Sciences, Iran)</i>
PE-04	Effectiveness of the ALT/AST Ratio for Predicting Insulin Resistance in a Korean Population: A Large-Scale, Cross-Sectional Cohort Study <i>Seul Ki Han (Yonsei Univ. Wonju)</i>

## MASLD, Clinical

PE-05	Association between Nonalcoholic Fatty Liver Disease and Breast Density in Premenopausal Women in Primary Institution <i>Min Seong Kim (Millenium Seoul IM Clinic)</i>
PE-06	Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease <i>Shiyu Xiao (Sichuan Provincial People's Hospital, China)</i>
PE-07	Quantifying Microvascular Changes in Early-Stage Nonalcoholic Steatohepatitis (NASH) through Multiscale Mathematical Modeling <i>Rifaldy Fajar (Karlstad Univ., Sweden)</i>
PE-08	Effects of Obeticholic Acid (OCA) in the Management of Nonalcoholic Steatohepatitis (NASH) <i>Tatia Khachidze (Grigol Robakidze Univ., Georgia)</i>
PE-09	Gut Microflora Composition in Patients with Non-Alcoholic Fatty Liver Disease <i>Tatia Khachidze (Grigol Robakidze Univ., Georgia)</i>
PE-10	The Predominant Impact of the Number of Risk Factors on Coronary Atherosclerosis Progression in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Aryoung Kim (Inje Univ.)</i>
PE-11	Effects of Lifestyle Modification on Liver Fat, Liver Function Test, and Fecal Microbiota in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Jong Woo Hahn (Seoul National Univ.)</i>
PE-12	Appendicular Skeletal Muscle Mass is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Severity in Young Men: A Cross-sectional and Longitudinal Study <i>Jaejun Lee (The Catholic Univ. of Korea)</i>
PE-13	Performance of Non-invasive Steatosis Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults <i>Jaejun Lee (The Catholic Univ. of Korea)</i>
PE-14	Impact of Korean Military Service on Steatotic Liver Disease: A Longitudinal Study of Pre-Enlistment and In-Service Health Check-Ups <i>Jaejun Lee (The Catholic Univ. of Korea)</i>

## MASLD, Clinical

PE-15	Limited Performance of the Steatosis-Associated Fibrosis Estimator Score in Young Asian Subjects with Steatotic Liver Disease <i>Jiwon Yang (Univ. of Ulsan)</i>
PE-16	Association of Weight-Adjusted-Waist Index with Liver Steatosis and Fibrosis in Biopsy Proved NAFLD <i>Young Kul Jung (Korea Univ.)</i>
PE-17	Exploring Autophagy-Related microRNAs in NAFLD Progression: A Machine Learning Approach to Epigenetic Mechanisms <i>Sahnaz Vivinda Putri (International Univ. Semen Indonesia, Indonesia)</i>
PE-18	Short-Chain Fatty Acids as Predictive Markers and Modulators of Metabolic Associated Fatty Liver Disease Progression Through Machine Learning Analysis <i>Sahnaz Vivinda Putri (International Univ. Semen Indonesia, Indonesia)</i>
PE-19	Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers <i>Jaejun Lee (The Catholic Univ. of Korea)</i>
PE-20	Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Burden among People Living with HIV (PLHIV): A Cross-Sectional Study <i>Natasha Bernadine A. Mapa (Makati Medical Center, Philippines)</i>
PE-21	Repurposing SGLT2 Inhibitor to Attenuate Oxidative Stress Mediated Hepatic Injury in Wistar Rats <i>Layth Ahmed Al-Khafaji (RAK Medical &amp; Health Sciences Univ., United Arab Emirates)</i>
PE-22	AI-Driven Analysis of Phytonutrient Impact on Non-Alcoholic Fatty Liver Disease Progression: A Machine Learning Approach <i>Andi Nursanti (Andini Persada College of Health Sciences, Indonesia)</i>
PE-23	Clinico-Demographic Profile of Individuals with Incidental Ultrasound Finding of Fatty Liver <i>Rekha Poudel (Mediplus Hospital and Trauma Center, Nepal)</i>
PE-24	Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among Hospital Staff, Single Center Study <i>Nyam Biziya (Dornod Medical Center, Mongolia)</i>

## MASLD, Clinical

PE-25	Association between Fatty Liver and Colonic Polyp <i>Khishgee (Intermed Hospital, Mongolia)</i>
PE-26	Relationship between the Hepatic Steatosis Index and Microalbuminuria: Using Large Sized Cohort Real World Data <i>Seul Ki Han (Yonsei Univ. Wonju)</i>

## Liver Cancer, Basic

PE-01	Cholangiocarcinoma Cancer Modelling by CRISPR-Cas9 and Hepatic Progenitor Organoid Recapitulates Cholangiocarcinoma Carcinogenesis and Pathophysiology <i>Michael Adisasmita (Hanyang Univ.)</i>
PE-02	Hesperidin Attenuates DEN Induced Liver Cancer in Rats via Inhibition of Activation of AMPK and Blocking of MTOR-Dependent Signaling Pathway <i>Deepika Singh (SHUATS, India)</i>
PE-03	Disparities in Hepatic Microbial Composition between Tumor and Adjacent Normal Liver Tissue: A Pivotal Role in Hepatocellular Carcinoma Development <i>Jae Hyun Yoon (Chonnam National Univ.)</i>
PE-04	Younger Male Predominance of TERT Genetic Alterations and HBV Integration: Implications for Sex Disparity in HBV-Related HCC <i>Hye Seon Kim (The Catholic Univ. of Korea)</i>
PE-05	Inhibition of SFK and Its Effect on Cancer Stem Cell Markers Expression in HBV-Related HCC <i>Korri El Khobar (Eijkman Research Centre for Molecular Biology - BRIN, Indonesia)</i>
PE-06	Liver-Specific Long Non-Coding RNA Suppresses Hepatocellular Carcinoma (HCC) Migration and Invasion, and Its Correlation with HCC Patient Survival in Hepatocellular Carcinoma Progression <i>Se Ha Jang (Ajou Univ.)</i>
PE-07	Therapeutic Potential of Methanol Extract from <i>Peronema Canescens</i> Targeting VEGFR-BRAF Signaling in Hepatocellular Carcinoma: Docking and ADMET Study <i>Rizki Rachmad Saputra (Universitas Palangka Raya, Indonesia)</i>

## Liver Cancer, Basic

PE-08	Clinicopathologic and Molecular Characteristics of Hepatic Angiomyolipoma: TP53 Mutation Can Be Associated with Malignant Behavior <i>In Hye Song (Univ. of Ulsan)</i>
PE-09	Diagnostic and Prognostic Significance of the PTEN Gene in Periapillary Carcinoma <i>Asgar Ali (All India Institute of Medical Sciences, India)</i>
PE-10	Association of Obesity with Risk of Liver Cancer: A Systematic Review and Meta-Analysis <i>Muh Syaiful Akbar (Hasanuddin Univ., Indonesia)</i>
PE-11	Synergistic Anticancer Effects of MicroRNA-21 Inhibitor Combined with Sorafenib in Hepatocellular Carcinoma <i>Jiye Kim (Univ. of Ulsan)</i>
PE-12	Polymeric Nanoparticles Loaded Gallic Acid Mitigates Diethylnitrosamine Induced Hepatic Cancer via Targeting Endoplasmic Reticulum (ER) Stress Markers, Apoptotic Markers and Autophagy Markers and PI3K/pAKT/mTOR/NF-κB/FOXO3a Pathway <i>Deepika Singh (SHUATS, India)</i>
PE-13	O-GlcNAcylation of PRDX1 Enhances Its Stability and Promotes Hepatocellular Carcinoma Progression via Enhancing LRP6-Mediated Wnt Signaling <i>Luo Dai (The First Affiliated Hospital of Guangxi Medical Univ., China)</i>
PE-14	Combined Hepatocellular-Cholangiocarcinoma: A Case Report and Literature Review <i>Amgalantuul Batdelger (National Cancer Center of Mongolia, Mongolia)</i>
PE-15	Therapeutic Potential of Avicularin in the Medicine for the Treatment of Various Forms of Cancerous Disorders: A Phytotherapeutic Approach for the Treatment of Hepatocellular Carcinoma <i>Dinesh Kumar Patel (SHUATS, India)</i>
PE-16	Biological Potential of Hernandezine for Their Antitumor Effects in Hepatocellular Carcinoma (HCC) in HepG2 and Hep3B Cells with Their Molecular Mechanisms <i>Dinesh Kumar Patel (SHUATS, India)</i>

## Liver Cancer, Basic

PE-17	Biological Potential and Therapeutic Effectiveness of Magnolin for the Treatment of Hepatocellular Carcinoma through Its Effect on Proliferation, Cell Cycle Arrest and Apoptosis <i>Dinesh Kumar Patel (SHUATS, India)</i>
PE-18	Molecular Docking and Structure-Based Drug Design Strategies for Liver Cancer <i>Shiv Kumar Yadav (Govt LBS PG College, India)</i>
PE-19	Detection of Liver Associated Noncoding RNAs in Liver Cancer Patients Tissue Based by Bioinformatics Analysis <i>Shiv Kumar Yadav (Govt LBS PG College, India)</i>
PE-20	The Impact of Self-Efficacy as Self Management on Hepatocellular Carcinoma (HCC) Patient in Indonesia <i>Rani Marsyanda (Sultan Thaha Islamic State Univ., Indonesia)</i>
PE-21	Solid Lipid Nanoparticles Loaded Hesperidin Modulates High Fat Diet and Diethylnitrosamine Induced Obesity and Hepatocarcinogenesis in a Rats via Targeting Protein Kinase C(PKC) $\alpha$ /Rac1 Signaling Pathway <i>Niti Singh (Marlabs Innovation Ltd., India)</i>

## Liver Cancer, Clinical

PE-01	Initial Experience and Feasibility of Laparoscopic Liver Resection and Regional Lymph Node Dissection of Intrahepatic Cholangiocarcinoma <i>JaRyung Han (Daegu Catholic Univ.)</i>
PE-02	The Relationship between Operative Approach and Pulmonary Complications after Hepatectomy for HCC: A Multicenter Overlap Propensity Score-Weighted Analysis of Laparoscopic vs. Open Hepatectomy <i>Tian Yang (Jilin Univ., China)</i>
PE-03	The Paradox of Bodyweight: Lean, but Not Obese, as a Predictor of Poor Prognosis after Surgical Resection for NAFLD-Associated Hepatocellular Carcinoma <i>Tian Yang (Jilin Univ., China)</i>
PE-04	Quantifying Intraoperative Decision Support: Real-Time Deep Learning Augmentation for Hepatic Vascular Assessment in Hepatobiliary Resections <i>Sahnaz Vivinda Putri (International Univ. Semen Indonesia, Indonesia)</i>

## Liver Cancer, Clinical

PE-05	Comparative Analysis of Local Ablative Treatment Efficacy in Very Elderly vs. Elderly Patients with Hepatocellular Carcinoma <i>Sun Woong Kim (Veterans Health Service Medical Center)</i>
PE-06	Biomarkers for Early Detection and Prognostication of Liver Cancer: A Meta-analysis <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>
PE-07	Combination of Radiation Therapy Improve Efficacy of Atezolizumab Plus Bevacizumab (ATE+BEVA) therapy IN Advanced Hepatocellular Carcinoma with High Risk Factor (Huge Tumor, Biliary and Main Portal Vein Invasion) <i>Sangyoun Hwang (Dongnam Institute of Radiological &amp; Medical Sciences)</i>
PE-08	Clinical Biomarker to Predict Efficacy of Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma after Failure of Prior Atezolizumab Plus Bevacizumab Therapy <i>Sangyoun Hwang (Dongnam Institute of Radiological &amp; Medical Sciences)</i>
PE-09	Improving Diagnostic Performance of Mucinous Cystic Neoplasm of the Liver: Validation and Modification of 2022 EASL Criteria <i>Jeong Ah Hwang (Sungkyunkwan Univ.)</i>
PE-10	A Real-Life Experience of Atezolizumab and Bevacizumab Therapy in Patient with Advanced Hepatocellular Carcinoma in Gwangju-Jeonnam Province <i>Ga Ram You (Chonnam National Univ.)</i>
PE-11	Clinical Characteristics and Risk Factors of Extrahepatic Recurrence after Hepatectomy of Hepatocellular Carcinoma without Intrahepatic Hepatocellular Carcinoma: A Multi-Institutional Observational Study <i>Jae Hyun Yoon (Chonnam National Univ.)</i>
PE-12	Metformin's Anti-Cancer Potential Short-Term Recurrence Following Hepatectomy for Hepatocellular Carcinoma <i>Janghan Jung (Hallym Univ.)</i>
PE-13	Vascular Endothelial Growth Factor and Hepatocyte Growth Factors Predicts Prognosis Post Stereotactic Body Radiation in Advanced Hepatocellular Carcinoma <i>Nirupma Trehanpati (Institute of Liver and Biliary Sciences, India)</i>

## Liver Cancer, Clinical

PE-14	The Efficacy and Safety of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma <i>Eunho Choi (Korea Univ.)</i>
PE-15	Comparison of Intrahepatic Metastasis and Multicentric Occurrence in Multiple Hepatocellular Carcinoma after Liver Transplantation <i>Hwa-Hee Koh (Yonsei Univ.)</i>
PE-16	Early Bevacizumab Dose and Time Modifications Affect Efficacy of Atezolizumab Plus Bevacizumab Regimen for Advanced Hepatocellular Carcinoma Patients <i>Federico Rossari (Vita-Salute San Raffaele Univ., Italy)</i>
PE-17	Survival Outcomes According to the Timing of Switching to Atezolizumab Plus Bevacizumab in TACE-Treated Patients with HCC <i>Jiwon Yang (Univ. of Ulsan)</i>
PE-18	Limited Generalizability of Results of a Retrospective Single-Center Cohort Study of Prognosis of Hepatocellular Carcinoma <i>Sung Won Chung (Univ. of Ulsan)</i>
PE-19	Pre- and Postoperative Predictors of Extrahepatic Recurrence after Curative Resection for Hepatocellular Carcinoma <i>Chang Hun Lee (Jeonbuk National Univ.)</i>
PE-20	Expression of Citrullinated Glial Fibrillary Acidic Protein Is Closely Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma <i>Sung-Eun Kim (Hallym Univ.)</i>
PE-21	Comparative Efficacy of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir on Hepatocellular Carcinoma Incidence: Nationwide Data Analysis <i>Hye-jin Yoo (Soonchunhyang Univ.)</i>
PE-22	Comparative Analysis of Malignant Hepatocellular Neoplasm, Not Otherwise Specified versus Hepatoblastoma and Pediatric Hepatocellular Carcinoma <i>In Hye Song (Univ. of Ulsan)</i>



## Liver Cancer, Clinical

PE-23	Exploring Prognostic Disparities of HCC Treatment in the Elderly: An Analysis of the Korean Nationwide Cancer Registry Data <i>Ha Il Kim (Hanyang Univ.)</i>
PE-24	Impact of Lymphadenectomy for Patients with Clinically Node-Negative Intrahepatic Cholangiocarcinoma: a Multicenter Retrospective Cohort Study <i>Meng Sha (Shanghai Jiao Tong Univ., China)</i>
PE-25	Effect of Biliary Drainage on Prognosis of Patients with Hepatocellular Carcinoma and Bile Duct Invasion <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
PE-26	Comparison of Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis <i>Jeayeon Park (Seoul National Univ.)</i>
PE-27	Clinical Outcomes of Transarterial Chemoembolization in Child-Turcotte Pugh Class A Patients with a Single Small ( $\leq 3\text{cm}$ ) Hepatocellular Carcinoma <i>Young-Joo Jin (Inha Univ.)</i>
PE-28	Inter-Reader Agreement for CT/MRI LI-RADS Category M Imaging Features: A Systematic Review and Meta-Analysis <i>Dong Hwan Kim (Univ. of Ulsan)</i>
PE-29	Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma <i>Byeong Geun Song (Sungkyunkwan Univ.)</i>
PE-30	Clinical Outcomes and Prognostic Factors of MRI-Guided Radiotherapy for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma Patients: A Single-Institutional Experience <i>Myungsoo Kim (The Catholic Univ. of Korea)</i>
PE-31	Outcomes Between Liver Resection and Transarterial Chemoembolization in Patients with Multinodular BCLC-A Hepatocellular Carcinoma <i>Sung Won Chung (Univ. of Ulsan)</i>
PE-32	X-Ray Vascular Chemoembolization of the Hepatic Artery for Focal Liver Lesions <i>Begimai Murzalieva (Kyrgyz State Medical Academy, Kyrgyzstan)</i>

## Liver Cancer, Clinical

PE-33	<p>Combined Portal and Hepatic Vein Embolization to Improve Liver Hypertrophy before Hepatectomy in Hepatocellular Carcinoma</p> <p><i>Van Sy Than (Viet Duc Univ. Hospital, Vietnam)</i></p>
PE-34	<p>Multidisciplinary Approach for HCC Management in Gastroenterology and Hepatobiliary Center, Bach Mai Hospital</p> <p><i>Thuy Pham Thi Ngoc (Bach Mai Hospital, Vietnam)</i></p>
PE-35	<p>Analysis of Varix Bleeding after Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma Patients</p> <p><i>Ahlim Lee (The Catholic Univ. of Korea)</i></p>
PE-36	<p>The First-Line Utilization of Atezolizumab Combined with Bevacizumab in Unresectable Hepatocellular Carcinoma: A Single-Center Retrospective Study in Vietnam</p> <p><i>Hoa Nguyen (National Cancer Hospital, Vietnam)</i></p>
PE-37	<p>Laparoscopic versus Open Major Hepatectomy for The Management of Hepatocellular Carcinoma in a Vietnamese Tertiary Hospital: A Five-Year Retrospective Comparative Study</p> <p><i>Thang Tran Manh (Vin Univ., Vietnam)</i></p>
PE-38	<p>Hepatocyte Nuclear Factor 1 Alpha Variants as Risk Factor for Hepatocellular Carcinoma Development with and without Diabetes Mellitus</p> <p><i>Mohamed Abdel-Samiee (National Liver Institute, Egypt)</i></p>
PE-39	<p>Evaluation of Circular RNA SMARCA5 as a Novel Biomarker for Hepatocellular Carcinoma</p> <p><i>Mohamed Abdel-Samiee (National Liver Institute, Egypt)</i></p>
PE-40	<p>Outcomes in Liver Recipients with Hepatocellular Carcinoma and Combined Portal Vein Tumor Thrombosis, Multicenter Study</p> <p><i>Jae Geun Lee (Yonsei Univ.)</i></p>
PE-41	<p>Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma</p> <p><i>Se Jin Choi (Univ. of Ulsan)</i></p>
PE-42	<p>Huge Ruptured Hepatocellular Carcinoma in Case of Dubin-Johnson Syndrome</p> <p><i>Cheon Soo Park (The Catholic Univ. of Korea)</i></p>

## Liver Cancer, Clinical

PE-43	Higher Objective Responses by Hepatic Arterial Infusion Chemotherapy Following Atezolizumab and Bevacizumab Failure than as The Initial Therapy in Hepatocellular Carcinoma <i>Ji Hoon Kim (The Catholic Univ. of Korea)</i>
PE-44	Impact of Skeletal Muscle Mass on Long-Term Outcomes in Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy <i>Ji Hoon Kim (The Catholic Univ. of Korea)</i>
PE-45	Reduced Occurrence of Hepatocellular Carcinoma in Hepatitis C Patients Following Direct-Acting Antiviral Therapy <i>Khishigmaa Lkhagvadorj (Molor Laboratory, Mongolia)</i>
PE-46	Frailty and Sarcopenia as a Predictor of Mortality in Hepatocellular Carcinoma Patients with Transarterial Chemoembolization <i>Roland Helmizar (Baiturrahmah Univ., Indonesia)</i>
PE-47	Lipid Metabolic Reprogramming in Tumor Microenvironment: Clostridium Cluster Cocktail Attenuate High-Fat Diet Induced Hepatocellular Carcinoma <i>Seol Hee Song (Hallym Univ.)</i>
PE-48	A Margin Morphology-Based Gross Classification System for Stratifying HCC <i>Zhong-Qi Fan (Jilin Univ., China)</i>

## Liver Transplantation

PE-01	Anti-Thymocyte Globulin (ATG) Use after Steroid Resistant Acute Rejection (SRAR) in Liver Transplantation: 1st Experience in Asan Medical Center (AMC) <i>Eun-Kyoung Jwa (Asan Medical Center)</i>
PE-02	Child's Condition after Liver Transplantation Surgery <i>Derizal Derizal (IP Trisakti, Indonesia)</i>
PE-03	Review of the Long-Term Quality of Life after Liver Transplantation <i>Mega Dwi Septivani (Politeknik Negeri Padang, Indonesia)</i>
PE-04	The Impact of Age on Liver Regeneration after Living Donor Right Hemihepatectomy in Elderly Donors <i>Na Reum Kim (Severance Hospital)</i>

## Liver Transplantation

PE-05	Mesenchymal Stem Cell Therapy for Enhancing Liver Regeneration Post-Hepatectomy: A Review <i>Nadyatul Husna (Alumnus of Universitas Andalas, Indonesia)</i>
PE-06	Comparative Analysis of Immune Cells and Gut Microbiome in Patients Exhibiting Tolerance and Rejection Following Liver Transplantation: A Preliminary Study <i>Soon Kyu Lee (The Catholic Univ. of Korea)</i>
PE-07	Effects of Graft Anatomy on Outcomes of Living Donor Liver Transplantation Using Right Liver: Donor Safety and Long-Term Recipient Results <i>Sang-Hoon Kim (Univ. of Ulsan)</i>
PE-08	Associations Between Clinical Factors and Biliary Complications Among Liver Transplant Recipients in Mongolia <i>Myagmarjargal Sodjamts (First Central Hospital of Mongolia, Mongolia)</i>
PE-09	Laparoscopic Donor and Recipient Explant Hepatectomy in Living Donor Liver Transplantation: A Single Center Experience in Vietnam <i>Thi The Trinh Nguyen (Vin Univ., Vietnam)</i>
PE-10	Diaphragmatic Hernia after Living-Donor Hepatectomy: A 10-Year Single-Center Case Series <i>Minha Choi (Asan Medical Center)</i>
PE-11	A Learning Curve for Laparoscopic Living Donor Hepatectomy Using Cusum Analysis <i>Sehyeon Yu (Korea Univ.)</i>
PE-12	Short-Term External Biliary Drainage in Living Donor Liver Transplantation Using Duct-to-Duct Anastomosis: a Single-Center Experience <i>Ji Su Kim (The Catholic Univ. of Korea)</i>
PE-13	Patient Survival Prediction Analyzing Pathological Images after Liver Transplantation <i>Seung Hyoung Ko (CHA Univ.)</i>
PE-14	Comparison of Survival Outcomes in Liver Transplantation Recipients with Refractory Ascites(RA) or Hydrothorax(RH) <i>Minyu Kang (Yonsei Univ.)</i>

## Liver Transplantation

PE-15	The Figure Out of Live Donor Liver Transplantation (LDLT) in Asia Using Bibliometrics Analysis <i>Muhammad Irzaq (Alumnus Padang State Univ., Indonesia)</i>
PE-16	Single Centre Experience of Acute and Chronic Rejection after Liver Transplantation <i>Lyazzat Nur (National Research Oncology Center, Kazakhstan)</i>

## Biliary and Pancreatic Disease

PE-01	Feasibility of Laparoscopic Hepatectomy for Hepatolithiasis <i>Thanh Dang Nhu (Hue Univ. of Medicine and Pharmacy, Vietnam)</i>
PE-02	Cancer Stem Cells-Derived Exosomal MiR-675-3p Promotes Epithelial-Mesenchymal Transition in Human Pancreatic Cancer Cells by Targeting the STAT3 Pathway <i>Feng Wang (Peking Univ. First Hospital, China)</i>
PE-03	Comparison of Intraperitoneal Nebulization with Instillation of Ropivacaine in Reducing Post-Operative Pain after Laparoscopic Cholecystectomy: A Double Blinded, Randomized Control Trial <i>Raj Kumar Nagarajan (JIPMER, India)</i>
PE-04	Role of Circulating miRNA as Diagnostic and Prognostic Biomarkers for Biliary Tract Cancer <i>Nadyatul Husna (Alumnus of Universitas Andalas, Indonesia)</i>
PE-05	Obstructive Jaundice of Non-Tumor Genesis: State of Immunity and Methods of Correction <i>Nodirjon Ruzimurodov (Institute of Immunology and Human Genomics, Uzbekistan)</i>
PE-06	Idiopathic Vanishing Bile Duct Syndrome in a Young Female: A Case Report <i>Min Ji Kim (Pusan National Univ.)</i>
PE-07	High Expression of Senescence Marker Protein-30 (SMP-30) Is Associated with 3-Year Mortality in Cholangiocarcinoma <i>Ji-Won Park (Hallym Univ.)</i>

## Biliary and Pancreatic Disease

PE-08	Diagnostic Efficacy of Preoperative Biopsy in Distinguishing Gallbladder Cancer from Cholecystitis <i>Min Jae Kim (Keimyung Univ.)</i>
PE-09	Early Predictors of Successful Kasai Portoenterostomy <i>Arjun Maria (Sir Ganga Ram Hospital, India)</i>
PE-10	Clinico Pathological Profile, Surgical Outcome and Survival Analysis after Pancreaticoduodenectomy: 7 Year Experience from Tertiary Care Teaching Hospital in Odisha <i>Swamy Rajesh Hudugur (IMS &amp; SUM Hospital, India)</i>
PE-11	Demographic, Clinicopathological Profile & Surgical Outcome in Chronic Calcific Pancreatitis Patients in Eastern India (Odisha): 7 Yrs Experience from a Tertiary Care Teaching Hospital <i>Swamy Rajesh Hudugur (IMS &amp; SUM Hospital, India)</i>
PE-12	Biological Effects of Atractylodin on Migration and Autophagy of Cholangiocarcinoma Cell through Its Different Molecular Mechanism <i>Dinesh Kumar Patel (SHUATS, India)</i>
PE-13	The Non-Invasive Approach to Pancreatic Fibrosis Assessment by Multidetector Computed Tomography: The Intermediate Results <i>Konstantin Lesko (The AS Loginov Moscow Clinical Scientific Center, Russia)</i>
PE-14	X-Ray Endobiliary Methods in the Treatment of Patients with Liver Alveococcosis Complicated with Obstructive Jaundice <i>Anzhelika Marshankulova (Kyrgyz Russian Slavic Univ., Kyrgyzstan)</i>
PE-15	Risk Factor for Conversion Additional Port in Single-Incision Laparoscopic Cholecystectomy in Patients with Acute Cholecystitis <i>Ja Yun Koo (The Armed Forces Medical Command)</i>
PE-16	Features of Choosing a Method for Emergency Laparoscopic Cholecystectomy in Patients with Chronic Diffuse Liver Diseases <i>Farukh Mahmudzoda (Avicenna Tajik State Medical Univ., Tajikistan)</i>
PE-17	Indicator for Prevention Elderly Disease of "Silent Disease" Pancreatic Cancer in Indonesia: Systematic Review <i>Muhammad Irzaq (Alumnus Padang State Univ., Indonesia)</i>

## Biliary and Pancreatic Disease

PE-18	To Identify the Cause of Gallstones and Conduct a Chemical Analysis of Them <i>Surya Ram Duwal (Central Diagnostic Laboratory and Research Center, Nepal)</i>
PE-19	Gallbladder Clear Cell Carcinoma: A Case Report <i>Bayanduuren Batsuuri (Mongolian National Univ. of Medical Science, Mongolia)</i>
PE-20	Muscle Splitting Mini Cholecystectomy <i>Ashish Prasad Rajbhandari (Stupa Hospital, Nepal)</i>
PE-21	Intraductal Papillary Neoplasm of the Bile Duct (Ipnb) With Invasion to the Stomach and Lef Lobe Atrophy - Case Presentation <i>Bekkozha Yeskendirov (National Research Oncology Center, Kazakhstan)</i>
PE-22	Percutaneous Transhepatic Endobiliary Interventions in Patients with Unresectable Cholangiocarcinomas Complicated by Mechanical Jaundice <i>Anastasiia Sochnieva (Kharkiv Polytechnic Institute, Ukraine)</i>

## Surgery, Technical Issues

PE-01	Comparative Study of Proficiency Improvement in ArtiSential Instruments According to Conventional Laparoscopic Surgery Experiences <i>Seoung Yoon Rho (Yonsei Univ.)</i>
PE-02	Tumor Thrombectomy via Surgically Reopened Umbilical Vein as a Palliative Treatment for Patient with Advanced Hepatocellular Carcinoma <i>Giang Truong Nguyen (National Hospital of Tropical Diseases, Vietnam)</i>
PE-03	Systematic Assessment of Surgical Techniques for Complex Liver Resections <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>
PE-04	Early Outcomes of Single Port Robotic Left Lateral Sectionectomy <i>Wan Joon Kim (Korea Univ.)</i>
PE-05	Our Experience in the Surgical Treatment of Liver Alveococcosis and Its Complications <i>Marshankulov Rezuan (Kyrgyz-Russian Slavic Univ., Kyrgyzstan)</i>

## Surgery, Technical Issues

PE-06	Radical Liver Resections during Repeated Surgical Intervention of Liver Alveococcosis <i>Edir Surov (Kyrgyz-Russian Slavic Univ., Kyrgyzstan)</i>
PE-07	9-Year Outcomes after Liver Resection for Giant and Enormous Hepatic Hemangioma: A Single Center Experience in Vietnam <i>Thi The Trinh Nguyen (Vin Univ., Vietnam)</i>
PE-08	Early Experience: Simultaneous Ipsilateral Portal Vein And Hepatic Artery Ligation for Rapid Quantitative Liver Hypertrophy <i>Jinhong Lim (Yonsei Univ.)</i>
PE-09	Extensive Liver Resections for Focal Lesions <i>Bakhadyr Bebezov (Kyrgyz-Russian Slavic Univ., Kyrgyzstan)</i>
PE-10	Prevalence of Variations of the Extra Hepatic Biliary Duct and Vascularization in the Mongolian <i>Munkhchuluun Bayanjargal (First Central Hospital of Mongolia, Mongolia)</i>
PE-11	First Case of Pure Laparoscopic Right Hepatectomy (PLRH) at Second State Central Hospital: Samsung Medical Center Approach <i>Gan Erdene Baatarjav (Second State Central Hospital, Mongolia)</i>
PE-12	Poshepatectomy Liver Failure and Its Predictors: A Single Center Experience in Kazakhstan <i>Abylaikhan Sharmenov (National Research Oncology Center, Kazakhstan)</i>
PE-13	Posthepatectomy Bile Leakage: A Single-Center Experience in Kazakhstan <i>Adina Kulanbayeva (National Research Oncology Center, Kazakhstan)</i>
PE-14	Robotic vs. Laparoscopic in Pancreatic Surgery <i>Fitri Kurnia (Universitas Muhammadiyah Sumatera Barat, Indonesia)</i>

## Others

PE-01	Decoding the Genomic Landscape of Hepatocellular Carcinoma: Personalized Hepatic Resection for Optimized Surgical Outcomes <i>Andi Nursanti (Andini Persada College of Health Sciences, Indonesia)</i>
-------	---



## Others

PE-02	The Assessment of Quality of Life in Patients with Chronic Liver Disease <i>Battur Batbayar (NB Clinic, Mongolia)</i>
PE-03	How to Prevent Hepatitis Early by Giving Hepatitis B (HepB) Vaccine from Infancy in Indonesia? <i>Derizal Derizal (IP Trisakti, Indonesia)</i>
PE-04	Comparative Performance of Hepatitis E Virus Diagnostic Methods: A Prospective, Nationwide Multicenter Study on Blood Samples from Patients with Acute Hepatitis <i>Chang Hun Lee (Jeonbuk National Univ.)</i>
PE-05	How Is Shared Decision Making Used in the Care of Patients with Liver Disease?: A Scoping Review <i>Ha Eun Kang (Yonsei Univ.)</i>
PE-06	Comparative Study on the Hepato-Protective Role of Vitamin C and Vitamin E on Mercury Induced Toxicity in <i>Heteropneustes Fossilis</i> Model <i>Vinod Thakur (Devi Ahilya Univ., India)</i>
PE-07	<i>Peronema Canescens</i> Bioactives: Implications for Parkinsonism in Cirrhosis - Molecular Docking and ADMET Investigation <i>Rizki Rachmad Saputra (Universitas Palangka Raya, Indonesia)</i>
PE-08	TGF- $\beta$ 1 Receptor Inhibition by Resveratrol Derivatives: Promising Therapeutic Approach for Liver Fibrosis <i>Rian Ka Praja (Universitas Palangka Raya, Indonesia)</i>
PE-09	Cost Analysis of Chronic Liver Related Disease: What Should We Do Next? <i>Vivi Usmayanti (Economics Faculty, Universitas Sriwijaya, Indonesia)</i>
PE-10	<i>Lavandula Angustifolia</i> Oil Extract: A Potential Therapeutic Agent for Hepatic and Renal Protection in Cholesterol Diet-Induced Hyperlipidemia in Female Rats <i>Ranbir Singh (Shakuntla Hospital and Research Center, India)</i>
PE-11	From Teacup to Treatment: Molecular Mechanisms of Green Tea Epigallocatechin-3-Gallate in the Treatment of Hepatic Tuberculosis <i>Qonita Sari Bustomi (Universitas Palangka Raya, Indonesia)</i>

## Others

PE-12	Immunohistochemical Subtypes of Hepatocellular Adenomas in Iranian Patients, A Cross Sectional Study in a Single Center <i>Javaneh Jafarshad (Tehran Univ. of Medical Sciences, Iran)</i>
PE-13	Long-Term Effect of Alcohol Consumption to the Incidence of Pancreatic Cancer: Country Level Analyses <i>Riska Dwi Astuti (Universitas Islam Indonesia, Indonesia)</i>
PE-14	Predictive Identification Activity of Curcumin Analogs as Hepatitis Antivirals by Molecular Docking Method <i>Andi Tenrlia (Univ. of Al Asyariah Mandar, Indonesia)</i>
PE-15	Rapid and Sensitive Method for the Detection Selective Androgen Receptor Modulators by Liquid Chromatography Mass Spectrometry (LC-MS/MS): A Severe Drug Induced Liver Injury (DILI) Causing Drugs <i>Awanish Kumar Upadhyay (National Dope Testing Laboratory, India)</i>
PE-16	Assessment of Knowledge About Risk Factors for Chronic Liver Disease Among Patients Admitted to Dornod Medical Center <i>Batsukh Dashnyam (Dornod Medical Center, Mongolia)</i>
PE-17	A Higher Blood Ferritin Level Can Accurately Distinguish between the Severity of the Coronavirus Disease 2019 Pneumonia and Liver Damage <i>Mohammad Afzal (Uttarakhand Medical Education Univ., India)</i>
PE-18	Knowledge, Attitude and Practice of Hepatitis B and Hepatitis C among University Students of Pokhara Valley, Nepal <i>Bishnu Raj Tiwari (Pokhara Univ., Nepal)</i>
PE-19	The Laboratory Findings of Liver Disease Suspected People Residing at Gandaki Province, Nepal <i>Ganga Sagar Bhattarai (Tribhuvan Univ., Nepal)</i>
PE-20	Cardiological Features of TACE Patients in Hepatocellular Carcinoma: Study on the Kazakhstan Population <i>Saule Kubekova (Astana Medical Univ., Kazakhstan)</i>
PE-21	The Impact of Intermittent Fasting on Liver Health: A Comprehensive Review <i>Sheffali Verma (Dr Bhim Rao Ambedkar Medical College, India)</i>

## Others

PE-22	How the Scientist Minimises Mortalities with the Technology Artificial Intelligence in Hepato-Pancreato-Biliary Surgery: Is That Effective? <i>Fikri Gemilang (UPN Veteran Jogjakarta, Indonesia)</i>
PE-23	Determining the Nutritional Status and Life Quality of Critically Ill Patients and Identifying the Results of Enteral Nutrition Treatment <i>Bayarmaa Nyamaa (Mongolian National Univ. of Medical Science, Mongolia)</i>
PE-24	Biological Test of Biliary Stent Which Has Advanced Features Applied to Biliary System Related to Mammal <i>Hyung Tae Kim (S&amp;G Biotech Inc.)</i>

## MEMO

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---


---

# Remarkable Response

The ORR was more than three times higher with lenvatinib versus control group.<sup>1</sup>

Based on the masked IIR according to mRECIST,  
about 41% of patients\* showed  $\geq 30\%$  decrease in tumor size.<sup>1,2</sup>

**40.6%\***  
Response Rate  
(Masked IIR according to mRECIST)



\* ORR is one of the secondary endpoints and this is the result of the post-hoc exploratory tumour assessments using mRECIST by masked central independent imaging review. For more information, please refer to the full text of the article. (Kudo M, et al. 2018)

**[Study design]** This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions. Patients were randomly assigned (1:1) via an interactive voice-web response system with region, macroscopic portal vein invasion, extrahepatic spread, or both; Eastern Cooperative Oncology Group performance status; and bodyweight as stratification factors to receive oral lenvatinib 12 mg/day for bodyweight  $\leq 60$  kg or 8 mg/day for bodyweight  $> 60$  kg or sorafenib 400 mg twice daily in 28-day cycles. The primary endpoint was overall survival, measured from the date of randomisation until the date of death from any cause. The efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis. Lenvatinib (median OS 13.6 months, 95% CI 12.1-14.9) was non-inferior to sorafenib (median OS 12.3 months, 95% CI 10.4-13.9) in overall survival in untreated advanced hepatocellular carcinoma (HR 0.92, 95% CI 0.77-1.06).

	Lenvatinib (n=478)	Sorafenib (n=476)	Effect size (95% CI)	P value
<b>Investigator review according to mRECIST</b>				
Objective response (%; 95% CI)	115 (24.1%, 20.2-27.9)	44 (9.2%, 6.6-11.8)	OR 3.13 (2.15-4.56)	<0.0001
<b>Masked Independent Imaging review according to mRECIST</b>				
Objective response (%; 95% CI)	194 (40.6%, 36.2-45.0)	59 (12.4%, 9.4-15.4)	OR 5.01 (3.59-7.01)	<0.0001
<b>Masked Independent Imaging review according to RECIST 1.1</b>				
Objective response (%; 95% CI)	90 (18.8%, 15.3-22.3)	31 (6.5%, 4.3-8.7)	OR 3.34 (2.17-5.14)	<0.0001

mRECIST, modified Response Evaluation Criteria in Solid Tumors; IIR, Independent imaging review; ORR, Objective Response Rate; CI, Confidence Interval; uHCC, unresectable hepatocellular carcinoma; OR, Odds ratio; OS, Overall Survival

**[References]** 1. Kudo M et al. Lancet. 2018 Mar 24;391(10126):1163-1173. 2. Lencioni R, Llovet JM. Semin Liver Dis. 2010 Feb;30(1):52-60

**Lenvatinib 4mg, 10mg Capsules (Lenvatinib mesilate) [Composition]** 4mg capsule: Active ingredient: lenvatinib mesilate (in house specification) - 4.90mg (4.0mg equivalent to lenvatinib free base) 10mg capsule: Active ingredient: lenvatinib mesilate (in house specification) - 12.25mg (10.0mg equivalent to lenvatinib free base) **[Therapeutic indication]** 1. Lenvima is indicated for the treatment of patients with progressive, locally recurrent or metastatic, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). 2. LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma. 3. LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. **[Dosage and administration]** 1) Postology: DTC in Adults the recommended daily dose of Lenvima is 24 mg taken orally. The daily dose is to be modified as needed according to the dose-toxicity management plan (see 2) Dose Adjustment section below). HCC: The recommended dose of LENVIMA is based on actual body weight. - For patients greater than or equal to 60 kg: 12 mg. - For patients less than 60 kg: 8 mg. Take LENVIMA orally once daily until disease progression or until unacceptable toxicity. There is no clinical evidence to support the use of 10 mg dose in HCC. **[Endometrial Carcinoma]** The recommended dose of LENVIMA is 20 mg orally once daily, in combination with pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until unacceptable toxicity or disease progression. Refer to the pembrolizumab prescribing information for recommended pembrolizumab dosing information. **[Precautions for Use]** 1) Hypersensitivity to the active substance or to any of the excipients. 2) Breast-feeding. 3. Careful Administration 3) Patients with hypertension. 4) Patients with thrombocytopenia or a history of the condition. 5) Patients with brain metastases. 4) Patients in whom the wound from a surgical procedure has not yet healed. 5) Patients with tumor invasion to the cervical artery, etc. **[Imported]** Eisai Korea Inc. 10F, Revasant, 6, Bongunsa-ro 86-gil, Gangnam-gu, Seoul, 152-878, Korea. Tel: 02-3451-5500. - Date of written manual: Jul 1st, 2021 - For details, please refer to the full prescribing information.



The Liver Week 2022  
March 30-April 3, 2022  
Coex, Seoul, Korea

The Liver Week 2023  
May 18-20, 2023  
Grand Hyatt, Incheon, Korea

GENERAL  
INFORMATION

# GENERAL INFORMATION

The Liver Week 2024

## ABOUT THE LIVER WEEK 2024

Date	June 27-29, 2024
Venue	Walkerhill, Seoul, Korea
Theme	Towards Precision Medicine in Practice and Research of Hepatology
Official Language	English
Official Website	<a href="http://www.theliverweek.org">www.theliverweek.org</a>
Hosted by	 The Korean Association for the Study of the Liver  THE KOREAN ASSOCIATION OF HBP SURGERY  THE KOREAN LIVER CANCER ASSOCIATION  The Korean Liver Transplantation Society

## REGISTRATION DESK

Location	Grand Hall Lobby		
Opening Hour	<b>June 27</b> 08:00-17:30	<b>June 28</b> 07:00-18:00	<b>June 29</b> 07:00-17:00

Participants will receive their name badges when collecting their meeting documents on site. You are required to wear your name badge during all meeting events.

## OPENING CEREMONY

Location	Room 1 (Vista I+II)
Date & Time	<b>June 28</b> 10:50-11:10

## CLOSING & AWARD CEREMONY

Location	Room 1 (Vista I+II)
Date & Time	<b>June 29</b> 16:20-16:40

## INDUSTRIAL EXHIBITION

Location	Exhibition Hall (Grand I+II+III) / Vista Lobby		
Opening Hour	<b>June 27</b> 09:00-17:10	<b>June 28</b> 09:10-16:10	<b>June 29</b> 09:10-16:40

**PREVIEW ROOM****FACULTY LOUNGE** for Invited Faculty and Committee Members

Location	Amber / Ida		
Opening Hour	<b>June 27</b> 08:00-17:10	<b>June 28</b> 06:30-17:50	<b>June 29</b> 06:30-16:40

All presenters are requested to come to the Preview Room at least 1 hour in advance of the presentations to verify if the data function properly on the equipment provided.

**ORAL POSTER PRESENTATION**

Location	Exhibition Hall (Grand I+II+III)	
Opening Hour	<b>June 28</b> 16:30-17:30	<b>June 29</b> 09:30-10:30

**E-POSTER EXHIBITION**

Location	Vista Lobby		
Opening Hour	<b>June 27</b> 13:15-17:10	<b>June 28</b> 09:10-17:50	<b>June 29</b> 09:10-16:40

**MEAL**

Breakfast (All Participant)	Breakfast will be served during breakfast sessions.
Lunch (All Participant)	A lunch box will be served during the industry luncheon symposium. Please check the program book and join the symposium as per your preference.
Welcome Reception (All Participant)	June 28, 2024, 17:50 - 19:00, Exhibition Hall (Grand Hall I+II+III)
Faculty Dinner (Invitation Only)	June 27, 18:00 - 20:00, Aston House There will be complimentary shuttle service from 17:15-17:50 in front of the Grand Walkerhill. Please wait at the designated sign for "The Liver Week 2024 Faculty Dinner".



## Welcome Reception

Date & Time  
 June 28, 2024, 17:50 - 19:00  
 Exhibition Hall (Grand I+II+III)

### WELCOME RECEPTION FOR ALL PARTICIPANTS

We cordially invite all participants to join us for the Welcome Reception. Enjoy a fun-filled evening with cool beer, delicious chicken, pizza, and more. Exciting live performances and raffle prizes await you!

Don't miss this opportunity to relax, mingle, and have a great time. See you there!



### USEFUL PHONE NUMBERS

119 Emergency (Fire & Ambulance)	112 Police	1330 Foreign Traveller Hotline
----------------------------------	------------	--------------------------------



평점안내

\* QR Code Scanner: 평점이 필요한 등록자께서는 매일 최초 입실 및 최종 퇴실시 (2회 이상) 명찰을 스캔하시기 바랍니다.

평점구분	27일(목)		28일(금)	29일(토)
	PG	TLW	TLW	TLW
대한의사협회	6점		6점	6점
대한내과학회 평생교육	6점	6점	6점	6점
대한내과학회 분과전문의	6점	None		
대한내과학회 전공의 외부학술회의	2점			
대한간학회 복부초음파 세부전문의	3점			
대한임상초음파학회	3점			
대한내과학회 전공의 초음파교육	17건			
대한내과학회 초음파 지도전문의 교육	3점			

- \* 평점은 시간당 부분평점 부여 (시간당 1점)됩니다.
- \* 대한내과학회 분과전문의 평점은 6월 27일(목) PG Course를 수강한 경우에만 인정됩니다.
- \* 학술대회는 분과전문의 자격갱신 시 학회 참석확인서 및 대한의사협회 교육센터의 이수확인서 제출 시 1일 2점 인정됩니다.
- \* 대한내과학회 전공의 외부학술회의 평점은 익일 6시간 이상, 양일 참석 시 2점이 인정 (총 12시간) 됩니다.
- \* 대한간학회 복부초음파 세부전문의, 대한임상초음파학회 평점은 6월 27일(목), Ultrasound Trainer Session 또는 Ultrasound Trainee Session & Ultrasound Hands-On Course 수강 시 인정됩니다.
- \* 대한내과학회 전공의 초음파교육은 6월 27일(목), Ultrasound Trainee Session & Ultrasound Hands-On Course 수강 시 인정
- \* 대한내과학회 초음파 지도전문의 교육 평점은 6월 27일(목), Ultrasound Trainer Session 수강 시 인정됩니다

# INDUSTRIAL EXHIBITION FLOOR PLAN


**B2**

★ QR Scanner



Diamond				
Roche		Yuhan		
Platinum				
Daewoong	Eisai		Gilead	
Gold				
AstraZeneca	Abbvie	Celltrion	Dong-A ST	Samil

# INDUSTRIAL EXHIBITION FLOOR PLAN



Silver					
Boryung		GC Biopharma		Pharma King	
Bronze					
Bukwang		CKD		Sysmex	
1	Novartis	6	Mitsubishi Tanabe	11	Astellas
2	Integra	7	GC Cell	12	Han Wha
3	ILDONG	8	Daewon	13	Samjin
4	PHARMICELL	9	Hanmi	14	BMS & ONO
5	Acme Medical	10	Siemens Healthineers	15	GC Wellbeing

# LIVER LEADERSHIP

Unfinished journey in viral hepatitis



2022  
EPCLUSA®

2022  
VOSEVI®

2017  
VEMLIDY®

2015  
HARVONI®

2015  
SOVALDI®

2011  
VIREAD®

\* 처방하기 전에 반드시 허가사항 전문을 확인하여 주시기 바랍니다.  
최신 허가사항은 QR 코드를 통해 확인하실 수 있으며, 길리어드사이언스 코리아 홈페이지([www.gilead.co.kr](http://www.gilead.co.kr)) 또는 식품의약품안전처 의약품통합정보 시스템 (<http://medrug.mfds.go.kr>) 에서도 보실 수 있습니다.

**엠플루사정**  
(소포스부비르, 벨파타스비르)



**EPCLUSA**  
sofosbuvir/velpatasvir  
400mg/200mg tablets

**보세비정**

(소포스부비르, 벨파타스비르, 복시판프레비르)



**VOSEVI**  
sofosbuvir/velpatasvir/cosimepranterviro  
400mg/200mg/150mg tablets

**베믈리드정**

(테노포비르알라미딘, 나미드레이푸마르산염)



**Vemlidy**  
tenofovir alafenamide  
253mg tablets

**하보니정**

(소포스부비르, 레디파스비르)



**HARVONI**  
sofosbuvir/ledipasvir  
400mg/80mg tablets

**소발디정**

(소포스부비르)



**SOVALDI**  
sofosbuvir  
400mg tablets

**비리어드정**

(테노포비르디소프록실푸마르산염)



**viread**  
tenofovir disoproxil fumarate  
300mg tablets



길리어드 사이언스 코리아(유)

서울특별시 중구 을지로5길 26 센터빌딩 서관 15층  
(대표전화: 02-6030-3300,  
제품관련문의: 0079-694-800-9172 (수신자 부담))

Tour Date: **Friday, June 28, 2024**

Lucky Draw Time: **17:50 @ Exhibition Hall** (Grand I+II+III)

Absentees will be excluded from the event.

Please get stamps from all the participating exhibition booths and bring it to the registration desk.

**VISTA LOBBY (B2)**

Roche

Yuhan

Daewoong

Eisai

Gilead

Astra  
Zeneca

Abbvie

Celltrion

Dong-A ST

Samil

**EXHIBITION HALL (B1)**

Boryung

GC  
Biopharma

Pharma  
King

Bukwang

CKD

Sysmex

Acme  
Medical

Astellas

BMS  
&  
ONO

Daewon

GC Cell

Han Wha

Hanmi

ILDONG

Integra

Tour Date: **Friday, June 28, 2024**

Lucky Draw Time: **17:50 @ Exhibition Hall** (Grand I+II+III)

Absentees will be excluded from the event.

Please get stamps from all the participating exhibition booths and bring it to the registration desk.



Galaxy Watch6  
Classic Golf Edition  
(Bluetooth)



AirPods Pro  
(2nd Generation)

**Tour Date: Saturday, June 29, 2024**

**Lucky Draw Time: 16:20 @ ROOM 1** (Vista I+II)

Absentees will be excluded from the event.

Please get stamps from all the participating exhibition booths and bring it to the registration desk.

**VISTA LOBBY (B2)**

Roche

Yuhan

Daewoong

Eisai

Gilead

Astra  
Zeneca

Abbvie

Celltrion

Dong-A ST

Samil

**EXHIBITION HALL (B1)**

Boryung

GC  
Biopharma

Pharma  
King

Bukwang

CKD

Sysmex

Acme  
Medical

Astellas

BMS  
&  
ONO

Daewon

GC Cell

Han Wha

Hanmi

ILDONG

Integra

**Tour Date: Saturday, June 29, 2024**

**Lucky Draw Time: 16:20 @ ROOM 1 (Vista I+II)**

Absentees will be excluded from the event.

Please get stamps from all the participating exhibition booths and bring it to the registration desk.



Galaxy S24 Ultra  
256GB

(1EA)



Dyson Airwrap™  
Multi-Styler and Dryer

(1EA)



AirPods Pro  
(2nd Generation)

(1EA)



SAMSUNG  
Gift Certificate  
(₩100,000)

(3EA)



# THE LIVER WEEK 2024 SUPPORTERS

## ◆ DIAMOND ◆



## ◆ PLATINUM ◆



## ◆ GOLD ◆



## ◆ SILVER ◆



## ◆ BRONZE ◆





# THE LIVER WEEK 2024



Program Book  
Abstract Book  
E-Posters  
and View More

[www.theliverweek.org](http://www.theliverweek.org)